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1 General Introduction 
 
1.1 Mass spectrometry of lipids 
Complex lipids such as glycerophospholipids and sphingolipids, in contrast to 
proteins, are composites of a wide range of building blocks. Permutations that may 
arise from lipid building blocks give rise to more than a dramatic number of structures 
that can be present in a given cell or tissue extract (1). Today about 1000 lipid 
species can be quantified from the postulated 9000 – 10000 that may exist in 
mammalian systems. This multitude of lipid species can’t be currently identified due 
to either a lack of sensitivity of MS-methods and preanalytics, or a lack of specificity 
of the current methods. The need to develop analytical tools that can readily tackle 
such a diverse range of molecular structures is a key reason that lipidomics has 
lagged behind her sister discipline proteomics. In lipidomics, mass spectrometry has 
been deployed in two ways, namely targeted lipidomics, which focuses on the 
identification and quantification of a single lipid class or subset of lipids in a tissue or 
cellular extract, and the untargeted lipidomics, which aims to identify and quantify all 
the lipids in a given biological matrix (2). The present work focuses on the targeted 
lipidomics approach for the analysis of minor, regulatory sphingolipid and 
glycerophospholipid species as well as for bile acid analysis. 
 
1.1.1 Electrospray Ionization (ESI) 
Early analysis of complex, high-molecular-weight lipids was conducted by fast 
atom bombardement (FAB) MS. FAB has made a major contribution to lipid MS, but 
was fundamentally limited by low overall sensitivity, the presence of matrix ions, and 
significant in-source fragmentation that precluded quantitative analysis (3). The 
application of ESI-MS to the analysis of lipids solved these problems. In contrast to 
FAB, ESI is a soft ionization technique. It produces protonated, deprotonated or 
adduct ions (e.g. Na+, Li+, NH4+) and only a negligible percentage of in-source 
fragmentation. Additionally, ESI-MS shows an increase of two to three orders of 
magnitude in sensitivity over FAB (4). Therefore, ESI has given rise to two main 
approaches for lipid analysis, namely online high-performance liquid 
chromatography-mass spectrometry (HPLC-MS) and direct infusion ESI-MS (shotgun 
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lipidomics). HPLC-MS is the technique of choice for the analysis of low-abundance 
signaling lipids such as sphingosine-1-phosphate (S1P), ceramide-1-phosphate 
(Cer1P) and lysophosphatidic acid (LPA). 
In summary, the application of ESI-MS as a soft ionization technique, originally 
developed for macromolecules (5), was an important breakthrough in the analysis of 
lipids. Especially, limits of detection were diminished to the femto molar rrange, using 
ESI-MS. 
 
1.1.2 Tandem mass spectrometry in lipidomics  
Triple quadrupole tandem MS is the most commonly used technique in the field 
of targeted lipidomics. The combination of soft-ionization methods such as ESI with 
tandem MS has undoubtedly been the most significant contribution to recent 
advances in lipidomics. Tandem MS is a reliable diagnostic tool for the structural 
elucidation of lipids, and the use of related scanning approaches [e.g., precursor ion 
and neutral loss scans and multiple reaction monitoring (MRM) (Fig. 1)] has 
significantly enhanced analytical sensitivity in both targeted and untargeted 
lipidomics (3).  
In targeted lipidomic approaches, the infusion of crude lipid extracts into the MS 
and the ionization via ESI can result in mass spectra with isobaric species and a high 
chemical noise. The specific fragmentation pattern by collision induced dissociation 
(CID) allows specific determination of each lipid class and species with significantly 
reduced noise (Fig. 1). Brugger et al. (6) demonstrated that the use of specific 
precursor ion and neutral loss scans on triple quadrupole mass spectrometers is a 
powerful tool for the analysis of phospholipids in complex lipid extracts. Subsequent 
investigations of the fragmentation behavior of ionized lipids have led to a broad 
array of potential precursor ion and neutral loss transitions. 
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Fig. 1. Schematic representation of the configuration of a triple quadrupole MS for scan 
types commonly employed in lipidomic analysis, including (a) normal, (b) product ion, (c) 
precursor ion, (d) neutral loss or neutral gain, (e) multiple reaction monitoring (MRM) 
Adapted from Blanksby et al. (3) 
 
The specificity and sensitivity of online HPLC-MS applications are enhanced 
significantly by the use of MRM, in which a triple quadrupole MS is programmed to a 
mass transition that is specific to target lipid species. In MRM experiments, a signal is 
detected only if an ionized lipid has the prescribed m/z ratio for both the precursor 
and the product ion, thus minimizing chemical noise. In this configuration, up to 100% 
of the target ions entering the instrument can be detected, leading to increased 
sensitivity and allowing detection and quantification of lipids at femto molar levels. 
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Therefore a large number of MRM transitions are necessary to monitor all lipid 
species in a single chromatogram.  
 
1.1.3 Linear ion trap mass spectrometry 
Due to their versatility, quadrupole linear ion trap (QLIT) mass spectrometers 
are becoming more and more popular in the growing field of lipidomics. The 
combination of triple quadrupole MS with LIT technology is particularly interesting, 
because Q3 (Fig. 1) can be either used in the classical scan-mode or as a trapping 
device. Q0, which is generally used to focus ion before entering Q1, can be also used 
as ion trap. Ions accumulate in the Q0 region while the Q3 trap is scanning ions 
during ion trap experiments. Thus, all specific scan functions of the triple quadrupole 
such as product ion, neutral loss, precursor ion, and MRM mode (Fig. 1) are 
maintained along with and in combination with the trap scan modes (7). The term 
‘enhanced’ is always used when Q0 accumulate ions and Q3 is operated as an LIT. 
Basically QLIT exhibits no new scan functions, however scan combinations of triple 
quadrupole mode and trap mode can be performed in the same LC-MS run leading 
to increased sensitivity and specificity. In lipidomics analysis the linear ion trap is 
used for qualitative analysis (8), whereas quantitative analysis is performed in the 
MRM-mode (9-11). The following QLIT scan modes are the most commonly used for 
lipidomic analysis. 
 
Enhanced MS mode 
The enhanced MS (EMS) mode also produces a conventional mass spectrum 
but with increased sensitivity as a result of ion trapping in Q3 while ions accumulate in 
Q0. Typically, ions within a defined mass range are collected in Q3 for a specified 
time and are then scanned at specific scan rates. Trap fill times in practice are in the 
range of 100 - 500 ms. Scanning rates of the LIT are 250, 1000 and 4000 Da/s, with 
the resolution being dependent on the scanning speed. The EMS scan is particularly 
interesting for lipid species identification using information dependent acquisition and 
it is often performed before the enhanced product ion scan (see Chapter 2.3.5.).  
 1. General Introduction 5 
 
Enhanced product ion mode 
In the enhanced product ion mode (EPI), the selection of the precursor ion is 
performed in Q1 (Fig. 1). Afterwards, CID occurs in the collision cell (Q2), and 
fragment ions are trapped in Q3, operated as LIT. These fragment ions are scanned 
at specific scan rates in Q3, resulting in increased sensitivity compared to classical 
product ion spectra. 
 
MS3 mode 
In the MS3 mode, accelerated precursor ions selected by Q1 are fragmented in 
the collision cell (Q2). The fragments and the residual precursor ions are transmitted 
into Q3, where they are trapped for several ms. The next-generation precursor ion is 
then isolated within the LIT. Fragmentation in the LIT occurs via excitation by a 
distinct frequency to give the sequential product ion spectrum. 
 
Information-dependent acquisition 
IDA is a procedure, that combines two or more different scan modes in a 
sequential fashion for the same LC-MS run. The first scan is defined as the survey 
scan (e.g. EMS), where data are processed to determine the ions of interest based 
on predefined selection criteria. If the selection criteria are fulfilled, a second scan 
(e.g. EPI) is performed. Ions of interest can then be further processed through an 
additional IDA by a third MS scan mode (e.g. MS3) (for an example see chapter 
2.3.5.).  
 
1.2 Chromatography 
Although shotgun or direct infusion MS offers some advantages for the 
analysis of lipids from complex mixtures, there are limitations in its use. The presence 
of isobaric species, ion suppression, and exact lipid identification requires a different 
analytical approach. Some of these problems can be solved by interfacing HPLC with 
on-line ESI-MS.  
Generally, the the selection of an appropriate chromatographic strategy is a 
major challenge in targeted lipid species. A set of non-naturally occurring internal 
standards is used for quantification. Frequently, non-naturally occurring short-chain 
lipid species are applied, since stable-isotope-labeled internal standards are not 
commercially available. Co-elution of analytes and internal standards is of major 
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importance, especially if gradient elution is applied. Basically, HPLC-MS analysis of 
lipid species can be categorized into three chromatographic principles. These are 
discussed in the following. 
 
Reversed-phase chromatography 
A combination of reversed phase (RP) HPLC and MS allows detailed analysis 
of individual molecular species with a high precision in a targeted approach. 
However, since RP-chromatography shows chain-length dependent lipid species 
separation within a lipid class, co-elution of analytes and internal standards may not 
be accomplished (12-16). Additionally, RP-chromatographic MS methods suffer from 
long run times. These exclude such methods from high sample throughput. 
 
Normal-phase chromatography 
The opposite chromatographic strategy is normal phase (NP) chromatography. 
‘Classical’ normal phase chromatography offers polar head group specific separation, 
which leads to co-elution of lipid species within each lipid class. However, classical 
NP chromatography may be impaired by limited reproducibility and insufficient peak 
shapes. Moreover, the use of apolar solvents may not provide optimal ionization 
conditions for ESI. 
 
Hydrophilic interaction chromatography 
Hydrophilic interaction chromatography (HILIC) combines the separation 
principle of ‘classical’ NP-chromatography with the use of polar solvents, which are 
commonly used for RP-chromatography. These two key features provide polar head 
group specific separation of lipid classes i.e. co-elution of lipid species within each 
lipid class. Furthermore, polar solvents for chromatographic separation provide 
optimal ionization conditions for ESI and therefore an increase in sensitivity. 
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1.3 Biological background 
 
All eukaryotic cells are surrounded by a membrane composed of a lipid 
bilayer, whose chemical nature and essential role in cell permeability were first 
proposed around a hundred years ago. Today it is known that there are four major 
classes of lipids, i) neutral lipids, such as triacylglycerols, which serve primarily to 
store energy; ii) glycerolipids, the major component of plasma membrane lipids that 
serve as substrates for bioactive lipids including diacylglycerol (DAG) and 
phosphoinositides; iii) sphingolipids, which also serve membrane and singnaling 
functions; and iv) sterols, which function in membrane structure and fluidity, as well 
as hormone production and cell and organism regulation (17) (Fig. 2).  
 
OR1
OR3
OR2
R1-3 = Fatty acid; H
Glycerolipid
OR1
NHR2
HO
R1 = e.g. phosphate, choline, H
R2 = fatty acid
Sphingolipid Sterol
HO
 
Fig. 2. General chemical structures of the three major classes of lipids in an eukaryotic cell 
membrane 
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 However, intensive research on lipid metabolism and function has revealed 
that imbalances of the major lipid signaling pathways contribute to disease 
progression in chronic inflammation, autoimmunity, cancer, atherosclerosis 
hypertension, heart hypertrophy, and metabolic and degenerative diseases (18).  
 
1.3.1 Glycerophospholipids 
Glycerophospholipids (GP) are among the principal structural components of 
cells, and contain a highly diverse group of biological active molecules with a large 
number of molecular species. Beside their cell membrane barrier function, some 
members of the GP subclasses are mediators of molecular signaling for numerous 
cellular functions (19). A third and usually overlooked function is energy storage in 
the form of fatty acyl components, which is important under extreme conditions such 
as starvation (20). The present work focuses on a subclass of GPs, the so called 
polyglycerophospholipids, including phosphatidylglycerol (PG), 
bis(monoacylglycero)phosphate (BMP) and cardiolipin (CL) (Fig. 3). 
 
R O O
P
O
OH
P
O
O
HO
R O
O
O
O
O
R
R
O
O
OH
O
O
Cardiolipin
R = alkyl (long chain)
P
O
OH
O
OOR
O
HO
O
HO
R
O
Bis(monoacylglycero)phosphate
P O
O
HO
O
O
R
O
O
HO
HO
R
O
Phosphatidylglycerol
 
Fig. 3. Structures of polyglycerophospholipids 
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1.3.1.1 The metabolism of polyglycerophospholipids in mammalian cells 
Phosphatidylglycerol is synthesized at the cytosolic side of the endoplasmatic 
reticulum (ER) and mitochondria as a common precursor for BMP synthesis in 
endolysosomes and CL synthesis in inner mitochondrial membranes. 
Biosynthesis of PG in mammalian cells occurs via the cytidinediphosphate-
diacylglycerol (CDP-DG) pathway, first elucidated by Kennedy and coworkers in 1963 
(21). Phosphatidic acid (PA) serves as precursor for PG biosynthesis. The first step is 
the conversion of PA to CDP-DG by the enzyme CDP-DG synthase, which is 
localized in both mitochondria and microsomes (Fig. 4) (22). Subsequently, glycerol-
3-phosphate and CDP-DG are converted to phosphatidylglycerophosphate (PGP) by 
the sequential action of PGP synthase, followed by dephosphorylation by a yet 
unknown phosphatase to form PG (22). Finally, CL is synthesized by condensation of 
PG and one molecule CDP-DG at the mitochondrial inner membrane, a reaction 
catalyzed by the enzyme CL-synthase. In contrast, the biosynthetic pathway of BMP 
remains unknown and needs to be investigated. 
 
 
Fig. 4. Biosynthetic pathway of polyglycerophospholipids in mammalian cells. Adapted and 
modified from Hullin-Matsuda et al. (23). 
Cardiolipin (CL) 
Phosphatidyl- 
glycerol (PG) 
Mitos 
Bismonoacyl(glycero)- 
phosphate (BMP) 
ER/Mitos 
ER/Mitos 
ER/Mitos 
Late endosomes 
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Fig. 5. Possible remodeling pathways of CL in mitochondria. Adapted and modified from 
Hullin-Matsuda et al. (23). 
 
Two enzymatic activities acting in CL remodeling have been described to date 
in the mitochondria (Fig. 5): 1) Tafazzin (TAZ) is a mitochondrial Coenzyme A (CoA)-
independent, acyl-specific phospholipid transacylase with a substrate preference for 
CL and phosphatidylcholine (PC), 2) MLCL AT is a mitochondrial monolysocardiolipin 
(MLCL) acyltransferase requiring acyl-CoA (preferentially unsaturated acyl-CoA, like 
linoleoyl-CoA in the transfer of acyl chain to MLCL). 
The remodeling pathway also involves phospholipase A activity (like 
mitochondrial phospholipase A2) to deacylate CL into MLCL and acyl-CoA: 
lysophosphatidylcholine acyltransferase (LPCAT) to reacylate 
lysophosphatidylcholine (LPC) (22;23).  
 
1.3.1.2 The function of polyglycerophospholipids 
Phospholipids play an important role to maintain the structural integrity of 
biological membranes. These membranes compartmentalize the cell, which is 
essential to create different environmental conditions, such as pH and ion gradients, 
required for enzyme specificity and substrate/product specificity. 
Polyglycerophospholipids are widely distributed in animals, plants and 
microorganisms. PG can be found as a minor component of cellular phospholipids, 
mostly at the cytosolic side of the ER and mitochondria. BMP depicts less than 1% of 
total phospholipids in animal tissues, except for alveolar (lung) macrophages where it 
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makes 14-18% of total phospholipids (20). It is found at high concentrations in the 
lysosomal compartment, especially in late endosomes and in the acidic vesicular 
transport complexes (endosomal sorting complex required for transport (ESCRTs)), 
where BMP is involved in the formation of multivesicular membranes characteristic of 
late endosomes (23). Furthermore, BMP plays an important role during SL 
degradation. SL degradation occurs on the luminal surface of intra-endosomal and 
intra-lysosomal membrane structures (Fig. 6). During endocytosis, intra-lysosomal 
membranes are formed, and prepared for digestion by a lipid-sorting process during 
which their cholesterol content decreases and the concentration of the negatively 
charged BMP increases. Hence, SL degradation requires anionic phospholipids like 
BMP, and therefore SL and GL metabolism is linked (24). BMP has also been shown 
to regulate cholesterol transport by acting as a collection and distribution device (25). 
BMP plays an important role in the efficient partitioning of cholesterol in lipid 
membranes and the subsequent transport of cholesterol out of the internal 
membranes of the multivesicular bodies. Accumulation of cholesterol within BMP-rich 
internal membranes is predicted to alter membrane properties (26). Thus, BMP is a 
critical component of the endosomal/lysosomal network and essential for the correct 
function of this system (26). 
 
 
Fig. 6. Endocytosis and role of BMP. Adapted and modified from Matsuo et al. (27). 
BMP 
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In animals, CL is found in highest concentrations in cardiac muscle, hence this 
lipid class was called cardiolipin, and is exclusively found in the mitochondria (28). 
CL is intimately involved in different cellular processes including stabilization of the 
electron transfer complex and therefore preventing mitochondrial apoptosis (28).  
CL is involved in the transduction of electrons and the production of ATP via a 
complex mechanism (29). Recent studies by Jiang et al. (30) demonstrated that 
complete absence of CL in yeast mitochondria results in a partially defective protein 
import into mitochondria and a decreased mitochondrial membrane potential. These 
deficiencies are partially compensated by high levels of the precursor PG. However, 
the deficient ADP/ATP carrier activity and decreased mitochondrial membrane 
potential can not be restored through elevated levels of PG (30). Moreover, the 
unique structure of CL is suggested to function for the maintainance of the electron 
transfer complex for physiological ATP production (31). 
Beside its function in energy metabolism, CL serves as a central switch in the 
mitochondrial apoptotic program, controlling the initiation of this process at different 
levels. CL is closely associated with cytochrome c at the outer leaflet of the 
mitochondrial inner membrane. While CL peroxidation may be crucial for enabling 
cytochrome c dissociation from the mitochondrial inner membrane, cytochrome c 
itself catalyzes CL peroxidation. Moreover, peroxy-CL directly activates the release of 
cytochrome c and other apoptogenic factors from the mitochondria. CL is also 
directly involved in mitochondrial outer membrane permeabilization by enabling 
docking and activation of pro-apoptotic Bcl-2 proteins. It appears therefore that CL 
has multiple roles in apoptosis and that CL metabolism contributes to the complexity 
of the apoptotic process. This makes CL a potentially interesting target for 
therapeutical intervention in diseases in which cell death is deregulated, such as 
cancer (28;32;33). 
 
1.3.1.3 Role of polyglycerophospholipids in specific pathologies 
Peter Barth and his colleagues described about a quarter of a century ago, a 
Dutch family with a three-generation history of infantile cardiomyopathy, in which 
abnormal mitochondria were implicated (34). The disorder showed an X-linked 
recessive mutation in the taffazin gene, clinically characterized by heart failure, 
myopathy, neutropenia and abnormal growth (35). This disorder, known today as 
Barth syndrome, is characterized by an alteration in CL remodeling.  
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At the biochemical level, Barth syndrome is characterized by decreased levels 
of CL (28). Under normal conditions, CL is degraded to MLCL and then converted 
back into CL in order to exchange its fatty acids (Fig. 4). Barth fibroblasts and 
taffazin-deficient yeast showed highly increased levels of MLCL. In addition, a shift is 
observed in the degree of unsaturation of CL acyl chains (36;37). This observation in 
conjunction with the low CL levels suggested a decline in the rate of reacylation 
relative to the rate of deacylation (34). Therefore, the abberrations in CL are used as 
a diagnostic marker, which can be used to quickly screen for Barth syndrome (28). In 
addition Barth lymphoblasts, showed changes in the composition of all major 
mitochondrial phospholipids, PC, phosphatidylethanolamine (PE) and CL (38). The 
complementary nature of the fatty acid alterations in CL and PC suggested that fatty 
acid transfer between these two lipids was inhibited in Barth syndrome (38). 
The pathogenesis of Barth syndrome is still not well understood. It has been 
demonstrated that the activity of selected respiratory chain complexes is reduced in 
muscle biopsies of Barth syndrome patients. Recent studies have confirmed these 
findings and have shown that the reduced respiratory chain activity is caused by 
reduced stability of the oxidative phosphorylation supercomplexes, and therefore the 
loss of ATP production. This reduction in energy production is likely to be the primary 
cause of the (cardio)myopathy (28). 
Beside the Barth syndrome, no other pathological conditions have been 
described which have a primary deficiency in CL metabolism due to mutations in a 
single gene. Several pathological conditions, however, have been linked to CL 
abnormalities, including Tangier disease, diabetes and heart disease (39).  
Tangier disease (TD) is an inherited disorder of lipid metabolism characterized 
by very low high density lipoprotein (HDL) plasma levels, cellular cholesteryl ester 
accumulation and reduced cholesterol excretion in response to HDL apolipoproteins. 
Molecular defects in the ATP binding cassette transporter 1 (ABCA1) have recently 
been identified as the primary cause of TD. ABCA1 plays a key role in the 
translocation of cholesterol across the plasma membrane, and defective ABCA1 
causes cholesterol storage in TD cells. Phospholipid analysis showed a three- to 
fivefold increase in the levels of CL, MLCL and dilysocardiolipin (40). Therefore, it is 
suggested, that increased CL levels result in decreased mitochondrial cholesterol 
oxidation via the enzyme cholesterol 27-hydroxylase, and thereby a reduction of 
oxysterols which enhances cholesterol solubility and stimulate cholesterol efflux.  
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The Niemann Pick disease (NPD) is another cholesterol storage disorder. 
Patients with NPD Types A and B have an inherited deficiency of acid 
sphingomyelinase activity, which leads to accumulation of sphingomyelin in late 
endosomes/lysosomes (41). However, also other lipids particularly BMP has been 
found to accumulate in fibroblasts from patients with NPD (41). Genetic analysis 
revealed loss-of-function mutations in NPC1 and NPC2 genes as the molecular 
triggers for the disease. Although the precise function of these proteins has not yet 
been clarified, recent research suggests that they orchestrate cholesterol efflux from 
late endosomes/lysosomes. NPC protein deficits result in impairment in intracellular 
cholesterol trafficking and deregulation of cholesterol biosynthesis. Disruption of 
cholesterol homeostasis is also associated with deregulation of autophagic activity 
and early-onset neuroinflammation, which may contribute to the pathogenesis of 
NPC disease (41).  
 
1.3.1.4 Quantitative analysis of cardiolipin and metabolites by tandem 
mass-spectrometry 
Electrospray ionization mass spectrometry (ESI-MS) has emerged as a 
powerful tool for the qualitative and quantitative analysis of complex phospholipids 
(2;42). A number of methods were described for CL analysis based either on direct 
MS (43-45) or LC-MS (8;22;46;47). Since BMP and PG are structural isomers (Fig. 
4), a chromatographic separation for the simultaneous, mass spectrometric analysis 
for these lipids in the presence of each other is required (25). ‘Classical’ NP-
chromatography may be hampered by limited reproducibility, insufficient peak shapes 
and solvent mixtures incompatible for ESI-MS-analysis. Therefore RP-
chromatography up to date was prevalent for the simultaneous analysis of BMP and 
PG species (25) or CL (8;22). However, since RP- chromatography shows chain 
length-dependent separation, co-elution of analytes and internal standards may not 
be accomplished. Nevertheless, co-elution is of major importance for compensation 
of matrix effects and varying ionization efficiencies, especially during gradient elution. 
Due to the fact that up to now, methods for the combined analysis of BMP, CL, PG, 
and PA species are lacking, and RP-chromatography might not solve this problem, 
development of novel methods are essential.  
Additionally, MS-analysis of GP species may exhibit an isotope overlap due to 
a variable number of double bonds. A correction of this overlap is especially 
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important for high molecular weight lipids like CL. Most assays published up to now 
quantified CL from MS spectra which may be corrected by the isotope pattern of the 
molecular ion (2). Isotopic overlap in MS/MS experiments is more complex since 
isotope distributions of charged fragments and neutral fragments have to be 
considered (48). Omission of isotopic correction leads not only to mis-quantification 
but also to mis-identification of species.  
Taken together, it is imperative to use structure specific and sensitive LC-
MS/MS methods including isotopic correction, to investigate alterations in 
polyglycerophospholipid metabolism in patients. 
 
1.3.2 Sphingolipids  
 
1.3.2.1 Structure and metabolism 
 Sphingolipids (SLs) are structurally distinguished from other lipid classes by 
their sphingoid long chain base backbone, from which SLs derive their name (Fig. 2). 
As is the case for all membrane lipids, SLs are amphiphatic molecules that have both 
hydrophobic and hydrophilic properties. The biochemical pathways of SLs are well 
described (49;50). The intracellular sites of biosynthesis take place in the 
endoplasmic reticulum (ER), Golgi apparatus and lysosomes (49-51). De novo SL 
biosynthesis starts with the condensation of palmitoyl-CoA and serine (alternatively 
alanine and glycine can be transferred) catalyzed by three diefferent serine palmitoyl 
transferase (SPTLC 1-3) resulting in 3-ketosphinganine (Fig. 7). 3-Ketosphinganine 
is subsequently reduced to form sphinganine (SPA), which is then N-acylated by 
(dh)ceramide-synthases to form dhCer (50;51). In addition, Ceramide (Cer) can also 
be formed through the hydrolysis of more complex SLs, such as sphingomyelin (SM). 
Cer is the key molecule in the SL pathway and is the precursor for the following 
products: 
- Cer can be glucosylated by the transfer of a UDP-glucose or UDP-galactose 
donor to form glucosylceramide (GluCer) or galactosylceramide (GalCer) from 
which higher glycosylated SLs are formed (50). 
- Cer can be linked to phosphocholine via the enzyme SM synthase to form SM 
- Cer is phosphorylated to form ceramide-1-phosphate (Cer1P). 
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- Cer can be deacylated to sphingosine (SPH) by ceramidases, from which 
various forms are known, acting either at neutral, acid or alkaline pH (52).  
SPH produced from Cer can be phosphorylated to sphingosine-1-phosphate 
(S1P) by sphingosine-kinase (SK). Two mammalian isoforms of SKs are known, SK1 
and SK 2 (53;54). Since S1P is an important signaling lipid, serving as first and 
second messenger, regulation of its intracellular level is critical. Thus S1P can be 
either degraded by S1P-phosphatase to form the precursor SPH, or by S1P-lyase, 
which yields hexadecenal and phospohethanolamine (55;56) (Fig. 3). However, 
platelets lack S1P-lyase activity (57) and have highly active SK, so they accumulate 
high concentrations of S1P (58). 
 HSAN1 is an inherited neuropathy found to be associated with several 
missense mutations in the SPTLC1 subunit of serine palmitoyltransferase. HSAN1 
mutations induce a shift in the substrate specificity of SPT, which leads to the 
formation of the two atypical deoxysphingoid bases (DSBs) 1-deoxy-sphinganine and 
1-deoxymethyl-sphinganine. Both metabolites lack the C1 hydroxyl group of 
sphinganine and can therefore neither be converted to complex sphingolipids nor 
degraded. Consequently, they accumulate in the cell (59). 
 In summary, the biochemical pathway of SL biosynthesis and degradation 
have been fully described (50;51;55;60;61). Since disturbances within the SL 
pathway are associated to several diseases (17), the next challenge in this area is to 
understand how these pathways are regulated and integrated in metabolism. 
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Fig. 7. Biosynthesis and metabolism of SLs 
 PC: Phosphatidylcholine; DAG: Diacylglycerol 
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1.3.2.2 Sphingolipids as bioactive molecules 
The structural diversity of SLs is associated with equally diverse functions. 
Part of the reason for the recent explosion in SL biology is the role of these lipids in 
intracellular signaling, particularly of SPH, Cer, S1P, Cer1P and 
sphingosylphophorylcholine (SPC) (62). Cer, SPH and S1P are the best-studied 
bioactive SLs, and they exert opposite effects in many systems, with Cer and SPH 
usually inhibiting proliferation and promoting apoptosis, and S1P stimulating 
differentiation and suppressing apoptosis (56;62;63). Therefore, this so called 
“sphingolipid rheostat” can direct a cell towards either an apoptotic or a survival 
program (Fig. 8). It is well established that Cer signaling has been intimately involved 
in the regulation of cell growth, differentiation, senescence and apoptosis (51). 
Furthermore, Cer has several intracellular targets that mediate its apoptotic action, 
including the protein phosphatases, cathepsin and protein kinase. By contrast, 
specific intracellular targets of S1P have remained elusive. Moreover, subsequent 
release of S1P through membrane transporters might contribute to inside out 
protection against apoptosis through the stimulation of S1P receptors, the so called 
Edg-receptor family. Indeed, exogenous S1P has been shown to regulate the 
expression of pro apoptotic and anti apoptotic proteins (64). Thus, S1P can be seen 
as a tumor-promoting lipid involved in the regulation of proliferation. Therefore, S1P 
may be regarded as a biomarker for cancer (64). 
Furthermore, beside the role as “cancer lipid”, S1P regulates the induction of 
inflammation and atherosclerosis through the activation of specific G-protein-coupled 
receptors on the cells of the immune, cardiovascular and nervous system (65-67). 
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Fig. 8. The sphingolipid rheostat. Adapted from Pyne et al. (64) 
 
More recent studies have broadened the attention to additional bioactive SLs 
such as Cer1P, GluCer and SPC. Cer1P has been implicated in playing roles in 
inflammation, proliferation and vesicular trafficking. The formation of arachidonic acid 
(AA) via the activation of phospholipase A2 (PLA2) is the initial rate-limiting step in 
eicosanoid biosynthesis. Cer1P mediates the activation of PLA2 and therefore the 
release of AA in response to interleukin-β (68). Furthermore, Cer1P appears to act in 
a similar fashion to S1P. Thus, Cer1P has anti-apoptotic functions via the inhibition of 
protein phosphatase 1, which has been attributed to Cer induced apoptosis (50). 
Thus, both ceramide kinase and SK are emerging as key determinants of the 
balance between cell death and survival. GluCer has shown to be involved in post-
Golgi trafficking and in drug resistance (50;69). 
Interestingly, SPC seems to have cell type specific functions. In some cell 
types, SPC elicit similar cellular responses to those of S1P but in other cells these 
two lipids have opposite effects (70).  
 
1.3.2.3 Sphingolipids in disease 
Within the past decade, real progress has been made in our understanding of 
how SLs contribute to disease processes, which is leading to novel therapeutic 
approaches based on interventions in SL homeostasis. 
Since Cer, S1P and Cer1P are involved in cell death and survival, these lipids 
might be involved in the growth of cancer cells. These findings have led to the 
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realization that manipulating apoptosis via the inhibition or activation of distinct 
enzymes within the SL pathway (Fig. 5) could be a novel way of approaching cancer 
therapy. A number of studies have shown that Cer can have anti-carcinogenic 
activity. Direct administration of Cer analoga decreased tumor activity and therefore 
induced apoptosis in cancer cells (70). In addition, anticarcinogenic effects have 
been observed upon increasing Cer levels by slowing its conversion to GluCer via 
GluCer-synthase, or to SPH via ceramidases (18;70). Thus, a number of 
chemotherapeutic agents appear to be related to their ability to activate Cer-induced 
apoptosis. In contrast to Cer, S1P is a contributing factor in carcinogenesis (17;64). 
Further, human SK1 is upregulated in many cancers. SK1 upregulation often 
correlates with higher clinical grade and chemotherapy resistance, whereas inhibition 
of SK activity increases apoptosis and autophagy in cancer cells. Additional studies 
implicate SK1 in adhesion and migration of cancer cells, properties associated with 
metastatic potential (71). These findings demonstrate that SK1 functions as an 
oncogene (71) and therefore, SK became a target in cancer therapy. 
Beside their role in cancer, emerging data support a function for SLs in 
metabolic diseases including obesity, diabetes, atherosclerosis and metabolic 
syndrome (17). Overnutrition increases plasma non-esterified fatty acids (NEFAs). As 
a consequence, increased palmitate concentrations induce de novo SL biosynthesis 
via action of SPTLC. Especially, aberrant Cer biosynthesis and therefore alterations 
in key Cer-mediated signaling pathways are associated to obesity and insulin 
resistance which causes type 2 diabetis (17). Moreover, the inflammatory factor 
(TNFα) has been shown to affect SL synthesis by routes that include SK (55). Recent 
data implicate S1P and Cer1P in inflammation. S1P is associated to inflammation via 
cyclooxygenase (COX-2) upregulation and subsequent production of prostaglandin 
E2 (PGE2). A particularly interesting series of studies demonstrated that a related SL 
metabolite, Cer1P, participates in regulating the AA cascade via activation of 
cytosolic phospholipase A2 (cPLA2), the major enzyme for pro-inflammatory AA 
production in cells (17;55). Thus, aberrant production of SLs might also promote 
inflammation. 
Although roles for SLs in mediating apoptosis, cell proliferation and 
inflammation are increasingly well defined, other SL actions cannot be excluded from 
consideration in mediating metabolic disease pathology. In fact, recent data implicate 
SLs in other cell processes that will probably prove relevant to metabolic disease. 
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These functions include autophagy, an alternative route for cell death, 
atherosclerosis and mitochondrial function that is required for energy production. 
Further work is needed to elucidate these functions, mechanisms and contribution to 
the pathogenesis of metabolic syndrome (17;18). 
SL content in various tissues undergoes dramatic alterations in several 
diseases. A lot of research in this area is rapidly developing with assistance of novel 
technologies, including lipid MS. This technology is just beginning to provide more 
information in the field of “sphingolipidomics”. 
 
1.3.2.4 Mass spectrometric analysis of sphingolipid species 
During the last decade liquid chromatography coupled to MS/MS has become 
a powerful tool for SL analysis (12-15;72-78). However, either these methods do not 
cover a broad spectrum of SL metabolites or they show disadvantages like laborious 
sample preparation, time consuming LC-separation, high sample volumes or 
insufficient data validation. Furthermore these methods lack co-elution of internal 
standards and analytes. RP-chromatography in contrast to NP-chromatography, 
which offers polar head group specific separation, shows chain length-dependent 
separation of species (13;73;75;77). Especially for lipid analysis, coelution of lipid 
species and internal standards within a lipid class is of major importance, since many 
lipid species only differ by their chain length or saturation degree. Hence, commonly 
used RP-C18 columns (12-15;72;73;77) may lead to limited reproducibility and in 
mis-quantification.  
Although analysis of the “sphingolipidome” by shotgun approaches has been 
recently demonstrated for yeast (79), an analysis of a more complex SL pattern in 
mammalian systems may be hampered, especially for minor metabolites, by signal 
suppressing matrix effects or lack of sensitivity (13;73;74). To understand regulatory 
and metabolic mechanisms involved in cellular SL homeostasis, specific, accurate 
and sensitive methods are necessary. Furthermore, “sphingolipidomic” studies in 
huge clinical trials require high sample throughput.  
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1.3.3 Bile acids 
 
1.3.3.1 Structure and biosynthesis 
Bile acids (BAs), together with cholesterol, phospholipids and bilirubin, 
comprise the principal constituents of bile (80). BAs were first isolated from bile early 
in the 19th century, and the field of bile acid chemistry preceded the development of 
classical biochemistry. Bile acids are amphipathic molecules with a steroid backbone 
that are synthesized from cholesterol exclusively in parenchymal cells (hepatocytes) 
of the liver and are subsequently stored in the gall bladder (81). The great number of 
BAs and bile alcohols with a surprising complexity in structure (Fig. 9) occurring in 
nature can be explained by the evolution of multiple biochemical pathways that serve 
to convert cholesterol, a poorly water soluble membrane lipid, into conjugated BAs or 
bile alcohols (82). BAs and alcohols are characterized by a highly water-soluble, 
amphipathic, membranolytic structure (Fig. 9). Beside their role as “cholesterol-
solubilizer”, BAs are involved in nascent bile formation and intestinal absorption of 
lipids and lipid-soluble molecules. Various transport proteins have been identified in 
the liver, which are tightly regulated by nuclear receptors such as the bile acid 
nuclear receptor Farnesoid X Receptor (FXR) and the Liver X Receptor (LXR) (83). 
Currently, BAs are also increasingly recognized as signaling molecules in a wide 
range of fields, such as energy homeostasis and metabolism of glucose and lipids. 
Bile acid-mediated activation of FXR is a major underlying pathway for these effects 
(80).  
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Fig. 9. Structure and nomenclature of BAs. 
 
BA synthesis is the primary pathway for cholesterol catabolism. Approximately 
500 mg of cholesterol is converted into BAs each day in the adult human liver (80). 
BA biosynthesis involves modification of the ring structure of cholesterol, oxidation 
and shortening of the side chain, and finally conjugation of BAs to amino acids (84) 
(Fig. 10). The major primary BAs are CA and CDCA (85).  
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Fig 10. Biosynthesis of bile acids. Reactions are numbered in bold type. The modifications 
introduced by an individual enzyme are indicated in red on the product of the reaction. 
Cumulative changes to the ring structures are indicated in green. 
Adapted from Russell et al. (85). 
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The steps leading to the formation of these molecules can be divided into two 
categories: those that modify the cyclopentanoperhydrophenanthrene ring or nucleus 
(Fig. 10) or those that oxidize and shorten the 8 carbon atom side chain of the sterol 
(not shown). The first step in modification of the ring structure (reaction 1, Fig 10) 
involves the introduction of a hydroxyl group at the position C-7 of cholesterol. This 
reaction is catalyzed by a unique cytochrome P-450 enzyme, cholesterol 7α-
hydroxylase, and utilizes molecular oxygen, NADPH, and a protein cofactor, 
cytochrome P-450 reductase. In the second step of the BA pathway, 7α-
hydroxycholesterol is acted upon by a microsomal 3β-hydroxy-C27- steroid 
oxidoreductase (reaction 2, Fig. 10). This reaction utilizes NAD+ as a cofactor. The 
7α-hydroxy-4-cholesten-3-one product of 30-hydroxy-C27-steroid oxidoreductase can 
take one of two paths in BA biosynthesis (Fig. 10). If this intermediate is acted upon 
by the second microsomal cytochrome P-450 enzyme of the pathway, sterol 12α-
hydroxylase (reaction 3, Fig. 10), then the resulting product is ultimately converted 
into CA. 7α-hydroxy-4-cholesten-3-one can alternatively serve as a substrate for a 
soluble 3-oxosteroid-5β-reductase (reaction 4, Fig. 10) to yield a sterol intermediate 
that is ultimately converted into CDCA. The products of the 3-oxosteroid-5β-
reductase reactions are the substrates for a soluble 3α-hydroxysteroid-
dehydrogenase enzyme (reaction 5, Fig. 10). The products of the 3α-hydroxysteroid-
dehydrogenase reaction next undergo oxidation and shortening of the side chain 
(85). Newly synthesized free BAs will be extensively conjugated (98%) into glycine- 
and taurine-conjugates.  
In the intestinal lumen, especially in the colon, gut flora deconjugates, oxidizes 
and dehydroxylates the primary BAs produced in the liver to generate secondary 
BAs. Once transported back to the liver, these secondary BAs can be further 
processed to form tertiary BAs, which represent only a marginal BA species under 
normal conditions. These synthesis and metabolic pathways allow the generation of 
more than 18 different BA species, which ensures the perfect solubilization and 
absorption of a broad range of lipophilic molecules in the intestine and a multitude of 
signaling activities in the body (80).  
 
1.3.3.2 Enterohepatic circulation 
To ensure the presence of adequate concentrations of these biologically 
active compounds at the sites of their actions, i.e. liver, biliary tract, and intestine, 
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BAs are maintained within the enterohepatic circulation by the combined actions of 
transporter systems in the liver and intestine (81). The primary transporter 
responsible for canalicular bile salt secretion is the bile salt export pump (BSEP). 
This membrane transporter belongs to the ATP-binding cassette (ABC) superfamily 
of proteins and therefore BSEP plays a critical role in the physiologic maintenance of 
the enterohepatic circulation of bile acids (86). 
The key components of the enterohepatic circulation are the synthesis of 
primary BAs and efficient intestinal absorption. The synthesis of primary BAs 
replaces the small amount of BAs not absorbed by the intestine. Intestinal absorption 
results in a recycling pool of BAs, permitting each BA to serve its function multiple 
times. Both the synthesis (input) of primary bile acids and intestinal absorption are 
highly regulated (82).  
 
1.3.3.3 Roles of nuclear hormone receptors 
BAs and oxysterols derived from cholesterol are signaling molecules that 
regulate cholesterol homeostasis in mammals. Many nuclear receptors play pivotal 
roles in the regulation of BA and cholesterol metabolism (87). BAs activate the 
farnesoid X receptor (FXR) to inhibit transcription for cholesterol 7-hydroxylase, and 
stimulate excretion and transport of BAs. Therefore, FXR is a BA sensor that protects 
the liver from accumulation of toxic bile acids and xenobiotics. Oxysterols activate the 
liver X receptors (LXR) to induce cholesterol 7-hydroxylase and ATP-binding 
cassette transporters and thus promote reverse cholesterol transport from the 
peripheral tissues to the liver for degradation to BAs. Therefore, FXR and LXR play 
critical roles in coordinated control of BA, cholesterol, and triglyceride metabolism to 
maintain lipid homeostasis. Nuclear receptors and BA/oxysterol-regulated genes are 
potential targets for developing drug therapies for lowering serum cholesterol and 
triglycerides and treating cardiovascular and liver diseases (87). 
 
1.3.3.4 Bile acids in diseases 
BAs are highly biologically active compounds and are therefore involved in 
several diseases. Some of the most common disease associations to BAs and 
possible drug targets are described in the following. 
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BA pathochemistry occurs in inborn errors of BA biosynthesis and conjugation. 
As around 14 enzymes are involved in the conversion of cholesterol to BAs (85), 
inborn errors of BA biosynthesis are not uncommon (88). Because of lack of 
feedback regulation by the end product of BA biosynthesis, there may be striking 
increase in the formation of intermediates. These intermediates accumulate in the 
hepatocytes inducing necrosis and or apoptosis (88).  
The essential physiologic function of BSEP in hepatobiliary bile salt secretion 
is apparent in several forms of cholestasis where BSEP gene mutations have been 
identified. A common result of these various gene mutations is the reduction or the 
total loss of expression of the BSEP protein on the canalicular membrane (86). 
Cholestasis results in intra-hepatic and systemic accumulation of substances 
normally secreted into bile (81). Particularly, accumulations of detergent BAs in 
millimolar amounts may lead to liver cell damage, inflammation, and eventually organ 
failure (81). Treatment options are very limited and, apart from liver transplantation 
for some of the inherited forms of cholestasis, mainly aimed at reduction of 
symptoms. 
BAs have been reported to reduce diet-induced obesity and prevent 
hyperglycaemia, which suggests that they also have effects on energy homeostasis 
(89). This metabolic effect is highly dependent on induction of the cAMP-dependent 
thyroid hormone-activating enzyme type 2 iodothyronine deiodinase (D2), as this 
effect is lost in D2-knockout mice (80). 
In addition to their pleiotropic effect on lipid homeostasis, BAs also affect 
glucose metabolism and therefore play an important role in dyslipidaemia and type 2 
diabetes (90). However, the exact mechanism in mediating the effects of BAs on 
glucose homeostasis still remains unclear and needs to be further investigated (80).  
From what is currently known, it is clear that FXR activation could have some 
interesting therapeutic applications. Through stimulation of BA conjugation and 
secretion from hepatocytes into the bile to enhance bile flow, FXR agonists could 
protect the liver against the hepatotoxic accumulation of BAs that is seen in 
cholestatic liver diseases such as primary biliary cirrhosis (91). FXR activation could 
also be beneficial to reduce levels of liver and serum triglyceride in conditions such 
as the metabolic syndrome, type 2 diabetes, and obesity (91). Also, the FXR-
dependent increases in biliary BAs and phospholipids could restore cholesterol 
solubility in the bile and thereby prevent gallstone formation (92). In bile, cholesterol 
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is solubilized in mixed micelles together with bile salts and phospholipids. Under 
supersaturated conditions, the sterol is solubilized by phospholipids into vesicles, 
called liquid crystals. As monohydrate crystals enucleate from these cholesterol-
enriched vesicles, they aggregate, fuse and eventually precipitate into larger 
pathogenic crystals which lead to the disease (92). 
 
1.3.3.5 Bile acids analysis by LC-MS/MS 
The study of BA functions requires methods which cover the complexity of this 
structurally diverse group of molecules. A number of methods using LC-MS/MS were 
developed allowing analysis of free and conjugated BAs without derivatization (93-
104). Nevertheless, most methods show disadvantages with time consuming 
extraction procedures (93;96;105), long analysis times (94-96;102-106) or lack of 
baseline separation of isobaric species (93;96;97;105;106). Direct BA analysis by 
ESI-MS/MS does not allow identification of isobaric species (107). For routine BA 
analysis, high sample throughput is of major importance. Hence, it is imperative to 
develop a LC-MS/MS based method with a run-time below 10 min including baseline 
separation of isobaric species. This method should be applied for BA routine 
diagnostics, as well as for the determination of bile acid species in huge clinical trials. 
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1.4 Scope and Objectives 
Biologically active lipids including SPH, S1P, Cer1P, PG, BMP, CL and BAs 
are involved in a multitude of important cellular functions such as migration, 
proliferation and apoptosis. Moreover, these lipids are partially ubiquitous lipid 
messengers, which function as ligands for G-protein-coupled receptors and mediate 
important physiological processes. Therefore, SLs, polyglycerophospholipids and 
BAs are known as potential biomarkers for various diseases, including 
atherosclerosis, obesity, inflammation, diabetes and cancer. To understand the 
differential role of these lipids in a regulatory network involved in cellular lipid 
homeostasis it is important to use structure-specific and quantitative methods. 
During the last decade liquid chromatography coupled to tandem MS (LC-
MS/MS) has become a powerful tool for lipid species analysis. However, existing 
methods for the analysis of the above mentioned lipids, show disadvantages like 
laborious sample preparation, time consuming LC-separation, high sample volumes 
or insufficient validation data. Therefore, high sample throughput may not be 
accomplished. Furthermore most of these methods lack co-elution of analytes and 
internal standard, a prerequisite for targeted lipid species analysis. 
Major aim of the present work was to develop novel LC-MS/MS methods for 
the analysis of GLs, SLs and BAs from biological materials. These methods should 
be characterized by high sample throughput, co-elution of analytes and internal 
standards, an easy sample preparation and an automated data analysis, to enable 
biomarker screening in huge clinical trials. 
Thus, the first aim of this thesis was to develop LC-MS/MS-methods for the 
simultaneous quantification of SLs and metabolites. Beside blood plasma SLs should 
be monitored in other biological matrices, such as cellular homogenates and tissues. 
Furthermore the present work aimed at the development of a fast and 
sensitive LC-MS/MS-method for the quantification of BA species in human plasma 
samples. This method should be validated according to FDA-guidelines for the 
application as a diagnostic parameter in the routine laboratory. 
Additionally, a method for the simultaneous identification and quantification for 
CL and metabolites should be developed. This method should be applied for 
monitoring alterations in the polyglycerophospholipid metabolism in different cell 
types and tissues. Moreover, since istopic overlap is a major problem, especially for 
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high molecular weight lipids like CL, this method should comprise, for the first time, 
correction for the complex isotope overlap of MS/MS experiments. 
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2 Simultaneous Quantification of Cardiolipin, 
Bis(monoacylglycero)phosphate and their Precursors 
by Hydrophilic Interaction LC-MS/MS including 
Correction of Isotopic Overlap 
 
2.1 Abstract 
 
Cardiolipin (CL) and bis(monoacylglycero)phosphate (BMP) are unique lipid 
structures with important biological roles for mitochondrial integrity and 
endolysosomal degradation, respectively. They are synthesized from common 
precursors, phosphatidylglycerol (PG) and phosphatidic acid (PA). Here we present a 
rapid method for the simultaneous quantification of BMP, CL, PG, and PA using 
hydrophilic interaction chromatography coupled with electrospray ionization tandem 
mass spectrometry (HILIC-MS/MS). HILIC provides co-elution of lipid species and 
their internal standards required for accurate quantification. Co-elution leads to 
isotope overlap of lipid species which was successfully corrected. This assay was 
validated in mouse heart tissue and primary human skin fibroblasts. It shows 
reproducibility and limits of detection sufficient for biomarker studies contributing into 
basic research on BMP and CL metabolism. 
 
2.2 Introduction 
 
Due to their unique molecular structures cardiolipin (CL) (1) and 
bis(monoacylglycero)phosphate (BMP)(2) play important roles in the mitochondrial 
electron transfer complex assembly and integrity and late endosomal lipid sorting and 
degradation  pathway (3), respectively. They are synthesized from 
phosphatidylglycerol (PG) which is formed from phosphatidic acid (PA) (4;5). 
However, biosynthesis of both CL and BMP is not well understood. The biological 
importance of these lipids is highlighted by their usage as biomarkers. For example, 
in Barth syndrome, CL concentration is reduced and CL species composition is 
altered (6;7). BMP is described as marker for lysosomal storage disorders and drug-
induced phospholipidosis(2;8). Since the biophysical properties of phospholipid 
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species also depend on the chain length and number of double bonds it is important 
to get access to lipid species to fully understand their function. 
In the last years electrospray ionization mass spectrometry has emerged as a 
powerful tool for the qualitative and quantitative analysis of complex phospholipids 
(9;10). A number of methods were described for CL analysis based either on direct 
mass spectrometry (MS) (11-13) or liquid chromatography coupled to MS (6;7;14;15). 
BMP analysis requires chromatography to separate the structural isomer PG (8). 
However, till now methods for the combined analysis of BMP, CL, PG, and PA 
species are lacking. 
Here we describe a method for the fast, simultaneous, quantification of BMP, 
CL, PG, and PA species in biological samples. This method applies hydrophilic 
interaction chromatography (HILIC) coupled to electrospray ionization tandem mass 
spectrometry including correction of isotope overlap. 
 
2.3 Experimental section 
 
2.3.1 Reagents 
Butanol, methanol (HPLC grade), citric acid monohydrate, disodium 
hydrogenphosphate and formic acid (98-100 %, for analysis) were purchased from 
Merck (Darmstadt, Germany). Water was obtained from B. Braun (Melsungen, 
Germany). Ammonium formate (Fluka, Buchs, Switzerland), were of the highest 
analytical grade available. Synthetic glycerophospholipids including CL (14:0)4, CL 
(14:1)3/15:1, CL (15:0)3/16:1 CL (18:1)4, PA 14:0/14:0, PA 16:0/16:0, PA 18:1/18:1, 
PA 18:0/20:4, PG 14:0/14:0, PG 16:0/16:0, PG 18:1/18:1, PG 18:0/20:4, BMP 
14:0/14:0, BMP 16:0/16:0, BMP 16:0/17:0 and BMP 18:1/18:1 were purchased from 
Avanti Polar Lipids, Inc. (Alabaster, AL, USA). Concentrations of lipid standard 
solution were determined by phosphorous assay (16). 
 
2.3.2 Sample preparation 
Aliquots of 50µg protein from fibroblast homogenates and 2.5mg wet weight 
from mouse heart tissue were used for analysis. 20µL of an internal standard mixture 
containing 20ng PA 28:0, 10ng PG 28:0, 10ng BMP 14:0/14:0 and 10ng CL (14:0)4 
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were added prior to lipid extraction. We applied a butanolic extraction procedure 
described by Baker et al. (17). In brief, 500µl cell homogenate or heart tissue were 
mixed with 60µL of buffer containing 200mM citric acid and 270mM disodium 
hydrogenphosphate (pH 4). Extraction was performed with 1mL of 1-butanol and 
500µL of water-saturated 1-butanol. The recovered butanol phase was evaporated to 
dryness under reduced pressure. The residue was re-dissolved in 50µL ethanol.  
 
2.3.3 HILIC-MS/MS 
Glycerophopholipid analysis was performed with hydrophilic interaction liquid 
chromatography-tandem mass spectrometry (HILIC-MS/MS). The LC equipment 
consisted of a 1200-series binary pump, a 1200-series isocratic pump and a 
degasser (Agilent, Waldbronn, Germany) connected to an HTC Pal autosampler 
(CTC Analytics, Zwingen, Switzerland). A hybrid triple quadrupole linear ion trap 
mass spectrometer API 4000 Q-Trap equipped with a Turbo V source ion spray 
operating in positive ESI mode was used for detection (Applied Biosystems, 
Darmstadt, Germany). Positive electrospray ionization was carried out at 5500V and 
the ion source was maintained at 500°C. Both quadru poles Q1 and Q3 were 
operated at a mass resolution of 0.5 Da FWHM with 5ms dwell time. The MRM mode 
was used with the parameters displayed in Table S-1. CL and BMP were analyzed 
using the DAG and MAG fragment with the lower molecular weight, respectively. The 
MS program was divided into two periods with an initial monitoring of PG and BMP 
and an analysis of PA and CL after 1.5min.  
Gradient chromatographic separation was performed on a Kintex 
(Phenomenex, Waldbronn, Germany) hydrophilic-interaction chromatography (HILIC) 
silica column (50 x 2.1mm), with a 2.6µm particle size equipped with a 0.5µm pre-
filter (Upchurch Scientific, Oak Harbor, WA, USA). The injection volume was 3µL and 
the column was maintained at 50°C. The mobile phase  consisted of water containing 
0.2% formic acid and 200mM ammonium formate (eluent A) and acetonitrile 
containing 0.2% formic acid (eluent B). A gradient elution was performed with 100% 
B for 0.2min, a step to 82% B until 2min, a linear increase to 50% B until 3min, 50% 
B up to 4min and re-equilibration from 4.1 to 4.5min with 100% B. The flow rate was 
set to 800µL/min. To minimize contamination of the mass spectrometer, the column 
flow was directed only from 1.0 to 3.0min into the mass spectrometer using a diverter 
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valve. Otherwise methanol with a 250µL/min flow rate was delivered into the mass 
spectrometer. 
 
2.3.4 Calibration 
Calibration was achieved by standard addition of naturally occurring 
glycerophospholipid species (PA 32:0, 36:2, 38:4; BMP 32:0, 36:2; PG 32:0, 36:2, 
38:4; CL (18:1)4, (15:1)316:1). A six point calibration was performed by adding the 
indicated amounts of a combined glycerophospholipid standard mixture to matrix 
samples. Calibration curves were calculated using linear regression analysis (Table 
S-2). The closest related calibration line was used for quantification of not calibrated 
species. For BMP and CL differences between symmetric and asymmetric species 
responses were corrected by a factor 2. 
 
2.3.5 Species identification 
Lipid extracts from the primary human skin fibroblasts and mouse heart tissue 
were used for glycerophopholipid species identification. CL and BMP molecular 
species were identified using an information dependent acquisition method (IDA), 
which included a survey scan in the enhanced MS (EMS) followed by an enhanced 
product ion scan (EPI) on the largest ions in the EMS scan. The EMS scan was 
performed at a rate of 1000Da/s at a spectral range of 1400-1600 for CL and 700-
900 for BMP. The EPI scan was performed at a scan rate of 1000Da/s at a spectral 
range of m/z 400-700 for CL and m/z 300-400 for BMP. PA and PG molecular 
species were identified by neutral loss scans of m/z 115 and 189, respectively. 
Detected molecular species were quantitated by MRM in fibroblast and mouse heart 
tissue lipid extracts (Table S-3 and 4). 
 
2.3.6 Correction of isotopic overlap 
The principle of isotopic overlap in MS/MS experiments were described by 
Ejsing et al. (18). Isotope pattern for the neutral fragments N (precursor overlap) and 
the charged fragments F (product overlap) used for analysis were calculated with the 
software tool implemented in Analyst (Applied Biosystems, Darmstadt, Germany). 
Previously established Excel Macros for the correction of isotopic overlap of 
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phosphatidylcholine and sphingomyelin (19) were adapted to correct both precursor 
and product isotopic overlap using a sequential algorithm starting from low mass 
species. Isotopic overlap resulting from the following isotope combinations were 
corrected: F2,4N0 and F0N2,4 as well as the overlap resulting from F2N2 (F2 = charged 
fragment containing two isotopes). 
 
2.4 Results and discussion 
 
2.4.1 Fragmentation of CL and related lipids 
Almost all previously published methods of quantification of CL, PG, BMP, and 
PA used negative ion mode (6-8;11-15;18;20-22). We tested ionization and 
fragmentation of these lipid classes in positive ion mode, avoiding positive-negative 
ion mode switching. In ammonium formate containing solvent, PG, BMP, and CL 
form both protonated and ammonia adduct ions whereas for PA only ammonia 
adducts were observed. Both protonated (data not shown) and ammonia adduct ions 
(Figure S-1) showed the similar fragment patterns. CL forms prominent diacylglycerol 
(DAG) fragment ions leading to two different product ions for asymmetrical CL 
species (Figure S-1A). PA exhibits a neutral loss of m/z 115 of the ammonia 
phosphate head group resulting in a DAG fragment (Figure S-1B) (22). The structural 
isomers BMP (Figure S-1C) and PG (Figure S-1D) differ in their fragment patterns 
showing MAG and DAG as major fragment ions, respectively. While the observed 
neutral loss of m/z 189 is specific to PG (22), PG species also form MAG fragments 
(8) (Fig. 2B). Thus, a specific determination of BMP requires separation from PG. 
Finally, we optimized MS/MS parameter for both protonated and ammonia adduct 
ions and found a higher sensitivity for ammonia adduct ions except for BMP (data not 
shown; MS-parameter see in Table S-1). Moreover, a higher sensitivity was found for 
positive compared to negative ion mode analysis (data not shown). Positive ion mode 
detection of CL has the advantage that only singly charged ions were observed 
compared to singly and doubly charged ions in negative ion mode (7;12;14;15). The 
ratio of singly to double charged ions is instrument design dependent and analysis of 
doubly charged ions requires a higher than unit resolution (15). This means that up to 
now assays for CL quantification are based on MS but not on MS/MS data 
(7;12;14;15;23). 
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2.4.2 Chromatography 
Due to the mass spectrometric interferences of PG with BMP analysis and in 
order to reduce ionization suppressions by matrix compounds, we established an LC 
separation for CL, PG, BMP, and PA. Since reversed phase chromatography shows 
chain length dependent separation, co-elution of analytes and internal standards may 
not be accomplished (6;14). However, co-elution is of major importance for 
compensation of matrix effects and varying ionization efficiencies, especially during 
gradient elution. ‘Classical’ normal-phase chromatography may be hampered by 
limited reproducibility, insufficient peak shapes and solvent mixtures incompatible for 
ESI-MS-analysis. Therefore, we developed a LC-separation based on hydrophilic 
interaction chromatography (HILIC) which provides co-elution of analyte species and 
internal standards within a given lipid class (Fig. 1). Moreover, we achieved excellent 
peak shapes, especially for BMP, PG and CL as well as baseline separation for PG 
and BMP within 4.5 min (including re-equilibration).  
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Fig. 1. BMP, PG, CL, PA chromatogram of a mouse heart tissue. 
Representative mass chromatograms obtained from a mouse heart tissue lipid extract are displayed.  
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2.4.3 Correction of isotope overlap 
HILIC provides co-elution of lipid species within each lipid class. 
Consequently, we observed an isotope overlap of species due to a variable number 
of double bonds. A correction of this overlap is especially important for high 
molecular weight lipids like CL. Most assays published up to now quantified CL from 
MS spectra which may be corrected by the isotope pattern of the molecular ion (9). 
Isotopic overlap in MS/MS experiments is more complex since isotope distributions of 
charged fragments and neutral fragments have to be considered (18). To illustrate 
isotopic overlap we acquired a product ion spectrum of monoisotopic CL (18:1)4 
which revealed only one signal at m/z 603.5 (Fig. 2A). However, the product ion 
spectrum of the M+2 isotope of CL (18:1)4 showed signals at m/z 603.5, 604.5 and 
605.5, corresponding to [DAG 36:2]+, [DAG 36:2 + 1]+ and [DAG 36:2 + 2]+ fragment 
ions, respectively (Fig. 2B). 
There are two types of isotope overlaps which need to be considered during 
quantitative analysis. One, termed as precursor-overlap, is due to isotopes in the 
neutral fragment (N0) but not in the product ion used for analysis (Fig. 3A), as for 
example observed for the M+2 isotope of CL 34:2/36:3 with CL 34:2/36:2 analyzed 
using the same product ion. The second type, termed as product-overlap, is derived 
from isotopes present in the charged product ion (F2) used for analysis (Fig. 3B). We 
calculated isotope profiles for both types of overlaps using Excel Macros for peak 
area corrections. BMP isotope overlaps were corrected similarly. 
In order to validate this approach, precursor- and product-overlaps were 
determined experimentally. The standard mixtures containing the symmetric species 
BMP 18:1/18:1 and CL (14:0)4 as well as the asymmetric species BMP 16:0/17:0 and 
CL (14:1)3(15:1) were analyzed. Both measured precursor- and product-overlaps 
resemble the theoretically calculated isotope profiles (Tab. 1). We analyzed mouse 
heart tissue and cultured human skin fibroblast with and without isotopic correction. 
Omission of isotopic correction leads not only to mis-quantification but also to 
misidentification of species. For example, 11 CL species in heart and 7 CL species in 
fibroblast would have been identified erroneously above detection limit without 
correction of isotope overlap (Table S-3 and 4). Since PA and PG molecular species 
are characterized by a specific neutral loss scan of m/z of 115 and 189, respectively, 
only a product-overlap has to be considered. 
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Fig. 2. Product ion spectra of CL (18:1)4. 
Product ion spectra of CL (18:1)4 of the monoisotopic [M+NH4]+ (Panel A) and the isotope +2 
[M+2+NH4]+ precursors (Panel B) obtained in the positive ionization mode are presented. 
Panel B shows the signals corresponding to the precursor- and the product-overlaps.  
 2. CL and BMP analysis by HILIC-MS/MS 49 
 
O O
P
O
OH
P
O
O
HO
O
O
O
O
O
O
O
NH4+
OH
O
O
[N0-F0]+ [F0]+
[N0-F2]+ [F2]+
CL 34:1/36:3
1447 575.5
CL 34:2/36:3
Product-overlap
[N0-F0]+ [F0]+
[N2-F0]+ [F0]+
CL 34:2/36:2
CL 34:2/36:3
Precursor-overlap
575.5
O O
P
O
OH
P
O
O
HO
O
O
O
O
O
O
O
NH4+
OH
O
O
577.5
mass transition:
1447 577.5mass transition:
A
B
F0
N2
F2
N0
 
Fig. 3. Structure and isotope distribution in CL 34:2/36:3. 
Panel A shows the structure, isotope distribution and the corresponding mass transition for 
the precursor-overlap.  
Panel B shows the structure, isotope distribution and the corresponding mass transition for 
the product-overlap.  
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Table 1. Isotope overlap 
Analyte 
Spiked amount 
[ng/ml] 
Analyte area 
[cps *103] 
Precursor-overlap [%] Product-overlap [%] 
measured theoretical measured theoretical 
BMP 16:0/17:0 250 382 ± 1 4.18 ± 0.33 3.91 2.71 ± 0.15 2.82 
 500 756 ± 39 4.01 ± 0.17 3.91 2.68 ± 0.05 2.82 
BMP 18:1/18:1 250 1020 ± 10 4.55 ± 0.22 4.16 3.17 ± 0.14 3.32 
 500 2025 ± 67 4.49 ± 0.11 4.16 3.15 ± 0.07 3.32 
CL (14:0)4 250 942 ± 80 10.75 ± 0.98 10.16 7.06 ± 0.53 6.82 
 500 1967 ± 35 10.69 ± 0.43 10.16 7.35 ± 0.30 6.82 
CL (14:1)3(15:1) 250 23.8 ± 1.6 11.14 ± 1.21 10.59 7.08 ± 0.98 6.80 
 500 44.8 ± 2.3 10.36 ± 0.5 10.59 6.80 ± 0.65 6.80 
A standard mixture spiked with the indicated concentration of BMP 16:0/17:0, BMP 18:1/18:1, CL (14:0)4, CL (14:1)3(15:1) was analyzed in a 
triplicate measurement. Precursor-overlap percentages were calculated as the peak areas of the [N2F0]+ → [F0]+ mass transition related to the 
monoisotopic mass transition. Product-overlap percentages were calculated as the peak areas of the  
[N0F2]+ → [F2]+ mass transition related to the monoisotopic mass transition. 
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2.4.4 Quantification 
For quantification purposes, the analytical response of glycerophospholipid 
species may depend on their degree of saturation and their fatty acid chain length 
(12;15;24). Thus, we established calibration lines by addition of saturated and 
unsaturated species (Table S-2). The calibration lines were linear in the tested 
concentration range with correlation coefficients >0.992. Polyunsaturated species 
showed a lower response compared to more saturated species. It is important to 
keep in mind that symmetric CL and BMP species show a double response 
compared to asymmetric species since both moieties of these species generate the 
same DAG and MAG fragment, respectively. Concentrations of the 
glycerophospoholipid species were calculated using the closest related calibration 
slope.  
 
2.4.5 Method validation 
Finally, we performed method validation in the samples of cultured primary 
human skin fibroblasts and mouse heart tissue. Overall precision showed CVs <9%, 
for the major, and <13%, for the minor species (Tables S-3 and -4). Limits of 
detection ranged from 1.5fmol for PA up to 119fmol for BMP species (Table S-1). 
Extraction efficiencies were between 60%, for the apolar CL, and up to 80%, for the 
polar PA species (Table S-5). The influence of the sample matrix on the signal 
intensities was similar in fibroblasts lysed in SDS and mouse heart tissues (data not 
shown). While the presence of the biological matrix showed no effect on BMP and 
slight signal suppression on CL (10%), PA and PG signals were enhanced up to 40% 
(Table S-5).  
 
2.5 Conclusion 
 
We developed a novel LC-MS/MS method for the quantification of PA, PG, 
BMP, and CL species in biological samples. This method shows a number of 
improvements compared to other existing methods. Moreover, a combined, rapid and 
sensitive quantification method of these biologically important lipid classes does not 
exist till now. Quantification of CL from MS/MS data provides information about the 
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DAG moieties, in contrast to summary composition derived from MS analysis. We 
could show that HILIC allows co-elution of analytes and internal standards, in our 
opinion, a prerequisite for quantification. This co-elution necessitates a correction of 
isotopic overlap of the species which differ in one double bond. Here we applied and 
validated previously described principles of isotope overlap in MS/MS experiments 
(18). As shown for CL, these corrections are required for accurate quantification and 
identification of lipid species.  
Finally, it should be mentioned that this method can be easily combined with 
previously established HILIC-MS/MS methods for lysophosphatidic acid and 
sphingolipid profiling (25;26), since the same butanolic extracts are used for all 
assays. 
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2.7 Supporting Information 
 
Table S-1. MS parameter and limit of detection (LOD) of glycerophospholipids studied.  
Lipid class MRM IS  
(MRM) 
CE 
[V] 
RT 
[min] 
LOD (n=3) 
[fmol] 
PA [M+NH4]+→DAG 
NL m/z 115 
PA 14:0/14:0 
(610.5→495.5) 
25 1.79 1.5 ± 0.3 
PG [M+NH4]+→DAG 
NL m/z 189 
PG 14:0/14:0 
(684.5→495.5) 
27 1.51 91 ± 14 
BMP [M+H]+→MAG BMP 14:0/14:0 
(667.5→285.3) 
37 1.41 119 ± 12 
CL [M+NH4]+→DAG CL 28:0/28:0 
(1259.0→495.5) 
43 1.75 36 ± 2 
MRM = multiple reaction monitoring, IS = internal standard, CE = collision energy, RT = 
retention time. LODs (injected amount) were calculated as a signal to noise ratio of 3. 
 
Table S-2. Calibration data 
Analyte Calibration range 
[pmol] 
Slope  
(mean ± S.D.) 
Correlation coefficient  
(mean ± S.D.) 
PA 16:0/16:0 4.0 – 40 0.0670 ± 0.005 0.992 ± 0.003 
PA 18:1/18:1 4.9 – 49 0.0678 ± 0.006 0.995 ± 0.002 
PA 18:0/20:4 3.1 – 31 0.036 ± 0.003 0.994 ± 0.002 
BMP 16:0/16:0 6.7 – 67 0.033 ± 0.003 0.996 ± 0.002 
BMP 18:1/18:1 9.4 - 94 0.025 ± 0.002 0.997 ± 0.004 
PG 16:0/16:0 4.3 – 43 0.171 ± 0.015 0.994 ± 0.002 
PG 18:1/18:1 3.6 – 36 0.196 ± 0.013 0.998 ± 0.002 
PG 18:0/20:4 1.5 – 15 0.119 ± 0.007 0.997 ± 0.004 
CL 30:0/31:1 7.6 – 76 0.034 ± 0.002 0.995 ± 0.002 
CL 36:2/36:2 5.9 - 59 0.047 ± 0.003 0.994 ± 0.002 
Calibration was performed by standard addition to mouse heart tissue homogenates. Each 
value represents the average of three determinations. 
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Table S-3. Intra- and Inter-day precisions in mouse heart tissues 
 
Analyte Conc. 
[pmol/mg tissue] 
Intraday-precision (%) 
(n=5) 
Interday-precision (%) 
(n=5) 
BMP 18:1/18:1 1.29 ± 0.10 7.5 8.7 
PG 32:0 0.58 ± 0.04 7.2 12.0 
PG 34:1 48.9 ± 2.1 4.2 6.8 
PG 36:3 5.42 ± 0.42 7.8 7.7 
PG 36:2 10.95 ± 0.66 6.0 9.73 
PG 36:1 2.18 ± 0.14 6.4 6.6 
PG 38:4 15.19 ± 0.58 3.8 8.7 
CL 34:3/36:4 4.54 ± 0.28 6.2 8.9 
CL 34:3/36:3 2.86 ± 0.23 8.0 7.3 
CL 34:2/36:3 4.94 ± 0.38 7.7 4.9 
CL 36:4/36:5 19.90 ± 1.15 5.8 11.1 
CL 36:4/36:4 92.74 ± 3.63 3.9 5.0 
CL 36:4/36:3 81.40 ± 2.4 3.0 8.8 
CL 36:3/36:3 31.73 ± 2.64 8.3 10.4 
CL 36:4/36:1 4.63 ± 0.30 6.5 8.6 
CL 36:3/36:2 10.08 ± 1.04 10.35 11.6 
CL 36:2/36:2 3.07 ± 0.32 10.3 11.8 
CL 36:4/38:6 10.42 ± 0.98 9.4 9.2 
CL 36:4/38:5 22.42 ± 1.29 5.8 9.0 
CL 36:3/38:6 3.27 ± 0.28 8.5 7.5 
CL 36:4/38:4 13.73 ± 1.16 8.5 11.3 
CL 36:3/38:5 4.48 ± 0.29 6.5 8.3 
CL 36:2/38:6 0.54 ± 0.06 10.9 6.6 
CL 36:3/38:4 10.90 ± 0.8 6.9 12.1 
CL 36:3/38:3 14.3 ± 1.3 9.0 6.8 
CL 36:4/40:8 104.5 ± 6.0 5.8 7.1 
CL 36:5/40:7 1.04 ± 0.13 13.0 12.6 
CL 36:3/40:9 1.82 ± 0.11 6.0 7.1 
CL 36:4/40:7 25.47 ± 1.25 4.9 10.5 
CL 36:3/40:8 19.18 ± 1.84 9.6 12.4 
CL 36:4/40:6 4.01 ± 0.41 10.0 11.8 
CL 36:3/40:7 6.35 ± 0.38 5.9 8.5 
CL 36:3/40:6 1.38 ± 0.14 10.3 13.7 
The displayed values are mean concentrations from mouse heart tissue lipid extracts and the 
coefficient of variation (CV) of 5 samples analyzed in series for intraday-precision and on 5 
different days for interday-precision. Tissue homogenate corresponding to 2.5mg wet weight 
were used for quantification. 
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Table S-4. Intra- and Inter-day precisions in primary human skin fibroblasts 
 
Analyte Conc. 
[pmol/mg cellular protein] 
Intraday-precision (%) 
(n=5) 
Interday-precision (%) 
(n=5) 
PA 32:0 17.77 ± 1.24 7.0 9.5 
PA 34:1 41.88 ± 3.56 8.5 8.1 
PA 36:2 13.53 ± 0.74 5.5 6.7 
PA 36:1 13.20 ± 1.37 10.3 12.3 
PA 38:4 15.64 ± 1.93 12.4 11.4 
BMP 16:1/18:1 43.02 ± 3.42 8.0 8.8 
BMP 16:0/18:1 36.43 ± 2.28 6.3 7.9 
BMP 18:2/18:2 13.89 ± 2.28 8.3 9.7 
BMP 18:2/18:1 165.90 ± 15.99 9.6 10.6 
BMP 18:1/18:1 388.77 ± 22.25 5.7 7.9 
BMP 18:1/18:0 84.66 ± 5.35 7.5 8.1 
BMP 18:1/20:4 168.12 ± 9.81 5.8 10.7 
BMP 18:1/20:3 146.39 ± 14.56 9.9 8.4 
BMP 18:1/20:2 70.49 ± 6.20 8.8 8.6 
BMP 18:0/22:6 64.35 ± 8.22 12.8 11.3 
BMP 18:1/22:5 294.03 ± 11.66 7.2 8.6 
PG 34:1 18.18 ± 1.42 7.8 6.1 
PG 36:3 2.54 ± 0.19 7.5 11.2 
PG 36:2 4.77 ± 0.44 9.3 8.5 
PG 36:1 16.53 ± 1.77 10.7 12.7 
CL 34:3/34:3 40.27 ± 3.73 9.3 9.4 
CL 34:2/34:2 53.63 ±4.37 8.1 6.3 
CL 34:3/36:4 46.75 ± 2.32 5.0 8.0 
CL 34:2/36:3 120.72 ± 9.60 8.0 11.8 
CL 36:4/36:4 33.81 ± 2.58 7.6 8.9 
CL 36:4/36:3 138.80 ± 6.09 4.4 3.3 
CL 36:3/36:3 168.62 ± 19.42 11.5 13.1 
CL 36:4/36:2 28.81 ± 2.39 8.3 11.9 
CL 36:4/36:1 12.9 ± 0.83 6.4 9.8 
CL 36:3/36:2 117.21 ± 8.77 7.5 4.3 
CL 36:2/36:2 88.72 ± 6.53 7.4 8.6 
CL 36:4/38:5 22.56 ± 2.07 9.2 11.5 
CL 36:4/38:4 17.45 ± 1.98 11.4 7.9 
CL 36:3/38:5 37.78 ± 2.98 7.9 8.7 
CL 36:3/38:4 14.6 ± 1.97 13.5 12.9 
CL 36:3/38:3 14.47 ± 1.58 10.9 6.5 
The displayed values are mean concentrations from primary human skin fibroblasts lipid 
extracts and the coefficient of variation (CV) of 5 samples analyzed in series for intraday-
precision and on 5 different days for interday-precision. Cell homogenate corresponding to 
50µg protein were used for quantification. 
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Table S-5. Recovery and matrix effects 
Analyte Spiked amount 
[pmol] 
Recovery (S.D.) 
(n=4) 
Matrix effect 
(n=4) 
PA 16:0/16:0 3.1 74 ± 8 133 ± 9 
PA 18:1/18:1 2.9 79 ± 9 142 ± 5 
PA 18:0/20:4 2.8 78 ± 8 140 ± 10 
BMP 16:0/16:0 6.7 62 ± 6 108 ± 9 
BMP 18:1/18:1 6.5 71 ± 7 109 ± 4 
PG 16:0/16:0 1.4 61 ± 2 128 ± 7 
PG 18:1/18:1 1.3 70 ± 6 134 ± 4 
PG 18:0/20:4 1.3 67 ± 8 141 ± 6 
CL 30:2/31:1 7.6 64 ± 3 88 ± 6 
CL 36:2/36:2 6.9 65 ± 8 91± 4 
Recovery and matrix effects were determined in mouse heart tissue homogenates 
corresponding to 2.5mg of wet weight. Recovery was calculated as percent of standards 
spiked before and after extraction. Matrix effects are calculated as the percentage of signal 
spiked after extraction (corrected by endogenous sphingolipid concentrations) related to a 
pure standard mixture. Each value represents the average of three determinations ± 
standard deviation.  
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Figure S-1. Product ion spectrum and proposed fragmentation of CL (14:0)4 (Panel A), PA 16:0/16:0 (Panel B), BMP 16:0/17:0 (Panel C) and PG 
16:0/16:0 (Panel D) in positive ionization mode. Collision energy was ramped from 5 to 130V. 
  3. S1P, LPA analysis 61 
 
3 High throughput analysis of sphingosine-1-phosphate, 
sphinganine-1-phosphate and lysophosphatidic acid in 
plasma samples by LC-MS/MS 
 
3.1 Abstract 
 
Lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P) are 
ubiquitous lipid messengers found in the blood and most cell types. Both 
lysophospholipids are ligands of G-protein-coupled receptors and mediate important 
physiological processes. Moreover, lysophospholipids are potential biomarkers for 
various diseases including atherosclerosis and cancer. Because existing 
methodologies are of limited value for a systematic evaluation of S1P and LPA in 
clinical studies, we developed a fast and simple quantitation method using liquid 
chromatography tandem mass spectrometry (LC-MS/MS). Sphingoid-base-1-
phosphates and LPA species were quantified using fragments of m/z 79 and 153 in 
negative ion mode, respectively. The internal standards LPA 17:0 and [13C2D2]-S1P 
were added prior to butanol extraction. Application of hydrophilic interaction 
chromatography (HILIC) allowed co-elution of analytes and internal standards with a 
short analysis time of 2.5min. Comparison of butanol extraction with a frequently 
used extraction method based on strong acidification of human plasma revealed an 
artificial formation of LPA from lysophosphatidylcholine. Validation according to FDA 
guidelines showed an overall imprecision < 12% CV and a limit of detection < 
6nmol/L for all lysophospholipid species. S1P and Sphinganine-1-phosphate (SA1P) 
concentrations in EDTA plasma were found to be stable for 24h at room temperature, 
whereas LPA concentrations increased substantially. Our validated LC-MS/MS 
methodology for the quantification of LPA, S1P and SA1P is characterized by simple 
sample preparation and short analysis time, therefore providing a valuable tool for 
diagnostic evaluation of these lysophospholipids as biomarkers. 
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3.2 Introduction 
 
Lysophospholipids in particular lysophosphatidic acid (LPA) and sphingosine-
1-phosphate (S1P), are bioactive lipids which elicit a wide range of cellular responses 
including cell survival, differentiation and migration (1-5). Blood concentrations of 
S1P and LPA are derived either from cellular release (S1P by platelets and red blood 
cells (5)) or enzymatic conversion of plasma lipids (lysophosphatidylcholine 
conversion to LPA by autotaxin (2;4)). Both LPA and S1P act on specific G-protein-
coupled receptors on cells of the immune, cardiovascular and nervous systems and 
thereby regulate the induction of inflammation, atherosclerosis and cancer (1-5). 
Based on their signaling functions and role in different diseases, LPA and S1P may 
gain clinical importance as biomarkers. However, so far, the quantitative analysis of 
LPA and S1P as diagnostic parameters in daily routine or large clinical studies is 
hindered by laborious and time-consuming methods.  
A commonly applied technique for the determination of S1P and LPA is liquid 
chromatography coupled to tandem mass spectrometry (LC-MS/MS) (6-13). Several 
methods lack co-elution of internal standard (IS) and analyte, necessary to 
compensate potential matrix effects or varying ionization efficiency, due to mobile 
phase gradients (7;10;11;14). Furthermore, laborious sample preparation (8;15), high 
sample volume (8;11-13), time-consuming derivatization procedures (15), and a lack 
of sufficient validation (8-11) exclude these methods from routine analysis. Up to now 
only one methodology for a combined LPA and S1P determination exists (11). Here, 
we report a simple and rapid LC-MS/MS method for the quantification of S1P, 
sphinganine-1-phosphate (SA1P) and LPA species. 
 
3.3 Materials and Methods 
 
3.3.1 LC-MS/MS analysis 
All analyses described here were performed on a hybrid triple quadrupole 
linear ion trap mass spectrometer API 4000 Q-Trap (Applied Biosystems, Darmstadt, 
Germany). The LC equipment consisted of a binary and isocratic pump (Agilent 1200 
series, Waldbronn, Germany) connected to an HTC Pal autosampler (CTC Analytics, 
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Zwingen, Switzerland). Chromatographic separation was performed on a 50 x 2.1mm 
(i.d.), 3µm particle size HILIC silica column (Waters Atlantis) equipped with a 10 x 
2.1mm guard column containing the same material. The column oven temperature 
was set to 50°C. The mobile phase consisted of wate r containing 0.2% formic acid 
and 50mmol/L ammonium formate (eluent A) and acetonitrile containing 0.2% formic 
acid (eluent B). A gradient elution was performed with 5% A for 0.7min, a linear 
increase to 25% A until 1.5min, followed by 50% A until 1.7min and re-equilibration 
from 1.7 to 2.5min with 5% A. A flow rate of 500µL/min was used except from 0 to 
0.5min and 1.7 to 2.5min, the flow rate was increased to 700µL/min. To minimize the 
potential contamination of the mass spectrometer, the column flow was directed only 
from 1.3 to 2.1min into the mass spectrometer using a divert valve. Otherwise 
methanol with a flow rate of 250µL/min was delivered into the mass spectrometer. 
The Turbo Ion Spray source was operated in the negative ionization mode using the 
following settings: Ion spray voltage = -4500V, ion source heater temperature = 
300°C, source gas 1 = 40psi, source gas 2 = 35psi a nd curtain gas = 20psi. LPA 
species revealed fragments resulting from the head group (m/z 79, m/z 153) and fatty 
acid moiety (m/z 255 for LPA 16:0) (Suppl.-Fig. 1A). To cover all LPA species and 
due to increased specificity, m/z 153 was chosen as product ion for LPA 
quantification. Product ion spectra of S1P and SA1P showed only one intense 
fragment of m/z 79 (Suppl.-Fig. 1B), which was then used for analysis (see Suppl.-
Tab. 1). The collision energy optimum for LPA species and sphingoid base-1-
phosphates was 30eV and 58eV, respectively.  
 
3.3.2 Species identification 
In order to obtain the naturally occurring lysophospholipid species, we 
analyzed  plasma lipid extracts using a precursor ion scan of 79 and 153 m/z 
revealing the following main species: S1P and SA1P containing a dihydroxy-C18:1 
base; LPA 16:0, LPA 18:0, LPA 18:1, LPA 18:2 and LPA 20:4. This pattern is in good 
accordance with the literature (7;9;11;16). Quantification was achieved by standard 
addition of S1P, SA1P, LPA 16:0, LPA 18:0, LPA 18:1, LPA 18:2 and LPA 20:4 to 
human plasma samples, at five different concentrations (Tab. 1).  
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3.3.3 Sample preparation 
Lysophospholipids such as LPA and S1P show a poor recovery using organic 
solvents like chloroform at neutral pH. Therefore, in a first step, we used a modified 
extraction procedure according to Bligh & Dyer with 6mol/L HCl (8;12). Although both 
LPA and S1P showed a high recovery (85-95%), this extraction method was poorly 
reproducible for plasma samples. Because lysophosphatidylcholine (LPC) might be 
degraded to LPA under highly acidic conditions (11), we added non-naturally 
occurring LPC 19:0 to plasma samples. Acidic chloroform extraction of spiked plasma 
converted about 2% of LPC 19:0 to LPA 19:0 (Suppl.-Tab. 2). This artificial formation 
of LPA from LPC required the presence of plasma, since acidic extraction of LPC 
19:0 without plasma did not result in LPA 19:0 formation (data not shown). For a LPC 
plasma concentration of 250µmol/L (17), strong acidic extraction could potentially 
cause a ~7-fold increase of LPA. To circumvent these problems, we used a butanolic 
extraction reported by Baker et al. (16) and did not observe any LPC-LPA conversion 
(data not shown). In brief, 75µL EDTA-plasma were mixed with 20ng each of LPA 
17:0 and stable isotope labeled [13C2D2]-S1P (Toronto Research, North York, ON, 
Canada) and 400µL buffer, containing 30mmol/L citric acid and 40mmol/L disodium 
hydrogenphosphate (pH 4.0). Extraction was performed with 1mL of 1-butanol and 
500µL of water saturated 1-butanol. The recovered butanol phase was evaporated to 
dryness under reduced pressure. The residue was re-dissolved in 200µL ethanol and 
10µL were injected.  
 
3.4 Results and Discussion 
 
3.4.1 Chromatography 
Most of the reported LC-MS/MS methods for LPA and S1P analysis use 
reversed phase chromatography (6;7;10-12;15;17) resulting in a separation of 
analytes and internal standards. In contrast, we established a separation based on 
hydrophilic interaction chromatography (HILIC) characterized by co-elution of 
analytes with their respective internal standards (Fig. 1). The retention times of LPA 
and S1P were 1.74min and 1.84min, respectively. Due to co-elution, SA1P and S1P 
as well as LPA species exhibited an isotope overlap. In order to avoid an 
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overestimation of species concentrations, peak areas were corrected according to 
the principles described previously (18) (Suppl.-Tab. 3). 
 
3.4.2 Validation 
Our established LC-MS/MS method was validated according to FDA 
Guidelines for Bioanalytical Methods (19). First, we evaluated a potential suppression 
of the analyte response due to matrix effects. Because no analyte free EDTA-plasma 
was available, an internal standard mixture was analyzed with or without plasma 
extract (Cspiked 0.5, 1, 2µmol/L). The presence of plasma extract caused a mean 
signal reduction (± SD) of 25.0 ± 1.8% and 2.5 ± 1.4% for [13C2D2]-S1P and LPA 
17:0, respectively. Moreover, co-elution of analytes and internal standards may result 
in suppression of the MS response for multi-component analytes. Although we found 
signal suppression by analyte co-elution, the ratios of internal standard to analyte did 
not change significantly (Suppl.-Tab. 4). 
 
3.4.3 Quantification 
Calibration by standard addition to plasma samples showed linearity and 
accuracy of the analytes in the spiked concentration range (Tab. 1). For accurate 
quantification considering the different responses of species, e.g. only 30% response 
to LPA 20:4 compared to other LPA (Tab. 1), multiple calibration lines were used. 
Furthermore, we tested the influence of the plasma lipid content on the response for 
the analytes by varying the cholesterol concentrations as a surrogate marker. The 
slopes of the calibration lines showed no notable differences at cholesterol 
concentrations of 2.97, 4.52 and 7.49mmol/L, respectively (Suppl.-Tab. 5). 
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Table 1. Standard addition of S1P, SA1P and LPA species to human plasma samplesa 
Analyte Concentration 
added, µmol/L 
Concentration 
measured (n=5), 
µmol/Lb 
Recovery of 
added analyte, 
(n=5), %b 
Linear regression 
equation (n=5) 
S1P 0 0.470 (0.061)  y=1.08x + 0.44µmol/L 
(r2=0.997) 
 0.352 0.773 (0.056) 109.8 (6)  
 0.703 1.174 (0.177) 109.3 (12.9)  
 1.407 1.829 (0.105) 96.6 (8.4)  
 2.111 2.485 (0.188) 96.1 (8.9)  
 3.518 3.999 (0.034) 99.8 (1.4)  
     
SA1P 0 
0.286 (0.049) 
 y=0.301x + 0.088µmol/L 
(r2=0.999) 
 0.175 0.439 (0.127) 88.3 (6.7)  
 0.350 0.651 (0.110) 97.4 (12.1)  
 0.700 1.022 (0.146) 105.8 (13.9)  
 1.05 1.313 (0.091) 98.1 (8)  
 1.75 2.039 (0.075) 100.2 (1.7)  
     
LPA 16:0 
0 0.051 (0.005) 
 y=2.13x + 0.053µmol/L 
(r2=0.999) 
 0.162 0.199 (0.023) 91.7 (14.7)  
 0.325 0.366 (0.057) 102.7 (12.4)  
 0.65 0.704 (0.061) 100.6 (9)  
 0.97 1.028 (0.045) 100.6 (4.8)  
 1.62 1.658 (0.023) 99.1 (1.3)  
     
LPA 18:0 0 
0.011 (0.001) 
 y=1.90x + 0.020µmol/L 
(r2=0.997) 
 0.0304 0.036 (0.003) 89.6 (6.7)  
 0.0607 0.070 (0.008) 98.3 (14.4)  
 0.1214 0.131 (0.008) 99.4 (6.3)  
 0.18 0.151 (0.009) 97.6 (2.3)  
 0.30 0.314 (0.0002) 99.7 (0.5)  
     
LPA 18:1 
0.0000 0.048 (0.006) 
 y=1.93x + 0.10µmol/L 
(r2=0.998) 
 0.0917 0.132 (0.007) 92.6 (10.9)  
 0.1834 0.232 (0.027) 100.2 (13.9)  
 0.3670 0.412 (0.027) 99 (6.8)  
 0.55 0.595(0.017) 99.3 (3.3)  
 0.92 0.964 (0.017) 99.9 (1.53)  
     
LPA 18:2 0 
0.379 (0.031) 
 y=1.99x + 0.70µmol/L 
(r2=0.999) 
 0.308 0.676 (0.063) 96.4 (14.9)  
 0.616 0.984 (0.092) 100.3 (16.1)  
 1.232 1.604 (0.070) 99.5 (5.1)  
 1.85 2.229 (0.052) 100.1 (2.2)  
 3.08 3.448 (0.017) 100.1 (0.8)  
     
LPA 20:4 0 
0.316 (0.026) 
 y=1.99x + 0.70µmol/L 
(r2=0.998) 
 0.291 0.584 (0.032) 92.1 (9.1)  
 0.582 0.880 (0.106) 96.9 (14.3)  
 1.164 1.511 (0.073) 102.7 (4.8)  
 1.75 2.065 (0.110) 100.2 (6.9)  
 2.91 3.200 (0.104) 99 (2.8)  
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Stock solutions of lipid species were prepared in methanol from authentic standards 
(Avanti Polar Lipids). To ensure the accuracy of calibrator concentrations, we performed a 
phosphate determination [Bartlett and Lewis (13 )]. Lysophospholipid standards were added 
to EDTA-containing plasma samples prior to extraction from a combined methanolic stock 
solution with the following concentrations (in g/mL): 1.0 (S1P), 0.5 (SA1P), 0.5 (LPA 16:0), 
0.1 (LPA 18:0), 0.3 (LPA 18:1), 1.0 (LPA 18:2), and 1.0 (LPA 20:4). For each analyte, 
calibration curves were calculated by least-squares fitting of the concentration against the 
peak area ratio of the analyte to the internal standard. The data shown were calculated from 
5 independent samples. The recovery of the added analytes was calculated by means of a 
separate 6-point calibration. 
Data are presented as the mean (SD). 
 
3.4.4 Precision 
The intra-day imprecisions were below 9% and the inter-day coefficients of 
variation (CVs) were below 11% (Suppl.-Tab. 6). The limit of detection, defined as a 
signal-to-noise ratio of 3, were found to be ~6nmol/L for S1P and SA1P and 
<2nmol/L for LPA (Suppl.-Tab. 1).  
68 3. S1P, LPA analysis  
 
 
 
 
LPA 18:2
time, min
0.0 0.5 1.0 1.5 2.0 2.5
In
te
n
si
ty
,
 
cp
s
0.0
2.0e+3
4.0e+3
6.0e+3
8.0e+3
1.0e+4
1.2e+4
1.4e+4
1.6e+4
time, min
0.0 0.5 1.0 1.5 2.0 2.5
In
te
n
si
ty
,
 
cp
s
0.0
5.0e+3
1.0e+4
1.5e+4
2.0e+4
2.5e+4
3.0e+4
3.5e+4
LPA 18:2 LPA 17:0
LPA 20:4
LPA 16:0
LPA 18:1
LPA 18:0
S1P
13C2D2-S1P
SA1P
1.84
1.74
 
Fig.1. Chromatograms of sphingoid base-1-phosphates and LPA analysis. 
Chromatograms show a human plasma sample (75µL), spiked with 20ng each [13C2D2]-S1P 
and LPA 17:0 as internal standards. Upper chromatogram displays LPA 16:0, 18:0, 18:1, 
18:2, 20:4 and 17:0; lower chromatogram displays S1P, SA1P and [13C2D2]-S1P.  
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3.4.5 Sample stability 
To investigate sample stability, EDTA-plasma samples were stored 
immediately at -80°C or frozen after 1, 4, 8 and 24 h incubation at room temperature. 
For immediately stored samples, we did not observe any concentration changes 
compared to freshly analyzed plasma samples (data not shown). S1P and SA1P 
were stable in EDTA-plasma and serum up to 24 hours at room temperature. In 
contrast, LPA concentrations increased up to 8-fold when samples were stored at 
room temperature for 24h (Suppl.-Tab. 7). This increase is most likely due to LPA 
conversion from LPC by the autotaxin an lyso-phospholipase D (2). In whole blood 
samples, sphingoid base-1-phosphates showed a rapid increase at room 
temperature (Suppl.-Tab. 9). Consequently, in order to achieve reliable results, 
immediate plasma separation and storage at -80°C is  of paramount importance. 
 
3.4.6 S1P and LPA level in human EDTA-plasma 
Finally, we determined LPA, S1P and SA1P in freshly drawn EDTA-plasma 
samples from healthy human volunteers (n=10, Suppl.-Tab. 10). The mean 
concentrations for S1P and SA1P were 0.59 and 0.19µmol/L, respectively. Total 
mean LPA concentrations were 0.7µmol/L with the two dominating species LPA 20:4 
(~55%) and LPA 18:2 (~25%) contributing 80% to the overall measured LPA 
concentrations. These values are in good agreement within previously reported 
concentrations (7;11;12;14-16). In contrast, total LPA concentrations determined 
after highly acidic extraction were much higher (~5µmol/L) most likely resulting from 
LPC degradation (8). 
 
3.5 Conclusion 
 
Compared to existing LC-MS-based reports (6;7;11;12;15;16), our novel 
method shows major advantages in terms of small sample volumes, easy sample 
preparation and short run times of 2.5min (Suppl.-Tab. 11). Most importantly, HILIC 
allows co-elution of analytes and internal standards, a prerequisite for accurate 
compensation of potential matrix effects and varying ionization efficiencies. In 
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summary, the simultaneous determination of S1P, SA1P and LPA described here 
may be a useful analytic tool for the clinical chemistry laboratory. 
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3.7 Data Supplement 
 
Suppl.-Table 1. Summary of precursor/product ion m/z’s for MRM detection.  
Analyte mass transition 
[m/z] 
collision energy 
[eV] 
limit of 
detection 
[nmol/L] 
S1P 378.2 → 79 58 6 
SA1P 380.2 → 79 58 4.95 
13C2D2-S1P 382.2 → 79 58 - 
LPA 16:0 409.2 → 153 30 0.37 
LPA 18:0 437.3 → 153 30 0.31 
LPA 18:1 435.3 → 153 30 0.55 
LPA 18:2 433.3 → 153 30 1.7 
LPA 20:4 457.2 → 153 30 1.26 
LPA 17:0 423.3 → 153 30 - 
 
Suppl.-Table 2. LPC degradation to LPA generation during strong acidic extraction.  
Spiked LPC 19:0  
 [µmol/L] 
LPA 19:0 generation 
[µmol/L] 
LPA generation  
[% of LPC] 
2.48 0.042 (0.041-0.044) 1.7 
4.96 0.11 (0.10-0.14) 2.2 
9.92 0.206 (1.89-2.2) 2.1 
The indicated concentration of LPC 19:0 were added to plasma. LPA was extracted by a 
modified Bligh and Dyer protocol in the presence of 6mol/L HCl. The displayed values are 
median and range of a triplicate measurement.  
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Suppl.-Table 3. 75µL human EDTA-plasma was spiked with increasing amounts of LPA 18:2 
and S1P.  
LPA 18:2  
spiked [ng] 
Ratio  
LPA 18:2/IS 
Uncorrected ratio 
LPA18:1/IS 
Corrected ratio  
LPA 18:1/IS 
0 1.624  
(1.552-1.691) 
0.384  
(0.375-0.427) 
0.355 
(0.348-0.382) 
20 2.451  
(2.443-2.695) 
0.402 
(0.377-0.439) 
0.356 
(0.331-0.381) 
60 4.67  
(4.537-4.771) 
0.482 
(0.488-0.516) 
0.353 
(0.335-0.369) 
100 6.459  
(6.396-6.810) 
0.552 
(0.518-0.555) 
0.366 
(0.348-0.400) 
    
S1P 
spiked [ng] 
Ratio  
S1P/IS 
Uncorrected ratio 
SA1P/IS 
Corrected ratio 
SA1P/IS 
0 0.803 
(0.796-0.852) 
0.257 
(0.235-0.258) 
0.224 
(0.209-0.237) 
20 1.578 
(1.555-1.723)  
0.248 
(0.244-0.290) 
0.222 
(0.2-0.237) 
60 2.956 
(2.953-3.106) 
0.3 
(0.27-0.302) 
0.216 
(0.201-0.236) 
100 4.225 
(4.052-4.332) 
0.343 
(0.315-0.351) 
0.227 
(0.213-0.258) 
Values represent peak area ratios of LPA 18:2 and 18:1 to LPA 17:0 as well as S1P and 
SA1P to 13C2D2-S1P, respectively. The LPA 18:1 and SA1P peak area ratios were shown 
before and after isotope correction. The displayed values are median and range of a triplicate 
measurement. 
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Suppl.-Table 4. 75µl EDTA-plasma were spiked either with the indicated amount of LPA 
16:0, 18:0, 18:2, 20:4 or S1P.  
 
spiked 
[ng] 
peak area 
[cps] 
% peak area 
of unspiked 
ratio 
analyte/IS 
% ratio analyte/IS 
of unspiked 
LPA 
18:1 0 
7245 
(6611-7492) 
100 
(91-103) 
0.343 
(0.315-0.351) 
100 
(92-102) 
 20 6452 (6275-6812) 
89 
(87-94) 
0.309 
(0.296-0.337) 
90 
(86-98) 
 60 6204 (6030-6650) 
85.6 
(83-92) 
0.302 
(0.289-0.315) 
88 
(84-92) 
 100 6914 (6440-7251) 
95.4 
(89-100) 
0.320 
(0.309-0.345) 
93 
(90-100) 
      
SA1P 0 1351 (1324-1512) 
100 
(98-112) 
0.157 
(0.15-0.173) 
100 
(96-110) 
 20 1160 (1143-1323) 
86 
(85-98) 
0.147 
(0.133-0.149) 
94 
(85-95) 
 60 1148 (1007-1205) 
85 
(75-89) 
0.166 
(0.152-0.177) 
106 
(97-113) 
 100 1047 (987-1103) 
76 
(73-82) 
0.141 
(0.139-0.162) 
90 
(89-103) 
The peak areas, and ratios analyte to internal standard as well as their percentage related to 
the unspiked sample were calculated for LPA 18:1 and SA1P, respectively. The displayed 
values are median and range of a triplicate measurement. 
 
Suppl.-Table 5. Influence of plasma cholesterol on the slopes of the calibration lines  
Plasma cholesterol 
[mmol/L] S1P LPA 16:0 LPA 18:0 LPA 18:1 LPA 20:4 
2.97 1.05 2.20 2.55 2.52 0.66 
4.52 0.93 2.26 2.58 2.75 0.66 
7.49 1.07 2.15 2.41 2.66 0.65 
Calibration lines were generated by standard addition of S1P, LPA 16:0, LPA 18:0, LPA 18:1 
and LPA 20:4. Regression line coefficients were all above 0.99 and the displayed values 
show the slope of the regression lines generated by linear regression. 
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Suppl.-Table 6. Intra- and inter-day-imprecisions. 
  S1P SA1P LPA 16:0 LPA18:0 LPA 18:1 LPA18:2 LPA20:4 Total LPA 
Intra-day 
Plasma 1 [µmol/L]  0.49 0.12 0.043 0.0085 0.055 0.17 0.37 0.65 
CV [%]  4.42 3.69 3.78 6.19 2.99 7.18 6.43 3.19 
Plasma 2 [µmol/L]  0.76 0.34 0.044 0.0086 0.052 0.30 0.43 0.89 
CV [%]  3.66 7.50 4.89 7.60 7.09 5.64 8.88 5.63 
Plasma 3 [µmol/L]  1.62 0.07 0.24 0.024 0.18 0.79 1.43 2.67 
CV [%]  6.06 5.07 6.69 8.65 7.42 5.63 7.58 6.04 
Inter-day 
Plasma 4 [µmol/L]  0.44 0.080 0.042 0.008 0.051 0.20 0.33 1.29 
CV [%]  8.20 8.47 9.80 8.58 7.04 3.93 5.42 10.58 
Plasma 5 [µmol/L]  0.70 0.11 0.045 0.009 0.052 0.26 0.39 0.70 
CV [%]  9.68 7.56 10.55 8.34 7.72 6.51 5.54 5.00 
Plasma 6 [µmol/L]  0.67 0.14 0.10 0.012 0.08 0.40 0.67 0.71 
CV [%]  7.84 7.79 9.64 8.0 9.40 11.46 10.06 5.66 
The displayed values are mean plasma concentrations in µmol/L and the coefficient of variation (CV) of 6 sample aliquots at 3 concentrations 
analyzed in series for intra-day and on 6 different days for inter-day imprecision. 
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Suppl.-Table 7. Plasma sample stability.  
Conditions S1P SA1P LPA 16:0 LPA 18:0 LPA 18:1 LPA 18:2 LPA 20:4 Total LPA 
1h RT 111 102 138 122 138 145 135 138 
4h RT 100 92 295 216 239 302 262 273 
8h RT 112 87 521 400 462 503 424 456 
24h RT 102 90 1087 777 856 821 756 801 
Separated plasma samples were stored at room temperature (RT) for the time indicated. The displayed values are percent (mean of two different 
plasma samples) related to plasma stored at -80°C u ntil analysis.  
 
Suppl.-Table 8. Serum sample stability.  
Conditions S1P SA1P LPA 16:0 LPA 18:0 LPA 18:1 LPA 18:2 LPA 20:4 Total LPA 
1h RT 94 92 118 119 121 130 99 103 
4h RT 94 112 287 237 248 288 128 148 
8h RT 95 104 520 345 436 526 158 206 
24h RT 96 101 2004 1237 1301 1485 298 477 
Separated serum samples were stored at room temperature (RT) for the time indicated. The displayed values are percent (mean of two different 
serum samples) related to serum stored at -80°C unt il analysis.  
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Suppl.-Table 9. Whole blood sample stability.  
Conditions S1P SA1P LPA 16:0 LPA 18:0 LPA 18:1 LPA 18:2 LPA 20:4 Total LPA 
1h RT 317 150 206 165 206 328 188 223 
4h RT 718 302 379 258 364 632 343 414 
8h RT 763 350 498 328 462 885 466 558 
24h RT 845 410 737 495 669 1112 718 803 
EDTA whole blood samples were stored at room temperature (RT) for the time indicated until separation of plasma. The displayed values are 
percent (mean of two different plasma samples) related to plasma stored at -80°C until analysis.  
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Suppl.-Table 10. Concentrations of sphingoid base phosphates and LPA in EDTA-plasma 
separated immediately upon drawing.  
Analyte Plasma [µmol/L] 
S1P 0.59 ± 0.15 
SA1P 0.19 ± 0.07 
LPA 16:0 0.058 ± 0.008 
LPA 18:0 0.010 ± 0.0012 
LPA 18:1 0.061 ± 0.05 
LPA 18:2 0.18 ± 0.05 
LPA 20:4 0.39 ± 0.09 
Total LPA 0.699 ± 0.20 
The displayed values are means ± SD of 10 healthy volunteers. 
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Suppl.-Table 11. Comparison of present method to previously published mass spectrometric methods for lysophospholipid quantification. 
Authors LC type 
Analysis 
time [min] 
Plasma volume 
[µL] IS S1P/SA1P 
Co-elution 
S1P/IS 
IS LPA 
Co-elution LPA 
species/IS 
Baker et al. Normal-phase >10 450 - - LPA !8:0 d35 yes 
Berdyshev et al. Reversed-phase C8 10 100 C17-S1P no - - 
Murph et al. Reversed-phase C5 7.5 500 LPA 17:0 no LPA 17:0 no 
Schmidt et al. Reversed-phase C18 14.5 n.d. C17-S1P no - - 
Shan et al. Reversed-phase C18 5 500 -  LPA 16:0 (13C16) only LPA 16:0 
Scherer et al. HILIC 2.5 75 13C2D2-S1P yes LPA 17:0 yes 
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Suppl.-Fig. 1. Product ion spectra and suggested fragmentation scheme of authentic LPA 
16:0 (Panel A) and S1P (Panel B) using negative ESI mode. 
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4 A rapid and quantitative LC-MS/MS method to profile 
sphingolipids 
 
4.1 Abstract 
 
Sphingolipids comprise a highly diverse and complex class of molecules that 
serve not only as structural components of membranes but also as signaling 
molecules. To understand the differential role of sphingolipids in a regulatory network 
it is important to use specific and quantitative methods. 
We developed a novel LC-MS/MS method for the rapid, simultaneous 
quantification of sphingolipid metabolites including sphingosine, sphinganine, phyto-
sphingosine, di- and trimethyl-sphingosine, sphingosylphosphorylcholine, 
hexosylceramide, lactosylceramide, ceramide-1-phosphate and dihydroceramide-1-
phosphate. Appropriate internal standards were added prior to lipid extraction. In 
contrast to most published methods based on reversed phase chromatography, we 
used hydrophilic interaction liquid chromatography (HILIC) and achieved good peak 
shapes, a short analysis time of 4.5 min and most important co-elution of analytes 
and their respective internal standards. In order to avoid an overestimation of species 
concentrations, peak areas were corrected regarding isotopic overlap where 
necessary. Quantification was achieved by standard addition of naturally occurring 
sphingolipid species to the sample matrix. The method showed excellent precision, 
accuracy, detection limits and robustness. As an example, sphingolipid species were 
quantified in fibroblasts treated with myriocin or sphingosine-kinase-inhibitor. 
In summary this method represents a valuable tool to evaluate the role of 
sphingolipids in the regulation of cell functions. 
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4.2 Introduction 
 
Sphingolipids comprise a highly diverse and complex class of molecules that 
serve not only as structural components of cellular membranes but also as bioactive 
compounds with crucial biological functions (1). Some metabolites, including 
ceramide, sphingosine and sphingosine-1-phosphate have been shown to be 
involved in different cell functions such as proliferation, differentiation, growth arrest 
and apoptosis (2). Especially the counter-regulatory functions of ceramide and 
sphingosine-1-phosphate, resembling the sphingolipid rheostat, indicate that not only 
a single metabolite concentration, but rather the relative levels of these lipids are 
important to determine the cell fate (2-5). Sphingolipids are associated to several 
diseases such as cancer, obesity and atherosclerosis (1;2;6-9). Structural diversity 
and inter-conversion of these sphingolipid metabolites represent technical 
challenges. Nevertheless, to understand the differential role of sphingolipids in a 
regulatory network, it is imperative to use specific and quantitative methods.  
During the last decade liquid chromatography coupled to tandem-mass 
spectrometry (LC-MS/MS) has become a powerful tool for sphingolipid analysis (10-
21). However, either these methods do not cover a broad spectrum of sphingolipid 
metabolites or they show disadvantages like laborious sample preparation, time 
consuming LC-separation or separation of analytes and internal standards.  
Therefore, we applied, as previously described for lysophosphatidic acid and 
sphingoid base phosphates, hydrophilic interaction chromatography (HILIC) coupled 
to mass spectrometry (18) to achieve co-elution of sphingolipid species and their 
internal standards. We present a fast and simple LC-MS/MS-method for the 
quantification of hexosylceramide (HexCer), lactosylceramide (LacCer), sphingosine 
(SPH), sphinganine (SPA), phyto-sphingosine (PhytoSPH), di- and trimethyl-
sphingosine (Di-; TrimetSPH), sphingosylphosphorylcholine (SPC), ceramide-1-
phosphate (Cer1P) and dihydroceramide-1-phosphate (dhCer1P). This method was 
validated and applied to fibroblasts treated with myriocin and a sphingosine-kinase 
inhibitor, respectively. 
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4.3 Material and Methods 
 
4.3.1 Chemicals and solutions 
Butanol, methanol (HPLC grade) and formic acid (98-100 %, for analysis) 
were purchased from Merck (Darmstadt, Germany). Water was obtained from B. 
Braun (Melsungen, Germany). Ammonium formate (Fluka, Buchs, Switzerland), citric 
acid monohydrate, disodium hydrogenphosphate (Merck, Darmstadt, Germany) were 
of the highest analytical grade available. Sphingosine-1-phosphate (d18:1); C17-
sphingosine (d17:1); sphingosine (d18:1); sphinganine (d18:0); C17-
sphingosylphosphorylcholine (d17:1); N,N-dimethyl- sphingosine (d18:1); N,N,N-
trimethyl-sphingosine (d18:1); phyto-sphingosine (t18:0); 
sphingosylphosphorylcholine (d18:1); C12:0-glucosylceramide; C16:0-
glucosylceramide; C24:1-galactosylceramide; C12:0-lactosylceramide; C16:0-
lactosylceramide; C24:0-lactosylceramide; C12:0-Cer-1-phosphate; C16:0-Cer-1-
phosphate and C24:0-Cer-1-phosphate were purchased from Avanti Polar Lipids 
(Alabaster, AL, USA) with purities higher than 99 %. 13C2D2-sphingosine-1-phosphate 
(d18:1) was purchased from Toronto Research Chemicals (Toronto, Canada). Stock-
solutions of individual sphingolipid compounds at a concentration of 1 mg/mL were 
prepared in methanol and stored at -20°C. Working s olutions of the desired 
concentrations were prepared by dilution in methanol. Myriocin and sphingosine-
kinase-inhibitor [2-(p-Hydroxyanilino)-4-(p-chlorphenyl) thiazole] were purchased 
from Calbiochem (San Diego, USA). 
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Table 1. MS parameter and LOD of sphingolipids studied 
Sphingolipid [M+H]+ 
m/z 
MRM IS (MRM) CE 
[V] 
RT  
[min] 
LOD  
[fmol] on column 
SPH 300.3 300.3→282.2 C17 SPH (286.3→268.2) 17 1.04 7.3 
  300.3→252.2 C17 SPH (286.3→238.2) 25 1.04 7.7 
SPA 302.3 302.3→284.2 C17 SPH (286.3→268.2) 21 1.04 6.1 
  302.3→254.2 C17 SPH (286.3→238.2) 29 1.04 8.84 
PhytoSPH 318.4 318.4→282.2 C17 SPH (286.3→268.2) 23 1.06 24.2 
DimetSPH 328.4 328.4→280.3 C17 SPH (286.3→268.2) 29 1.02 0.2 
TrimetSPH 342.4 342.4→60.1 C17 SPH (286.3→268.2) 49 1.05 0.1 
SPC 465.3 465.3→184 C17 SPC (451.3→184) 31 1.75 4.9 
HexCer var. M+H+→264.3 C12 GluCer (644.5→264.3) 55 0.80 0.6 
LacCer var. M+H+→264.3 C12 LacCer (806.6→264.3) 65 0.94 2.7 
Cer1P var. M+H+→264.3 C12 Cer1P (562.4→264.3) 39 1.29 6.3 
dhCer1P var. Neutral loss 98 C12 Cer1P (562.4→262.3) 29 1.29 53.6 
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4.3.2 Cell culture 
Primary human skin fibroblasts were cultured as described previously (22) in 
Dulbecco´s modified Eagle´s medium supplemented with L-glutamine and 10% fetal 
calf serum in a humidified 5% CO2 atmosphere at 37°C. For lipid analysis, cells were  
seeded into 6-well plates and grown to confluence. Cells were rinsed two times with 
ice-cold phosphate buffer saline (PBS) and either lysed in 0.2% sodium dodecyl 
sulfate (SDS) in water or scraped in PBS. Subsequently samples were subjected to 
centrifugation at 240 g for 7 min and the resulting pellet was homogenized in distilled 
water by sonication. Fibroblasts treated with myriocin or sphingosine kinase inhibitor 
(Calbiochem) as indicated in Figure 4 were lysed in 0.2% SDS. Aliquots of the cell 
homogenates were taken for protein determination. Protein concentrations were 
measured using bicinchoninic acid as described previously (23).  
 
4.3.3 Sample preparation 
Unless otherwise indicated aliquots of 100 µg protein from the fibroblast 
homogenates were used for sphingolipid analysis. 20 µL of an internal standard 
mixture containing 20 ng SPH d17:1, 2 ng SPC d17:1, 20 ng GluCer 12:0, 20 ng 
LacCer 12:0 and 20 ng Cer1P 12:0 were added prior to lipid extraction. We applied a 
butanolic extraction procedure described by Baker et al. (24). In brief, 500 µl cell 
homogenate corresponding to 100 µg of cellular protein were mixed with 60 µL of a 
buffer containing 200 mM citric acid and 270 mM disodium hydrogenphosphate (pH 
4). Extraction was performed with 1 mL of 1-butanol and 500 µL of water-saturated 1-
butanol. The recovered butanol phase was evaporated to dryness under reduced 
pressure. The residue was redissolved in 200 µL ethanol.  
 
4.3.4 Sphingolipid analysis by LC-MS/MS  
Sphingolipid analysis was performed by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). The HPLC equipment consisted of a 1200 series binary 
pump (G1312B), a 1200 series isocratic pump (G1310A) and a degasser (G1379B) 
(Agilent, Waldbronn, Germany) connected to an HTC Pal autosampler (CTC 
Analytics, Zwingen, CH). A hybrid triple quadrupole linear ion trap mass spectrometer 
API 4000 Q-Trap equipped with a Turbo V source ion spray operating in positive ESI 
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mode was used for detection (Applied Biosystems, Darmstadt, Germany). High purity 
nitrogen was produced by a nitrogen generator NGM 22-LC/MS (cmc Instruments, 
Eschborn, Germany).  
Gradient chromatographic separation was performed on an Interchim 
(Montlucan, France) hydrophilic-interaction chromatography (HILIC) silica column (50 
x 2.1 mm), with a 1.8 µm particle size equipped with a 0.5 µm pre-filter (Upchurch 
Scientific, Oak Harbor, WA, USA). The injection volume was 2 µL and the column 
was maintained at 50°C. The mobile phase consisted of water containing 0.2% 
formic acid and 200 mM ammonium formate (eluent A) and acetonitrile containing 
0.2% formic acid (eluent B). Gradient elution was performed with 100% B for 0.1 min, 
a step to 90% B until 0.11 min, a linear increase to 50% B until 2.5 min, 50% B until 
3.5 min and re-equilibration from 3.51 to 4.5 min with 100% B. The flow rate was set 
to 800 µL/min. To minimize contamination of the mass spectrometer, the column flow 
was directed only from 1.0 to 3.0 min into the mass spectrometer using a diverter 
valve. Otherwise methanol with a flow rate of 250 µL/min was delivered into the mass 
spectrometer. 
The Turbo Ion Spray source was operated in the positive ionization mode 
using the following settings: Ion spray voltage = 5500V, ion source heater 
temperature = 400°C, source gas 1 = 40psi, source g as 2 = 35psi and curtain gas 
setting = 20psi. Analytes were monitored in the multiple reaction monitoring (MRM) 
mode, mass transitions and MS parameters are shown in Table 1. Quadrupoles Q1 
and Q3 were working at unit resolution. 
 
4.3.5 Calibration and quantification 
Calibration was achieved by standard addition of naturally occurring 
sphingolipid species (S1P, GluCer 16:0, GalCer 24:1, LacCer 16:0 and 24:0, Cer1P 
16:0 and 24:0, SPH, SPA, SPC, DimetSPH, TrimetSPH, PhytoSPH). A 6 point 
calibration was performed by adding the indicated amounts (0–300 pmol) of a 
combined sphingolipid standard mixture to matrix samples. Calibration curves were 
calculated by linear regression without weighting. 
Data analysis was performed with Analyst Software 1.4.2. (Applied 
Biosystems, Darmstadt, Germany). The data were exported to Excel spreadsheets 
and further processed by self programmed Excel macros which sort the results, 
calculate the analyte/internal standard peak area ratios, generate calibration lines 
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and calculate sample concentrations. Where necessary isotopic overlap of the 
species was corrected based on theoretical isotope distribution according to 
principles described previously (25). Analytes and their corresponding internal 
standards are shown in Table 1. 
 
4.3.6 Analysis of sphingosine-1-phosphate, ceramide and 
sphingomyelin 
Sphingosine-1-phosphate (S1P) was analyzed by LC-MS/MS as described 
previously (18). Ceramide and sphingomyelin species were analyzed by flow 
injection analysis ESI-MS/MS (25;26). 
 
4.4 Results 
 
4.4.1 Sphingolipid fragmentation 
To analyze various sphingolipid classes we applied ESI in the positive ion 
mode and acquired product ion spectra. The fragmentation patterns obtained were in 
accordance to previous studies for SPH, SPA, Cer1P and glycosylated ceramide 
species (Tab. 1) (12;16;19;21;27;28). Glycosylated ceramides displayed [M+H]+ ions 
as well as [M+H-H2O]+ ions generated by in-source fragmentation (data not shown). 
Since [M+H]+ ions exhibited much higher intensities we did not use [M+H-H2O]+ for 
further analysis of glycosylated ceramides. As expected, 
sphingosylphosphorylcholine showed only one intense fragment ion at m/z 184 due 
to the loss of the phosphocholine head group (29). DimetSPH showed beside 
fragments resulting from a loss of one water molecule (m/z 310) or one water 
molecule and a formaldehyde molecule (m/z 280), and an ion at m/z 110, possibly a 
conjugated iminium ion (Fig. 1 A). TrimetSPH showed only one intense fragment 
representing a trimethylammonium-ion at m/z 60 (Fig. 1 B). In contrast to Cer1P 
species showing a sphingoid base fragment, dihydro-Cer-1P displayed a neutral loss 
of phosphoric acid in positive ion mode (Fig. 1 C). Collision induced dissociation of 
PhytoSPH showed two prominent fragment ions, resulting from the loss of one and 
two water molecules (Fig. 1 D). 
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Fig.1. Product ion spectrum and proposed fragmentation of DimetSPH (A), TrimetSPH (B), dhCer1P (C), and PhytoSPH (D) in positive ion mode 
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4.4.2 Hydrophilic interaction chromatography (HILIC) of 
sphingolipids 
Due to the relatively low level of the selected sphingolipids in crude lipid 
extracts, a direct analysis using “shotgun approaches” may be hampered by signal 
suppression caused by other matrix components (12;19;27). Therefore, we decided 
to establish an HPLC separation of sphingolipids with a short analysis time and 
coelution of analyte and internal standard. The latter is of major importance to 
compensate for matrix effects and varying ionization efficiencies, especially during 
gradient elution. Since reversed phase chromatography shows chain length 
dependent separation, coelution of analytes and internal standards may not be 
accomplished (13;16;19;27). ‘Classical’ normal phase chromatography offers polar 
head group specific separation, but may be impaired by limited reproducibility and 
insufficient peak shapes. Moreover, the use of apolar solvents may not provide 
optimal ionization conditions for ESI. Hence, we established an LC separation based 
on hydrophilic interaction chromatography (HILIC) which shows lipid head group 
selectivity along with the use of polar solvents. Using a sub-2-micron particle size we 
achieved baseline separation for all sphingolipid classes within 2 min and 4.5 min 
total run time including re-equilibration (Fig. 2 and 3). Gradient elution was performed 
with a mixture of acetonitrile and water including 0.2% formic acid and 200 mM 
ammonium formate. Addition of formic acid improved the ionization efficiency, an 
optimum was found at 0.2%. For optimum performance and reproducibility it is 
recommended to use at least a concentration of 10 mmol/L ammonium formate in the 
mobile phase. Therefore, 200 mmol/L buffer and 0.2% formic acid were added to 
mobile phase A and 0.2% formic acid to mobile phase B. 
Since numerous MS transitions are required to cover the naturally occurring 
sphingolipid species and their internal standards, we split the MS program into 4 
periods: 0 – 0.75 min (HexCer); 0.75 – 0.89 (LacCer); 0.89 – 1.5 (sphingosine and 
related compounds); 1.5 – 4.5 (SPC) (Fig. 2). 
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Fig. 2. Chromatogram of a sphingolipid standard mixture. Displayed are MS/MS transitions 
representative of distinct sphingolipid classes and their respective internal standards. 
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chromatogram obtained from a human skin fibroblast lipid extract. 
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4.4.3 Extraction efficiency and matrix effects 
To analyze polar sphingolipids from one lipid extract, we tested a butanolic 
extraction as previously described for sphingosine-1-phosphate analysis (18). The 
extraction efficiency was determined in fibroblast homogenate by adding a 
sphingolipid standard mixture before and after extraction (Tab. 2). Mean recoveries 
were between 60-70% and did not vary with concentration of standard added.  
We assessed matrix effects by analyzing a standard mixture in methanol and 
also spiked into fibroblast lipid extracts (Tab.2). Addition of fibroblast cell extract did 
either not influence or slightly increase the signals up to 20%.  
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Table 2. Recovery and matrix effects 
Analyte Spiked 
amount 
[pmol] 
Recovery 
(S.D.) 
(n=4) 
Matrix effect 
(n=4) 
GluCer 16:0 50 66 ± 3 107 ± 4 
 250 62 ± 3 100 ± 5 
GalCer 24:1 50 62 ± 3 108 ± 5 
 250 60 ± 2 101 ± 4 
LacCer 16:0 50 59 ± 2 116 ± 3 
 250 62 ± 3 117 ± 4 
LacCer 24:0 50 60 ± 2 113 ± 3 
 250 61 ± 3 103 ± 5 
Cer1P 16:0 30 68 ± 4 100 ± 4 
 150 64 ± 3 106 ± 5 
Cer1P 24:0 30 64 ± 3 105 ± 4 
 150 62 ± 6 112 ± 5 
dhCer1P 16:0 10 64 ± 7 106 ± 10 
 50 61 ± 2 106 ± 8 
dhCer1P 24:0 10 67 ± 5 109 ± 6 
 50 62 ± 7 105 ± 3 
SPH 60 72 ± 4 100 ± 5 
 300 72 ± 3 111 ± 3 
SPA 30 68 ± 3 100 ± 5 
 150 66 ± 3 104 ± 4 
PhytoSPH 10 69 ± 7 103 ± 6 
 50 70 ± 2 105 ± 4 
DimetSPH 6 69 ± 3 120 ± 6 
 30 63 ± 5 108 ± 7 
TrimetSPH 6 71 ± 2 100 ± 3 
 30 64 ± 5 113 ± 7 
SPC 20 67 ± 8 106 ± 2 
 100 70 ± 7 101 ± 4 
Values represent the percent recovery of standards spiked before and after extraction to 
examine extraction efficiencies. Matrix effects are calculated from fibroblast lipid extracts 
corresponding to 50 µg of cellular protein spiked after extraction (corrected by endogenous 
sphingolipid concentrations) in percent of the same sphingolipid standard mixture used as 
spike. Each value represents the average of four determinations ± standard deviation 
 
4.4.4 Quantification of sphingolipid species 
In order to compensate for variations in sample preparation and ionization 
efficiency, a set of non naturally occurring sphingolipids, GluCer 12:0, LacCer 12:0, 
SPH d17:1, Cer1P 12:0 and SPC d17:1 was added as internal standards (IS) prior to 
extraction. The ratio between analyte and IS was used for quantification as indicated 
in Table 1. We generated calibration lines by addition of different concentrations of 
naturally occurring sphingolipids to human skin fibroblasts (Tab. 3). For glycosylated 
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ceramide species, a possible chain length dependency was addressed by generating 
2 independent calibration lines with a short chain (16:0) and a long chain fatty acid 
(24:0). The obtained standard curves were linear in the tested calibration range. 
Additional evidence for the specificity of the method is derived from the fact that both 
mass transitions used for SPH and SPA analysis (Tab. 1) revealed similar results 
(data not shown). 
Due to coelution, monounsaturated species exhibit an overlap of the M+2 
isotope peak with the corresponding saturated species. To correct this overlap, we 
applied an previously described algorithm based on calculated isotope distributions 
(25). To test this procedure we added increasing amounts of GluCer 24:1 (m/z 810.7) 
to fibroblast homogenate and calculated analyte to IS ratios of GluCer 24:0 (m/z 
812.7) with and without isotope correction. While GluCer 24:0 to IS ratio increased 
almost 2-fold upon addition of 200 pmol GluCer 24:1 without correction, no significant 
increase was detected after correction of isotope overlap (Tab. 4). 
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Table 3. Calibration data of different sphingolipids.  
Sphingolipid Calibration 
range 
[pmol] 
Slope  
(mean ± 
S.D.) 
Correlation 
coefficient  
(mean ± S.D.) 
GluCer 16:0 25 – 250 59.3 ± 5.6 0.997 ± 0.003 
GalCer 24:1 25 – 250 56.1 ± 3.5 0.998 ± 0.001 
LacCer 16:0 25 – 250 123.6 ± 7.8 0.996 ± 0.002 
LacCer 24:0 25 – 250 107.0 ± 6.0 0.994 ± 0.002 
Cer1P 16:0 15 – 150 153.5 ± 8.2 0.997 ± 0.002 
Cer1P 24:0 15 – 150 134.1 ± 6.2 0.994 ± 0.001 
SPH 30 – 300 25.0 ± 1.3 0.996 ± 0.002 
SPA 15 – 150 18.6 ± 2.4 0.998 ± 0.001 
PhytoSPH 10 – 100 9.1 ± 0.5 0.996 ± 0.002 
DimetSPH 0.3 – 3 70.6 ± 4.5 0.999 ± 0.001 
TrimetSPH 0.3 – 3 68.7 ± 7.1 0.996 ± 0.004 
SPC 10 – 100 41.0 ± 3.2 0.996 ± 0.003 
Calibration lines were generated by plotting the ratios of the areas analyte to IS against the 
spiked concentrations (pmol). Each value represents the average of four determinations ± 
SD 
 
Table 4. Correction of isotope overlap.  
GluCer 24:1 
spiked [pmol] 
Ratio 
GluCer 24:1/IS 
Uncorrected ratio 
GluCer 24:0/IS 
Corrected ratio 
GluCer 24:0/IS 
0 2.86 ± 0.16 1.32 ± 0.12 1.18 ± 0.08 
25 4.41 ± 0.24 1.53 ± 0.11 1.28 ± 0.07 
50 5.99 ± 0.39 1.71 ± 0.16 1.35 ± 0.07 
100 8.43 ± 0.44 1.84 ± 0.16 1.30 ± 0.08 
150 10.58 ± 0.52 2.06 ± 0.23 1.36 ± 0.12 
200 16.66 ± 0.99 2.47 ± 0.26 1.33 ± 0.15 
Fibroblast homogenates (100 µg cellular protein) were spiked with increasing amounts of 
GluCer 24:1. Values represent peak area ratios of GluCer 24:1 and 24:0 to GluCer 12:0. The 
GluCer 24:0 peak area ratios are shown before and after isotope correction. The displayed 
values are mean of three independent samples. 
 4. Sphingolipid profiling by LC-MS/MS 97 
 
4.4.5 Assay characteristics 
Assay accuracy was calculated using three spiked fibroblast lipid extracts at 
different concentrations, covering the entire calibration range. Accuracy was found 
between 90 and 110% (Tab. 5).  
Precision was determined in 3 fibroblast samples, containing 25, 50 and 100 
µg of cellular protein (Tab. 5). Coefficients of variation (CVs) were below 10% for 
most species for both intraday and interday precision (Tab. 5). 
Since no analyte free matrix was available, we calculated the limit of detection 
(LOD) defined as a signal-to-noise-ratio of three. While for most of the analyzed 
sphingolipid classes, less than 10 fmol are sufficient for quantification, PhytoSPH and 
dhCer-1P displayed a LOD up to 50 fmol on column (Tab. 1). 
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Table 5. Intraday and interday precisions and accuracy.  
Sphingolipid 
species 
Protein 
[µg] 
Intraday- 
[pmol±S.D.] 
CV 
[%] 
Interday- 
[pmol±S.D.] 
CV[%] spiked 
[pmol] 
Accuracy 
[%] 
HexCer 16:0 
 
25 µg 
50 µg 
100 µg 
2.6±0.1 
5.1±0.3 
10.1±0.8 
4.13 
5.14 
7.89 
2.2±0.2 
5.0±0.2 
9.3±0.6 
7.4 
3.1 
7 
25 
150 
250 
110±8 
109±5 
104±5 
HexCer 22:0 
 
25 µg 
50 µg 
100 µg 
2.5±0.1 
5.1±0.4 
10.3±0.4 
5.7 
8.7 
4.1 
3.0±0.2 
6.1±0.4 
10.7±0.6 
5.7 
5.5 
5.4 
  
HexCer 24:0 
 
25 µg 
50 µg 
100 µg 
7.8±0.4 
15.3±0.7 
30.3±1.1 
5.3 
4.6 
3.7 
8.6±0.4 
17.6±1.0 
33.4±0.8 
4.2 
5.1 
2.4 
  
HexCer 24:1 
 
25 µg 
50 µg 
100 µg 
5.1±0.4 
10.0±0.6 
19.9±0.6 
6.9 
6.1 
2.9 
5.5±0.4 
12.1±0.7 
20.3±0.8 
4.3 
6.2 
3.9 
25 
150 
250 
109±7 
108±5 
104±2 
LacCer 16:0 
 
25 µg 
50 µg 
100 µg 
1.1±0.1 
2.6±0.1 
4.5±0.6 
9 
5 
13 
1.4±0.1 
2.6±0.2 
4.2±0.4 
7.3 
6.8 
8.6 
25 
150 
250 
97±4 
100±6 
99±6 
LacCer 22:0 
 
25 µg 
50 µg 
100 µg 
0.66±0.08 
1.4±0.1 
2.6±0.2 
11.9 
8.1 
7.3 
0.70±0.08 
1.5±0.13 
2.6±0.24 
11.3 
9.1 
9.4 
  
 
LacCer 24:0 
 
25 µg 
50 µg 
100 µg 
1.7±0.1 
3.8±0.2 
7.3±0.9 
7.8 
5.9 
11.8 
2.3±0.1 
4.8±0.3 
7.8±0.8 
6.1 
7.2 
9.9 
25 
150 
250 
95±5 
97±5 
95±5 
LacCer 24:1 
 
25 µg 
50 µg 
100 µg 
1.2±0.05 
2.9±0.2 
5.4±0.7 
4.4 
8.5 
12 
1.5±0.1 
3.6±0.2 
5.7±0.5 
6.5 
6.7 
9.2 
  
SPH 
 
25 µg 
50 µg 
100 µg 
2.5±0.1 
5.1±0.5 
8.7±0.7 
4.3 
9.4 
8.3 
2.1±0.2 
4.6±0.5 
8.5±0.7 
9.7 
10.9 
7.9 
30 
180 
300 
95±5 
97±6 
95±5 
SPA 
 
25 µg 
50 µg 
100 µg 
n.d. 
n.d. 
0.62±0.08 
 
 
13.3 
 
 
0.81±0.06 
 
 
7.4 
15 
90 
150 
104±8 
107±5 
99±2 
PhytoSPH 
 
25 µg 
50 µg 
100 µg 
n.d. 
n.d. 
2.4±0.2 
 
 
7.5 
 
 
2.2±0.2 
 
 
8.6 
10 
60 
100 
97±9 
96±9 
97±5 
DimetSPH 
 
25 µg 
50 µg 
100 µg 
0.12±0.01 
0.27±0.03 
0.44±0.03 
9.3 
9.7 
4.8 
0.13±0.01 
0.24±0.03 
0.44±0.03 
11.2 
9.4 
6.6 
0.3 
1.8 
3 
108±9 
96±9 
90±5 
TrimetSPH 
 
25 µg 
50 µg 
100 µg 
0.12±0.01 
0.22±0.03 
0.37±0.03 
9.3 
11.9 
8.4 
0.11±0.01 
0.23±0.03 
0.45±0.04 
11 
11.6 
9.7 
0.3 
1.8 
3 
93±8 
109±7 
95±5 
SPC 
 
25 µg 
50 µg 
100 µg 
n.d. 
n.d. 
0.58±0.06 
 
 
11.0 
 
 
0.64±0.06 
 
 
9.7 
10 
60 
100 
111±8 
107±5 
109±4 
Cer1P 16:0 
 
25 µg 
50 µg 
100 µg 
n.d. 
1.3±0.09 
3.2±0.02 
 
6.4 
8.0 
 
1.5±0.1 
3.5±0.3 
 
6.8 
7.5 
15 
90 
150 
109±8 
106±7 
101±4 
Cer1P 24:0 
 
25 µg 
50 µg 
100 µg 
n.d. 
n.d. 
4.9±0.4 
 
 
8.4 
 
 
5.5±0.5 
 
 
9.3 
15 
90 
150 
107±8 
110±9 
103±6 
dhCer1P 24:0 
 
25 µg 
50 µg 
100 µg 
n.d. 
n.d. 
6.4±0.5 
 
 
8.1 
 
 
5.9±0.5 
 
 
8.1 
5 
30 
50 
92±5 
102±7 
100±5 
The displayed values are mean concentrations in pmol and the coefficient of variation (CV) of 
human skin fibroblasts lipid extracts corresponding to 25, 50 and 100 µg of cellular protein. A 
pool of fibroblast homogenates was aliquoted and lipid extracts were analyzed in series for 
intraday precision (n=6) and on 6 different days for interday-precision (n=6). 
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Accuracy is displayed as the mean of the assayed concentration (corrected by endogenous 
sphingolipid concentrations in human skin fibroblasts) in percent of the spiked concentration. 
Each value represents the average of three determinations ± standard deviation 
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Table 6. Lipid extracts prepared from fibroblasts either homogenized in water by sonication or lysed in 0.2% SDS. 
 
HexCer LacCer SPH SPA PhytoSPH Cer1P 
Fatty acid 16:0 22:0 23:0 24:1 24:0 16:0 22:0 23:0 24:1 24:0    16:0 
Water 253±13 129.1±7.0 41.2±3.7 290±16 315±19 42.2±3.3 50.6±7.1 16.1±2.9 1356±13 94.5±2.4 72.8±7.1 15.8±2.1 20.7±0.1 3.7±0.5 
0.2%SDS 233±5 119.7±0.4 36.0±1.5 265±4 278±10 46.6±1.1 55.0±6.2 17.8±1.9 136±9 110.5±9.5 84.6±4.4 16.1±1.6 17.4±0.7 4±0.5 
The displayed values are mean [nmol/mg cellular protein] ± standard deviation of 3 independent samples. 
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4.4.6 Preparation of cell culture samples and sample stability 
Since a main application of this method is the analysis of cultured cells we 
tested different methods to harvest the cells. First, a precursor ion scan of m/z 264 
was applied to check which HexCer, LacCer and Cer1P species are found in primary 
human skin fibroblasts. For both HexCer and LacCer, we found 16:0, 22:0, 23:0, 24:0 
and 24:1 species; for Cer1P only 16:0 was detected. To compare sample 
preparations, fibroblasts were either scraped in PBS and homogenized in water by 
sonication or lysed in 0.2 % sodium dodecyl sulfate (SDS). Both sample preparations 
did not differ in their ionization response since IS signals were similar (data not 
shown). Cells lysed in water showed about 10% higher HexCer and PhytoSPH levels 
as well as slightly decreased LacCer 16:0, 22:0, 24:0 and 15% decreased SPH level 
(Tab. 6). For reproducibility, SDS showed advantages compared to water, which 
gave higher SDs. 
Next we tested the stability of the homogenates. Fibroblast homogenates 
prepared either in water or SDS were frozen immediately or after 6h at room 
temperature. Storage at room temperature showed no effect on most sphingolipid 
levels, except a slight increase of SPH and Cer1P in SDS and PhytoSPH in water 
(Tab. 7). 
 
Table 7. Sample stability 
% change 
after 6h RT 
HexCer LacCer SPH SPA PhytoSPH Cer1P 
Water 98 ± 1 105 ± 6 100 ± 3 96 ± 5 113 ± 9 98 ± 7 
0.2%SDS 101 ±7 96 ± 9 111 ± 2 101± 8 97 ± 5 113 ± 3 
Fibroblasts, either homogenized in water by sonication or lysed in 0.2% SDS, were stored 
immediately at -80°C or for 6 h at room temperature . The displayed values are percent of the 
immediately stored fibroblast cell homogenates. The displayed values are the mean ± SD of 
3 independent samples. 
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4.4.7 Analysis of fibroblasts treated with myriocin/sphingosine-
kinase inhibitor 
To test feasibility of this novel method we treated primary human skin 
fibroblasts either with myriocin, an inhibitior of serine-palmitoyl transferase (SPT) (30) 
or sphingosine-kinase inhibitor (SKI) (30-33). To obtain the full range of sphingolipid 
concentrations we additionally analyzed sphingosine-1-phosphate, sphingomyelin 
and ceramide species using previously described methods (18;25;26;28).  
Myriocin decreased cellular S1P and SPC levels at sub-nanomolar 
concentrations to 60% and 40% of the untreated control (Fig. 4A). The other 
analyzed sphingolipid classes showed only minor changes upon treatment with 
myriocin up to 1 nM (Fig. 4A/B). The most pronounced effects were observed at 5 nM 
myriocin, with decreased Cer, HexCer, LacCer and free sphingoid bases 
concentrations and a further decline of S1P and SPC level.  
SKI treatment of fibroblasts at nanomolar concentrations decreased S1P and SPC by 
more than 50% (Fig. 4C). Micromolar concentrations of SKI resulted in S1P below 
and SPC concentration close to the LOD, and lead to a pronounced increase in the 
level of the free sphingoid base. Interestingly, increased levels of SPA were 
paralleled by dihydro-SM (Fig. 4C/D). SKI treatment in the pharmacological range 
(0.5-5 µM) (34) did not change Cer and SM levels significantly (Fig. 4). Surprisingly, 
SKI treatment decreased LacCer at low concentrations.  
Taken together these data show that drug treatments that affect enzymes 
involved in sphingolipid metabolism may not only affect the targeted metabolites, but 
the whole pathway.  
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Fig. 4. The effect of myriocin and sphingosine kinase inhibitor on intracellular sphingolipids in primary human skin fibroblasts. 
Cells were treated with increasing concentrations of myriocin (A + B) and sphingosine kinase inhibitor (C + D) for 24 hours, respectively. SPH 
(closed circle), SPA (open circle), SPC (closed triangle), S1P (open triangle), HexCer (open triangle) and LacCer (closed square) were quantified 
by LC-MS/MS; Cer (closed triangle), SM (closed circle) and dhSM (open circle) were quantified by flow injection analysis (ESI-MS/MS). Values 
represent the mean ± SD of three independent samples. 
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4.5 Discussion 
 
Sphingolipid metabolism consists of a dynamic network of molecules including 
important bioactive signaling molecules (1-9). Therefore, to understand the function 
of sphingolipids it is necessary to assess a sphingolipid profile instead of one single 
metabolite.  
Although analysis of the “sphingolipidome” by shotgun approaches has been 
recently demonstrated for yeast (35), an analysis of a more complex sphingolipid 
pattern in mammalian systems may be hampered, especially for minor metabolites, 
by signal suppressing matrix effects or lack of sensitivity (12;19;27).  
In this study we present a novel LC-MS/MS method to quantify various 
sphingolipid species from cultured cells. In contrast to most previous methods using 
reversed-phase chromatography (10;11;15;16;19;21;27), we applied hydrophilic 
interaction chromatography (HILIC) which allows coelution of analytes and non 
natural occurring internal standards. This is a key feature of LC-based MS-methods 
since matrix effects and ionization response may vary during LC-separation 
especially when gradient methods are used. Consequently, only coelution of analytes 
with adequate internal standards may compensate for these effects and prevent mis-
quantification. Due to the coelution of multiple species an isotopic overlap of species 
is possible. Therefore, we corrected peak areas according to principles described 
previously (25) to avoid an overestimation of species.  
Further advantages of our method are a short analysis time of 4.5 min per 
sample and a simple liquid-liquid extraction as sample preparation. Since the 
presented method uses the same butanolic extraction and LC components as a 
previously described method for S1P and lysophosphatidic acid analysis (18) it is 
possible to analyze both sets of analytes from one extract. Consequently, one can 
achieve with two straightforward liquid-liquid extractions (Bligh and Dyer and butanol) 
a full coverage of the main sphingolipid metabolites (25;26) as well as 
glycerophospholipids (22;25;36) and cholesterol/cholesteryl ester (37). Calibration 
was performed in the sample matrix by addition of naturally occurring species prior to 
lipid extraction. This allows compensation for potential matrix effects on ionization 
and extraction efficiency as well as for small retention time differences observed 
between short chain and very long chain species. Moreover, a full validation was 
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performed according to FDA guidelines (28). This extensive validation showed 
excellent precision, accuracy and sensitivity for all analyzed sphingolipid classes. 
First applications of this method showed that sample preparation methods 
may influence sphingolipid levels particularly HexCer and free sphingoid bases. Due 
to reproducibility and handling reasons we prefer a direct lysis of cultured cells with 
0.2% SDS instead of scraping cells. However, immediate freezing of the samples 
until analysis is advisable. Finally, treatment of fibroblasts with myriocin and SKI 
demonstrated the importance of methods covering multiple instead of single 
sphingolipid metabolites. Since treatment affected not only direct metabolites but 
almost the whole pathway including unexpected concentration changes of some 
species.  
In summary, we could show that LC-MS/MS-based sphingolipid-profiling using 
HILIC may provide a powerful tool to understand regulatory and metabolic 
mechanisms involved in cellular sphingolipid homeostasis. Similar as previously 
shown for glycerophospholipid metabolism (22) this method can be also used for 
metabolic profiling using stable isotope labeled precursors. 
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5 Sphingolipid profiling of human plasma and FPLC-
separated lipoprotein fractions by hydrophilic 
interaction chromatography tandem mass spectrometry 
 
5.1 Abstract 
 
Sphingolipids comprise bioactive molecules which are known to play important 
roles both as intracellular and extracellular signalling molecules. Here we used a 
previously developed hydrophilic interaction chromatography tandem mass 
spectrometry (HILIC-MS/MS) method to profile plasma sphingolipids.  
Method validation showed sufficient precision and sensitivity for application in 
large clinical studies. Sample stability testing demonstrated that immediate plasma 
separation is important to achieve reliable results. Analysis of plasma from 25 healthy 
blood donors revealed a comprehensive overview of free sphingoid base, 
sphingosylphosphorylcholine (SPC), hexosylceramide (HexCer), lactosylceramide 
(LacCer), and ceramide-1-phosphate (Cer1P) species level. Beside the major 
sphingoid base sphingosine (d18:1) we found d16:1 and d18:2 species in most of 
these lipid classes. Interestingly, despite HexCer serves as precursor of LacCer 
pronounced differences were detected in their species profiles. Additionally, 
sphingolipids were quantified in lipoprotein fractions prepared by fast performance 
liquid chromatography (FPLC). HexCer and LacCer showed similar distributions with 
about 50% in LDL, 40% in HDL and less than 10% in the VLDL fraction. More than 
90% of sphingoid base phosphates were found in HDL and albumin containing 
fractions. 
In summary, HILIC-MS/MS provides a comprehensive picture of minor 
sphingolipid species in plasma and their lipoprotein levels. Comparing profiles from 
tissues or blood cells, these species profiles may help to address the origin of plasma 
sphingolipids.  
 5. Plasma sphingolipid analysis by LC-MS/MS 111 
 
5.2 Introduction 
 
Sphingolipids comprise bioactive molecules (1-7) that influence various 
cellular functions including growth arrest, apoptosis, proliferation and differentiation. 
Beside their intracellular signalling functions, sphingolipids act extracellularly by 
binding to specific receptors. They play important roles in several diseases including 
cancer, vascular and metabolic diseases (1;5;6;8-10).  
A number of publications investigated plasma level of sphingomyelin, 
ceramide species and sphingosine-1-phosphate as well as their biological function 
and disease association (3;11-19). Apart from two recent publications (20;21) only 
limited information is available on the occurrence of minor sphingolipid species in 
human plasma.  
Recently we developed a fast and reliable liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) method for sphingolipid profiling based on 
hydrophilic interaction chromatography (HILIC) which allows the simultaneous 
quantification of sphingoid bases and their methylated products, 
sphingosylphosphorylcholine (SPC), hexosylceramide (HexCer), lactosylceramide 
(LacCer) and ceramide-1-phosphate (Cer1P) species (22).  
Aim of this study was to provide a detailed sphingolipid pattern of human 
plasma and lipoprotein fractions. Therefore, we analyzed sphingolipid species of 
human plasma from healthy blood donors by HILIC-MS/MS (22;23). Additionally, we 
analyzed the sphingolipid class and species composition of lipoprotein fractions 
separated by fast performance liquid chromatography (FPLC) (19)  
 
5.3 Material and Methods 
 
5.3.1 Subjects 
Blood samples were obtained from healthy normo-lipidemic volunteers. 
Informed consent and approval of the Hospital Ethics Committee were obtained. 
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5.3.2 Sample preparation 
75 µL human EDTA-plasma were used for sphingolipid analysis. 20 µL of an 
IS-mixture (20 ng 13C2D2-S1P, 20 ng SPH d17:1, 2 ng SPC d17:1, 20 ng GluCer 
d18:1/12:0, 20 ng LacCer d18:1/12:0 and 20 ng Cer1P d18:1/12:0) were added prior 
to lipid extraction. We used a butanolic extraction procedure described by Baker et 
al. (24). In brief, human-EDTA plasma was mixed with 400 µL of a buffer containing 
30 mM citric acid and 40 mM disodium hydrogenphosphate (pH 4). Extraction was 
performed with 1 mL of 1-butanol and 500 µL of water-saturated 1-butanol. The 
recovered butanol phase was evaporated to dryness under reduced pressure. The 
residue was redissolved in 50 µL ethanol. 
 
5.3.3 Sphingolipid quantification by LC-MS/MS  
Sphingolipid analysis was performed by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) as described previously (22;23) except following changes: 
Gradient chromatographic separation was performed on a Interchim (Montlucan, 
France) hydrophilic-interaction chromatography (HILIC) silica column (50 x 2.1 mm, 
2.2 µm particle size) equipped with a 0.5 µm pre-filter (Upchurch Scientific, Oak 
Harbor, WA, USA). The injection volume was 2 µL for sphingolipid analysis in 
positive (22) and 10 µL for S1P analysis (23) in negative ionization mode. The 
MS/MS parameter used are shown in Tab. 1. 
Quantification was achieved by a 6 point standard addition calibration of 
natural occurring sphingolipid species to plasma (S1P, SA1P, GluCer d18:1/16:0, 
GalCer d18:1/24:1, LacCer d18:1/16:0, LacCer d18:1/24:0, Cer1P d18:1/16:0, Cer1P 
d18:1/24:0, SPH d18:1, SPH d18:0, SPH t18:0, SPC d18:1, DimetSPH, TrimetSPH). 
Because of their co-elution, sphingolipid species may exhibit isotope overlap. To 
avoid overestimation of these species, their peak areas were corrected based on 
theoretical isotope distribution according to principles described previously (25). 
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Table 1. MS parameter (IS = internal standard, CE = collision energy) and limit of detection of sphingolipids studied.  
Sphingolipid [M+H]+/[M-H]- 
m/z 
MRM IS (MRM) CE  
[V] 
Retention time  
[min] 
LOD  
[nmol/L] 
SPH d16:1 272.3 272.3→254.2 SPH d17:1 (286.3→268.2) 17 0.95 - 
SPH d18:2 298.3 298.3→280.2 SPH d17:1 (286.3→268.2) 17 0.95 - 
SPH d18:1 300.3 300.3→282.2 SPH d17:1 (286.3→268.2) 17 0.95 8.8 
 300.3 300.3→252.2 * SPH d17:1 (286.3→238.2) 25 0.95 10.1 
SPH d18:0 302.3 302.3→284.2 SPH d17:1 (286.3→268.2) 21 0.95 9.7 
SPH d20:1 328.3 328.3→282.2 SPH d17:1 (286.3→268.2) 17 0.95 - 
SPH t18:0 318.3 318.3→282.2 SPH d17:1 (286.3→268.2) 23 0.95 16.8 
Dimethyl-SPH 328.4 328.4→280.2 SPH d17:1 (286.3→268.2) 29 0.95 0.3 
Trimethyl-SPH 342.4 342.4→60.1 SPH d17:1 (286.3→268.2) 49 0.95 0.3 
SPC d16:1 437.3 437.3→184 SPC d17:1 (451.3→184) 31 1.70 - 
SPC d18:1 463.3 463.3→184 SPC d17:1 (451.3→184) 31 1.70 2.7 
SPC d18:2 465.3 465.3→184 SPC d17:1 (451.3→184) 31 1.70 - 
HexCer d16:1 var. M+H+→236.3 GluCer d18:1/12:0 (644.5→264.3) 55 0.68 - 
HexCer d18:1 var. M+H+→264.3 GluCer d18:1/12:0 (644.5→264.3) 55 0.68 3.8 
HexCer d18:2 var. M+H+→262.3 GluCer d18:1/12:0 (644.5→264.3) 55 0.68 - 
LacCer d16:1 var. M+H+→236.3 LacCer d18:1/12:0 (806.6→264.3) 63 0.82 - 
LacCer d18:1 var. M+H+→264.3 LacCer d18:1/12:0 (806.6→264.3) 63 0.82 4.2 
LacCer d18:2 var. M+H+→262.3 LacCer d18:1/12:0 (806.6→264.3) 63 0.82 - 
Cer1P d18:1 var. M+H+→264.3 Cer1P d18:1/12:0 (562.4→264.3) 39 1.07 3.6 
S1P d18:1 ** 378.1 378.1→79 13C2D2-S1P (382.1→78.9) -58 1.49 6 
S1P d18:0 ** 380.1 380.1→79 13C2D2-S1P (382.1→78.9) -58 1.49 6 
* A neutral loss of m/z 48 also used to analyze the sphingoid bases d16:1, d18:2, d18:0, d20:1. 
** Analyzed in negative ion mode as described previously [23]. 
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5.3.4 Lipoprotein separation by FPLC 
VLDL, LDL and HDL were isolated from healthy blood donors (n=25) as 
described previously (19). In brief, a Pharmacia Smart System® FPLC equipped with 
a Superose 6 PC 3.2/30 column (GE Healthcare Europe GmbH, Munich, Germany) 
was used with Dulcobecco’s PBS containing 1 mM EDTA as a running buffer. After 
loading of 50 µL plasma into the system, a constant flow of 40 µL/min was applied, 
and fractionation was started after 18 min with 80 µL per fraction. Fractions 1-20 
containing the human plasma lipoproteins were used for further analysis. In order to 
check lipoprotein fractionation cholesterol and triglyceride levels of each fraction 
were determined on a Cobas Integra 400 (Roche Diagnostic, Penzberg, Germany) 
using standard enzymatic, colorimetric methods. Mass spectrometric analysis was 
performed either from single fractions or pooled lipoprotein fractions (fractions 3 to 6 - 
VLDL, 7 to 11 - LDL and 12 to 17 – HDL, 18 to 20 - LPDS). 
 
5.3.5 Preparation of lipoproteins by ultracentrifugation 
Lipoprotein fractions were isolated from plasma of healthy volunteers by 
sequential ultracentrifugation as described previously (26). 
 
5.4 Results 
 
5.4.1 Sphingolipid species of human EDTA-plasma 
Here we applied a previously established LC-MS/MS method for sphingolipid 
profiling based on hydrophilic interaction chromatography (HILIC) for the analysis of 
human plasma samples (22). Key feature of this method is co-elution of analytes and 
internal standards permitting an accurate compensation of matrix effects and varying 
ionization efficiencies (Fig. 1). To identify naturally occurring sphingolipid species, we 
screened in an initial step human EDTA-plasma samples (n=15). It is known that 
plasma sphingolipids contain beside the major base sphingosine d18:1 (mono-
unsaturated dihydroxy base with 18 carbon atoms) (4;27;28) also significant amounts 
of other sphingoid bases including d16:1 and d18:2 (29). Therefore, we performed 
several precursor ion scan experiments using characteristic fragment ions (Tab. 1). 
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Free sphingoid bases (SPH) d18:1 and d18:0 as well as a variety of 
hexosylceramides (HexCer), lactosylceramides (LacCer) species and 
sphingosylphosphorylcholine (SPC) with d16:1, d18:1 and d18:2 backbones were 
detected (Tab. 2). We did not find methylated sphingoid bases and only ceramide-1-
phosphate Cer1P d18:1/16:0.  
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ig. 1. Chromatogram of a representative human EDTA-plasma sample. 
Displayed is a representative mass chromatogram obtained from an human EDTA-plasma 
sphingolipid extract 
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Table 2. Plasma concentrations of sphingolipids and their distribution on lipoprotein fractions. 
Sphingolipid C [µmol/L] 
Mean (SD) 
VLDL (%) LDL (%) HDL (%) LPDS (%) 
SPH d18:1  0.038 (0.013) - - - - 
SPH d18:0  0.012 (0.006) - - - - 
SPH d16:1  n.d. - - - - 
SPH d18:2  n.d. - - - - 
SPH t18:0  n.d. - - - - 
Dimethyl-SPH n.d. - - - - 
Trimethyl-SPH n.d. - - - - 
SPC d18:1  0.053 (0.030) 14.2 (0.4) 35.7 (9.9) 45.8 (5.8) * 4.3 (0.68) * 
SPC d16:1  0.009 (0.006) - - - - 
SPC d18:2  0.027 (0.017) - - - - 
HexCer Total  6.35 (1.77) 8.0 (4.9) 49.1 (8.3) 42 (8.8) n.d. 
HexCer d16 1  0.22 (0.09) 6.6 (4.8) 50.2 (13.4) 43.3 (13.5) n.d. 
HexCer d18 1  5.56 (1.54) 8.1 (4.8) 49.5 (8.2) 41.5 (8.6) n.d. 
HexCer d18 2  0.57 (0.19) 7.7 (6.5) 45 (8.7) 46.8 (10.3) n.d. 
LacCer Total  2.92 (0.97) 8.2 (5.2) 46.4 (10.2) 44.4 (10) n.d. 
LacCer d16 1  0.13 (0.05) n.d. 48.7 (11.5) 51.3 (11.5) n.d. 
LacCer d18 1  2.54 (0.84) 9.0 (5.8) 46.9 (10.2) 43.1 (9.9) n.d. 
LacCer d18 2  0.26 (0.10) 5.4 (4.8) 42.3 (11.5) 52.1 (13.1) n.d. 
Cer1P d18:1 0.062 (0.020) - - - - 
S1P d18:1 0.53 (0.09) 1.7 (1) 6.4 (3.8) 90.1 (14.5) * 1.8 (0.1) * 
S1P d18:0 0.29 (0.09) 1.8 (3.2) 3.2 (5.7) 90.8 (13.2) * 4.1 (3.8) * 
The displayed values are means ± SD of 25 healthy volunteers from freshly drawn EDTA-
plasma and their relative distribution on lipoprotein fractions. Lipoprotein fractions were 
prepared by FPLC separation (following fractions were pooled 3-6 VLDL, 7-11 LDL, 12-17 
HDL, 18-20; see Fig. 4). Due to concentrations below or close to the limit of detection, 
lipoprotein distribution was not calculated for free sphingoid bases, SPC d16:1/d18:2 and 
Cer1P. For Cer1P only Cer1P d18:1/16:0 was detected above LOD. * HDL fractions contain 
a significant amount of albumin. n.d. not detected above LOD. 
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5.4.2 Validation of plasma sphingolipid analysis 
To test validity of our analytical setup we performed a number of experiments. 
EDTA-plasma of 3 donors was analyzed 5 times in a row for intra-assay precision 
and at 5 different days for inter-assay precision. The coefficients of variation (CV) 
were below 8% for the major species and below 20% for the minor d16:1 and d18:2 
containing HexCer and LacCer species, respectively (data not shown). For 
quantification a set of non naturally occurring internal standards were added prior to 
lipid extraction. Calibration lines generated by standard addition showed correlation 
coefficients >0.99 in the tested calibration range (data not shown). Limits of detection 
(LODs) were determined in 3 different human plasma samples as a signal to noise 
ratio of 3 and were found to be <20 nmol/L (Tab.1).  
Sample stability was investigated for separated EDTA plasma and whole 
blood at room temperature. Sphingolipid levels in separated plasma samples did not 
change significantly up to 24h when stored at room temperature (Tab. 3). Whole 
blood samples showed an increase of SPH d18:1 and d18:0 levels and a decrease of 
SPC and Cer1P levels at room temperature (Tab. 4). Consequently, immediate 
plasma separation is important to achieve reliable results.  
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Table 3. Stability of plasma samples.  
Conditions HexCer 
Mean (SD) 
LacCer 
Mean (SD) 
SPH 
Mean (SD) 
SPA 
Mean (SD) 
SPC 
Mean (SD) 
Cer1P 
Mean (SD) 
1h RT 103 (5) 110 (9) 96 (10) 91 (4) 93 (12) 104 (8) 
4h RT 97 (8) 101 (4) 92 (8) 102 (10) 102 (4) 103 (5) 
8h RT 111 (12) 108 (9) 107 (4) 107 (5) 111 (8) 102 (12) 
24h RT 108 (8) 113 (19) 97 (9) 101 (11) 102 (2) 112 (9) 
EDTA plasma is stored for the indicated time at room temperature (RT). The displayed 
values are percent of the immediately stored plasma sample. Plasma is stored at -80°C until 
analysis. The values are mean of two donors. 
 
Table 4. Stability of whole blood samples.  
Conditions HexCer 
Mean (SD) 
LacCer 
Mean (SD) 
SPH 
Mean (SD) 
SPA 
Mean (SD) 
SPC 
Mean (SD) 
Cer1P 
Mean (SD) 
1h RT 101 (12) 98 (9) 105 (7) 92 (10) 83 (2) 104 (13) 
4h RT 106 (6) 104 (4) 136 (6) 112 (3) 61 (4) 88 (4) 
8h RT 111 (14) 108 (10) 177 (9) 132 (14) 62 (15) 82 (14) 
24h RT 117 (15) 118 (12) 191 (20) 152 (8) 62 (13) 81 (10) 
EDTA whole blood is stored at room temperature (RT) and plasma is separated at the time 
indicated. The displayed values are percent of the immediately stored plasma sample. The 
values are mean of two donors. 
 
5.4.3 Plasma level of sphingolipid species 
We quantified the sphingolipid profile in samples of EDTA-containing plasma 
and serum, prepared from blood samples freshly drawn from human volunteers 
(n=25). Sphingolipid concentrations showed no notable differences between plasma 
and serum samples (data not shown). Mean concentrations of the analyzed 
sphingolipid classes are shown in Tab.2. The major sphingoid base was d18:1 with 
76% of all free bases, 60 % of SPC and almost 90 % of HexCer and LacCer. 
Additionally, d16:1 and d18:2 bases contribute similarly to HexCer (3.5% and 9.0% of 
total) and LacCer (4.5% and 8.9% of total), respectively.  
In a next step we calculated species profiles of the analyzed glycosylated 
ceramides. Interestingly, HexCer and LacCer species showed significantly different 
species pattern (Fig. 2 and 3). Whereas the main HexCer species contained 22:0, 
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24:1 and 24:0 amide-linked fatty acids, more than 80% of LacCer consisted of 
LacCer 16:0 and 24:1. Remarkably, the proportion of HexCer d18:1/16:0 was 2-fold 
higher compared to the proportion of HexCer d16:1/16:0 and HexCer d18:2/16:0. 
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Fig. 2. HexCer species pattern of plasma and lipoprotein classes.  
HexCer species were calculated as % mol of the lipid species related to the total HexCer 
concentration in plasma and lipoprotein fractions, respectively (mean ± SD, n=25 different 
donors; fractions were pooled as described in Tab. 2). Calculations were made separately for 
the different sphingoid base backbones. 
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Fig. 3. LacCer species pattern of plasma and lipoprotein classes.  
LacCer species were calculated as % mol of the lipid species related to the total LacCer 
concentration in plasma and lipoprotein fractions, respectively (mean ± SD, n=25 different 
donors; fractions were pooled as described in Tab. 2). Calculations were made separately for 
the different sphingoid base backbones. 
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5.4.4 Sphingolipid distribution on lipoprotein fractions 
To gain insight into the sphingolipid composition of lipoproteins we used a 
previously established FPLC-size exclusion chromatography (19). In a first step, we 
quantified single FPLC fractions prepared from EDTA plasma by HILIC-MS/MS 
(22;23). As expected, most of the sphingolipids revealed a distribution representing 
the three main lipoprotein classes VLDL, LDL and HDL. The majority of both HexCer 
and LacCer were found in LDL and HDL fractions with similar distribution also for 
their distinct sphingoid base backbones (Fig. 4A-B). S1P d18:1 and d18:0 were 
abundantly present in HDL (Fig. 4C). SPC was found in all three lipoprotein fractions 
VLDL, LDL, HDL with the highest level in HDL. For both sphingoid base phosphates 
and SPC, a minor fraction also was observed in the lipoprotein deficient serum 
(LPDS). These distribution profiles are indicative for albumin binding. Since albumin 
co-elutes with HDL fractions in the used FPLC method (19), HDL and albumin-bound 
fractions cannot be differentiated for sphingoid base phosphates and SPC.  
Similar to our previous study (19) we analyzed pooled VLDL, LDL, HDL, LPDS 
lipoprotein fractions of 25 healthy blood donors. The distribution of the sphingolipid 
classes across the main lipoproteins are displayed in Tab. 2. These data confirm the 
distribution observed in the single fraction analysis (Fig. 4). Additionally, the species 
profiles of HexCer and LacCer were analyzed in pooled lipoprotein fractions (Fig. 2 
and 3). In general, the species profiles of the lipoprotein fractions resemble those of 
plasma. VLDL shows some striking differences with increased HexCer d16:1/24:1 
and LacCer d18:2/16:0 proportions.  
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Fig. 4. Sphingolipid profile of FPLC fractions from a human EDTA-plasma sample. 
Sphingolipids were quantified by HILIC-MS/MS from FPLC separated fractions in positive 
and negative ionization mode, respectively. Displayed are percentages of each fraction 
related to total sphingolipid class concentration: (A) SPC, S1P, SA1P distributions, (B) 
HexCer d18:1, d16:1 and d18:2 distributions, (C) LacCer d18:1, d16:1 and d18:2 
distributions. 
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5.5 Discussion 
 
Several studies indicated a disease association of plasma sphingolipid 
species and their potential application as biomarker (3;11-18). Here we applied and 
validated a previously reported HILIC-MS/MS method for sphingolipid quantification 
in cell cultures (22) for the analysis of plasma. Main advantage of HILIC compared to 
reversed phase chromatography is co-elution of analytes and internal standards, a 
prerequisite to compensate for matrix effects and variations in ionization efficiency. 
Furthermore, the butanol extracts may be used in parallel for the quantification of 
sphingoid base-phosphates and lysophosphatidic acid (LPA) species, respectively 
(23). 
Validation showed precision <8% for the major sphingolipids and <20% for the 
minor sphingolipids sufficient for clinical studies. Although testing of sample stabilities 
revealed only relevant changes in whole blood samples for free sphingoid bases and 
SPC, it is generally recommended to separate plasma immediately and to store it at 
-80°C until analysis. Particularly, an instant free zing of plasma is mandatory for a 
combined analysis of sphingoid base-phosphate and LPA (23).  
HILIC-MS/MS was applied to screen and quantify sphingolipid species level of 
both EDTA-plasma and lipoprotein fractions prepared by FPLC. During the final 
preparation of this manuscript two other studies using LC-MS/MS were published on 
plasma lipid species level (21) and sphingolipid level in plasma/serum and 
lipoproteins (20). While Quehenberger et al. (21) provided data on various sphingoid 
backbones, Hammad et al. (20) only analyzed d18:1 and d18:0-based sphingolipid 
species.  
For free sphingoid bases the levels reported were quite heterogeneous: All 
studies detected SPH d18:0 (Hammad – 4 nM; Quehenberger – 64 nM; this study 12 
nM), and SPH d18:1 (Hammad – 6 nM; Quehenberger – 91 nM; this study 38 nM). A 
biomarker study on fumonisin consumption based on conventional HPLC after 
fluorescence derivatization quantified sphinganine and sphingosine levels of 6 and 
20 nM, respectively. 
It is known that the vast majority of HexCer in human plasma is 
glucosylceramide and only a small fraction of galactosylceramide (21;30-33). A mean 
HexCer level of 6.3 µM reported in this study closely matches concentrations of 6.0 
µM found by Dawson et al. (31) (analyzed by TLC followed by GC-MS) and 6.5 µM 
126 5. Plasma sphingolipid analysis by LC-MS/MS  
 
 
 
by Hammad et al., whereas Quehenberger et al. reported 2.3 µM. LacCer level of 2.9 
µM in our study were lower compared to 4.5 µM detected by Dawson et al. (31) and 
10.4 µM by Hammad et al. 
A Cer1P level of 62 nM measured in this study was dramatically lower than 
540 nM determined by Hammad et al. and the species profiles differed considerably 
(this study detected only 16:0; Hammad: 26:0, 18:0 as major and 16:0 as minor 
species). For SPC d18:1 Murph et al. reported 20 nM, a similar order of magnitude as 
53 nM in this study.  
As previously described by Karlsson et al. (29) we found beside the major 
d18:1 sphingoid backbone significant amounts of d16:1 and d18:2. Interestingly, 
although GluCer is the precursor of LacCer, HexCer differs completely in its species 
pattern (Fig. 3 and 4). The pattern described in this study does not correspond to a 
previous report showing only a minor fraction of C24-fatty acids in HexCer and a 
significant fraction of C22 and C24 species in LacCer (32). However, major HexCer 
(except lower Hex 24:1 fraction) and LacCer species found by Hammad et al. and 
HexCer species in the study by Quehenberger et al. were comparable to our study.  
Additionally, we describe the distribution of HexCer, LacCer, SPC and 
sphingoid base phosphates on lipoprotein fractions separated by a previously 
established FPLC method (19). As described by Dawson et al. (31), HexCer and 
LacCer showed a similar distribution on lipoprotein fractions. Compared to this report 
using ultracentrifugation we found lower proportions in VLDL (8% vs. 13-14%) and 
LDL (46-49% vs. 59-60%) but higher glycosylated ceramides in the HDL fraction (42-
44% vs. 26-28%). The distribution of sphingoid base phosphates measured in this 
study confirms data by Murata et al. (34) (measured by radioreceptor-binding assay) 
and Hammad et al. in lipoprotein fractions prepared by ultracentrifugation. Since HDL 
and albumin overlap in the FPLC separation used (19), we can only report that more 
than 90% of sphingoid base phosphates reside in these fractions (90% Murata et al.; 
95% S1P 18:1 Hammad et al.). Interestingly, LDL carries with 6% a 2-fold higher 
fraction of S1P 18:1 compared to S1P 18:0 (Tab. 2) which is in contrast to Hammad 
et al. where 14% of S1P 18:0 was found in the LDL fraction. Taken together a 
number of discrepancies were observed between studies of sphingolipid species 
concentration in plasma and lipoproteins. Consequently, further studies and 
standardization of methods are required to establish reliable sphingolipid level in 
human plasma. 
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In summary, HILIC-MS/MS provides a comprehensive overview of minor 
sphingolipid species in plasma and lipoproteins. These species profiles may help to 
address the origin of plasma sphingolipids by comparison with tissue or blood cell 
species pattern (35). Moreover, the presented method may be used for the plasma 
sphingolipid profiling in large clinical studies to find novel lipid biomarker. 
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6 Rapid quantification of bile acids and their conjugates in 
serum by liquid chromatography – tandem mass 
spectrometry 
 
6.1 Abstract 
 
Beside their role as lipid solubilizers, bile acids (BAs) are increasingly 
appreciated as signaling factors. As ligands of G-protein coupled receptors and 
nuclear hormone receptors BAs control their own metabolism and act on lipid and 
energy metabolism. To study BA function in detail, it is necessary to use methods for 
their quantification covering the structural diversity of this group.  
Here we present a simple, sensitive liquid chromatography-tandem-mass 
spectrometry (LC-MS/MS) method for the analysis of bile acid profiles in human 
plasma/serum. Protein precipitation was performed in the presence of stable-isotope 
labeled internal standards. In contrast to previous LC-MS/MS methods, we used a 
reversed-phase C18 column with 1.8µm particles and a gradient elution at basic pH. 
This allows base line separation of eighteen bile acid species (free and conjugated) 
within 6.5min run time and a high sensitivity in negative ion mode with limits of 
detection below 10nmol/L. Quantification was achieved by standard addition and 
calibration lines were linear in the tested range up to 28µmol/L. Validation was 
performed according to FDA guidelines and overall imprecision was below 11% CV 
for all species.  
The developed LC-MS/MS method for bile acid quantification is characterized 
by simple sample preparation, baseline separation of isobaric species, a short 
analysis time and provides a valuable tool for both, routine diagnostics and the 
evaluation of BAs as diagnostic biomarkers in large clinical studies. 
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6.2 Introduction 
 
Bile acid (BA) synthesis from cholesterol in liver is the primary pathway of 
cholesterol catabolism. Thereby cholesterol is modified by oxidation, shortening of 
the side chain and finally conjugation by glycine and taurine, respectively (1;2). 
These amphiphatic molecules are essential to solubilize dietary lipids and vitamins to 
promote their absorption. The most abundant BAs in humans comprise the primary 
BAs cholic acid (CA) and chenodeoxycholic acid (CDCA) and the secondary BAs 
deoxycholic acid (DCA), lithocholic acid (LCA) and ursodeoxycholic acid (UDCA) 
formed by deconjugation and dehydroxylation by intestinal bacteria in the colon. BAs 
are effectively reabsorbed and transported back to the liver to enter again 
enterohepatic circulation (1;2). 
Beside their well established role in dietary lipid absorption and cholesterol 
homeostasis, BAs are increasingly recognized as signaling molecules with endocrine 
functions (1;3;4). BAs are ligands for G-protein-coupled receptors such as TGR5 and 
modulators of several nuclear hormone receptors, most important farnesoid X 
receptor (FXR). Through activation of these diverse signaling pathways, BAs can 
regulate their own metabolism, but also lipid and energy homeostasis. In summary, 
these signaling functions make BA metabolism an attractive pharmacological target 
for treatment of vascular and metabolic diseases such as obesity, type 2 diabetes 
and atherosclerosis (1;3).  
The study of BA functions requires methods which cover the complexity of this 
structurally diverse group of molecules. In the last years a number of methods using 
liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) were 
developed allowing analysis of free and conjugated BAs without derivatization (5-16). 
Nevertheless, most methods show disadvantages with time consuming extraction 
procedures (5;8;17), long analysis times (6-8;14-18) or lack of baseline separation of 
isobaric species (5;8;9;17;18). Direct BA analysis by ESI-MS/MS does not allow 
identification of isobaric species (19).  
Here we present a validated method for the quantification of 18 free and 
conjugated BAs in plasma (serum) by LC-MS/MS with a short analysis time of 6.5min 
and baseline separation of isobaric species suitable for high-throughput analysis of 
patient samples. 
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6.3 Material and Methods 
 
6.3.1 Chemicals and solutions 
Acetonitril, methanol (HPLC grade), ammonium acetate (98%), hydrochloric 
acid  (HCl) and ammonium hydroxide (25%, for analysis) were purchased from VWR 
Int. GmbH (Darmstadt, Germany). Water was obtained from B. Braun (Melsungen, 
Germany). Bile acid standards were purchased from Sigma-Aldrich Chemie GmbH 
(Taufkirchen, Germany), Steraloids Inc. (Newport, USA), Campro Scientific GmbH 
(Berlin, Germany), Larodan Fine Chemicals AB (Malmö, Sweden) and were at least 
of 95% purity.  
 
6.3.2 Samples and sample preparation 
EDTA-plasma and serum were obtained from healthy volunteers, using 
standard venipuncture techniques. Samples were immediately centrifuged at 2000 x 
g for 10min. Plasma and serum were removed and stored at -20°C until analysis. To 
investigate sample stability, plasma and serum samples were aliquoted, immediately 
stored at -20°C or stored after 1, 4, 8 and 24h at room temperature. The immediately 
stored samples served as reference point. 
The sample preparation procedure was based on a published method (6) with 
slight modifications. 100µL EDTA-plasma/serum were spiked with 10µL of IS-mixture 
(2.4µmol/L D4-CA, 2.6µmol/L D4-DCA, 4µmol/L D4-CDCA, 0.6µmol/L D4-LCA, 
2.6µmol/L D4-UDCA, 4.6µmol/L D4-GCA, 14µmol/L D4-GCDCA). To increase 
extraction efficiency, 30µL of 1mol/L HCl were added. For protein precipitation, 
plasma/serum were mixed with 1mL acetonitril, followed by 1min vortex-mixing. After 
15min of centrifugation (14000 x g), the supernatant was evaporated to dryness 
under reduced pressure. The samples were re-dissolved in 100µL methanol/water 
(1/1; v/v, containing 10mmol/L ammonium acetate and 0.1% ammonium hydroxide). 
After an additional centrifugation step 5µL of the methanolic supernatant were used 
for LC-MS/MS-analysis.  
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6.3.3 LC-MS/MS analysis 
BA analysis was performed by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). The HPLC equipment consisted of a 1200 series binary 
pump (G1312B), a 1200 series isocratic pump (G1310A) and a degasser (G1379B) 
(Agilent, Waldbronn, Germany) connected to an HTC Pal autosampler (CTC 
Analytics, Zwingen, CH). A hybrid triple quadrupole linear ion trap mass spectrometer 
API 4000 Q-Trap equipped with a Turbo V source ion spray operating in negative ESI 
mode was used for detection (Applied Biosystems, Darmstadt, Germany). High purity 
nitrogen was produced by a nitrogen generator NGM 22-LC/MS (cmc Instruments, 
Eschborn, Germany).  
Gradient chromatographic separation of BAs was performed on a 50 x 2.1 
(i.d.) mm Macherey-Nagel NUCLEODUR C18 Gravity HPLC column, packed with 
1.8µm particles equipped with a 0.5µm pre-filter (Upchurch Scientific, Oak Harbor, 
WA, USA). The injection volume was 5µL and the column oven temperature was set 
to 50°C. Mobile phase A was methanol/water (1/1; v/ v), mobile phase B was 100% 
methanol, both containing 0.1% ammonium hydroxide (25%) and 10mmol/L 
ammonium acetate (pH 9). A gradient elution was performed with 100% A for 0.5min, 
a linear increase to 50% A until 4.5min, followed by 0% A from 4.6 until 5.5min and 
re-equilibration from 5.6 to 6.5min with 100% A. The flow rate was set to 500µL/min. 
To minimize contamination of the mass spectrometer, the column flow was directed 
only from 1.0 to 5.0min into the mass spectrometer using a divert valve. Otherwise 
methanol with a flow rate of 250µL/min was delivered into the mass spectrometer. 
The Turbo Ion Spray source was operated in the negative ion-mode using the 
following settings: Ion spray voltage = -4500V, ion source heater temperature = 
450°C, source gas 1 = 40psi, source gas 2 = 35psi a nd curtain gas setting = 20psi. 
Analytes were monitored in the multiple reaction monitoring (MRM), mass transitions 
and MS parameters are shown in Table 1. Quadrupoles Q1 and Q3 were working at 
unit resolution. 
 
6.3.4 Calibration and quantification 
Calibration was achieved by addition of BAs to EDTA-plasma (serum). A 
combined BA standard solution containing the indicated amounts (0.5 – 70.5µmol/L) 
was placed in a 1.5ml tube and excess solvent was evaporated under reduced 
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pressure before adding EDTA-plasma/serum. Calibration curves were calculated by 
linear regression without weighting. 
Data analysis was performed with Analyst Software 1.4.2. (Applied 
Biosystems, Darmstadt, Germany). The data were exported to Excel spreadsheets 
and further processed by self programmed Excel macros which sort the results, 
calculate the analyte/internal standard peak area ratios, generate calibration lines 
and calculate sample concentrations.  
 
6.4 Results 
 
6.4.1 Fragmentation of BAs 
First we tested the fragmentation of de-protonated BAs in negative ion mode. 
Unconjugated BA showed no prominent product ion. Therefore, we used a MS/MS 
transition without fragmentation and optimized the collision energy to get the highest 
signal to noise ratio for free BAs in plasma samples (data not shown). For conjugated 
BAs, fragment ions of the glycine (m/z 74) taurine (m/z 80) moiety were selected 
(Table 1). These transitions resemble those used in previous studies (5;6;8;19).  
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Table 1. MS parameter and limit of detection (LOD) of the BAs studied. 
Bile acid [M-H]- 
m/z 
MRM IS CE 
(V) 
RT 
[min] 
LOD 
[nmol/L] 
CA 407.3 407.3→407.3 D4-CA -30 2.56 5.79 
CDCA 391.3 391.3→391.3 D4-CDCA -30 3.51 2.28 
DCA 391.3 391.3→391.3 D4-DCA -30 3.71 6.52 
LCA 375.3 375.3→375.3 D4-LCA -30 4.50 9.84 
UDCA 391.3 391.3→391.3 D4-UDCA -30 1.92 8.82 
HDCA 391.3 391.3→391.3 D4-UDCA -30 2.15 8.34 
GCA 464.3 464.3→464.3 D4-GCA -72 2.52 2.46 
GCDCA 448.3 448.3→74 D4-GCDCA -70 3.44 2.35 
GDCA 448.3 448.3→74 D4-GCDCA -70 3.65 2.09 
GLCA 432.3 432.3→74 D4-GCDCA -64 4.41 0.55 
GUDCA 448.3 448.3→74 D4-GCA -70 1.84 2.82 
GHDCA 448.3 448.3→74 D4-GCA -70 2.08 1.56 
TCA 514.3 514.3→80 D4-GCA -116 2.48 4.50 
TCDCA 498.3 498.3→80 D4-GCDCA -116 3.38 1.75 
TDCA 498.3 498.3→80 D4-GCDCA -116 3.61 1.64 
TLCA 482.3 482.3→80 D4-LCA -108 4.35 0.46 
TUDCA 498.3 498.3→80 D4-UDCA -116 1.83 3.19 
THDCA 498.3 498.3→80 D4-UDCA -116 2.08 0.37 
D4-CA 411.2 411.2→411.2  -30 2.56 - 
D4-CDCA 395.3 395.3→395.3  -30 3.51 - 
D4-DCA 395.3 395.3→395.3  -30 3.71 - 
D4-LCA 379.3 379.3→379.3  -30 4.49 - 
D4-UDCA 395.3 395.3→395.3  -30 1.92 - 
D4-GCA 468.3 468.3→74  -72 2.52 - 
D4-GCDCA 452.3 452.3→74  -70 3.44 - 
IS = internal standard, CE = collision energy, RT = retention time 
6.4.2 Analysis of BAs by LC-MS/MS 
Because it is impossible to differentiate isobaric BA species by mass 
spectrometry a separation of isobaric species is necessary. To achieve a fast 
separation we chose a reversed-phase C18 column with a small particle diameter of 
1.8µm. Similar to most previous methods a water–methanol gradient was used for LC 
separation. Although most studies used acidic mobile phases, we tested the 
influence of the pH on BA separation. Compared to acidic pH 4 (Fig. 1A), basification 
of the mobile phase to pH 9 greatly improves resolution of BA species (Fig. 1B). 
Finally, we could accomplish baseline separation of isobaric species within 
6.5min (standard mixture Fig. 2 A-C and a representative human EDTA-plasma 
sample Fig. 2 D-F). Since 25 MS transitions are necessary to cover the main natural 
occurring bile acid species and their respective internal standards, we divided the MS 
program into 2 periods from 0 to 3min (12 transitions) and from 3 to 6.5min (13 
transitions). Using these periods further increased precision and sensitivity (data not 
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shown). Because we applied only a simple protein precipitation as sample 
preparation pre- and post-run was diverted into waste to prevent contamination of the 
mass spectrometer. Despite the use of crude samples, a column lifetime greater than 
1000 injections was observed.  
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Fig. 2. Effect of mobile phase pH on the separation of BAs. Displayed are mass 
chromatograms obtained using a bile acid standard mixture and the same linear gradient. 
The mobile phases consisted of methanol/water (1:1, v/v) (eluent A) and methanol (eluent B) 
containing 10mM ammonium acetate as well as (A) 0.1% formic acid or (B) 0.1% ammonia 
(25%).D) unconjugated, (B and E) glycin-conjugated and (C and F) taurin-conjugated BAs. 
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6.4.3 Matrix effects 
Due to the use of crude samples and the fast LC separation we analyzed the 
influence of the matrix on signal intensities. Because no analyte free EDTA-plasma 
was available, an internal standard mixture (D4-CA, D4-CDCA. D4-DCA, D4-LCA, D4-
UDCA, D4-GCA and D4-GCDCA) was analyzed with or without plasma extract. The 
presence of plasma extract caused a mean signal reduction (± S.D.) of 25 ± 6%.  
 
6.4.4 Quantification 
In order to compensate for variations in sample preparation and ionization 
efficiency, a set of stable isotope labeled BAs, D4-CA, D4-CDCA. D4-DCA, D4-LCA, 
D4-UDCA, D4-GCA and D4-GCDCA were added as IS prior to extraction. We 
generated calibration lines by addition of different concentrations of naturally 
occurring BAs to human EDTA-plasma (Suppl.-Fig. 1.). A five point calibration was 
performed within the concentration range indicated in Tab 2. For each analyte a 
calibration line was calculated by least square fitting of concentration against the 
peak area ratio of analyte to internal standard (Tab. 1.). The obtained standard 
curves were linear in the tested calibration range (Suppl.-Fig. 1.).  
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Table 2. Calibration data of the BA species (n=4). 
Bile acid Calibration 
range 
up to [µM] 
Slope  
(mean ± 
S.D.) 
Intercept 
(mean ± 
S.D.) 
Correlation 
coefficient  
(mean ± S.D.) 
CA 4.4 1.26±0.12 0.258±0.229 0.9983±0.0006 
CDCA 8 1.54±0.14 0.430±0.295 0.9951±0.0019 
DCA 5.2 2.05±0.11 0.733±0.392 0.9971±0.0032 
LCA 0.4 4.74±0.06 0.136±0.149 0.9993±0.0006 
UDCA 4.7 2.01±0.14 0.129±0.072 0.9956±0.0048 
HDCA 4.7 4.64±0.21 0.861±0.712 0.9962±0.0014 
GCA 9.4 1.07±0.02 0.239±0.201 0.9971±0.0015 
GCDCA 28.2 0.45±0.05 0.376±0.428 0.9970±0.0004 
GDCA 3.3 0.39±0.03 0.186±0.222 0.9964±0.0021 
GLCA 0.2 4.73±0.07 0.378±0.470 0.9968±0.0010 
GUDCA 0.32 0.48±0.03 0.074±0.060 0.9963±0.0044 
GHDCA 0.32 0.79±0.09 0.023±0.025 0.9971±0.0025 
TCA 2.8 0.72±0.08 0.016±0.014 0.9972±0.0024 
TCDCA 9.2 0.27±0.03 0.019±0.012 0.9960±0.0024 
TDCA 0.77 0.36±0.04 0.011±0.012 0.9975±0.0024 
TLCA 0.2 4.27±0.14 0.025±0.022 0.9991±0.0015 
TUDCA 0.32 0.49±0.05 0.002±0.001 0.9966±0.0018 
THDCA 0.32 0.50±0.10 0.001±0.002 0.9967±0.0045 
 
6.4.5 Assay characteristics 
Assay accuracy was calculated using three spiked plasma samples in different 
concentration levels (low, medium, high), covering the entire range of plasma BA 
levels. We found mean accuracies (± S.D.) between 89 and 111%. Similarly, 
extraction efficiency was tested by the addition BAs before and after sample 
preparation. Recoveries were calculated by the ratio of spiked BA area before and 
after extraction. The mean relative recovery was >80% and no correlation to the 
spiked amount was observed (Suppl.-Tab. 1.).  
Precision of the developed method was determined in 3 unspiked plasma 
samples, containing low, medium and high bile acid levels. Coefficients of variation 
(CVs) were <9% for intraday precision and <11% for interday precision (Suppl.-Tab. 
2).  
The limit of detection (LOD) was determined in three different human plasma 
samples as a signal-to-noise-ratio of three. LOD was below 10nmol/L for all BA 
species (Tab. 1). 
Stability of human EDTA-plasma was assessed immediately and after storage 
for 1, 4, 8 and 24h at room temperature. Immediately frozen samples did not differ in 
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BA levels compared with samples stored for 1, 4, 8 and 24h at room temperature 
(data not shown). 
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Fig. 2. Chromatogram of BAs. Displayed are representative mass chromatograms obtained 
using a bile acid standard mixture (A-C) and an extracted EDTA-plasma sample (D-F). (A 
and D) unconjugated, (B and E) glycin-conjugated and (C and F) taurin-conjugated BAs. 
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6.4.6 Quantitation of plasma and serum BAs 
The method was applied to BA quantitation of plasma and serum samples of 
29 healthy volunteers (11 females and 18 males), between 20 and 47 years of age 
(Tab. 3). Bile acid concentrations showed no notable differences between EDTA-
plasma and serum samples (data not shown). The main species detected were 
CDCA and DCA and their glyco-conjugates, whereas glycol- and tauro-conjugates of 
HDCA were not detectable in most samples of healthy volunteers. 
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Table 3. Bile acid levels in human serum  
Bile acid Serum (n=29) 
Mean (S.D.; range) 
[µmol/L] 
CA 0.2 (0.18; 0.053-0.68) 
CDCA 0.34 (0.28; 0.065-1.19) 
DCA 0.48 (0.34; 0.058-1.32) 
LCA 0.030 (0.018; n.d.-0.084) 
UDCA 0.11 (0.085; 0.021-0.33) 
HDCA 0.21 (0.17; 0.030-0.67) 
GCA 0.41 (0.36; 0.067-1.02) 
GCDCA 1.71 (0.80; 0.47-3.21) 
GDCA 0.38 (0.26; 0.048-0.88) 
GLCA 0.068 (0.047; 0.009-0.165) 
GUDCA 0.28 (0.15; 0.084-0.63) 
GHDCA n.d. (n.d.-0.0092) 
TCA 0.048 (0.083; n.d.-0.35) 
TCDCA 0.21 (0.23; 0.017-0.86) 
TDCA 0.044 (0.037; n.d.-0.14) 
TLCA 0.019 (0.016; n.d.-0.060) 
TUDCA 0.007 (0.006; n.d.-0.025) 
THDCA n.d. (n.d.-0.023) 
Mean values of healthy donors are expressed in µmol/L, S.D. and range are indicated in 
parentheses.  
 
6.5 Discussion 
 
In the last years BAs came under the spotlight due to their role as signaling 
molecules regulating their own as well as lipid and energy metabolism (1;3;4). In 
order to study BA function in detail, methods covering the full spectra of BA species 
are necessary. To use these methods in large clinical studies, these methods should 
require only a minimal sample preparation and a short analysis time. LC-MS/MS 
provides information about free and conjugated BAs together with an easy sample 
preparation.  
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However, up to now there are no LC-MS/MS methods published with a 
sufficient separation of isobaric BA species below 10min runtime (5;6;8;9;11;14;16-
19). Therefore, we developed a LC-MS/MS method for simultaneous determination of 
free and conjugated BAs in plasma and serum with a runtime of 6.5min. Shortening 
of the run time was permitted by application of basic conditions (10mM NH4Ac, 0.1% 
NH3, pH 9; Fig. 1) and a small particles column. Changing to 1.8µm particle diameter 
not only allows fast baseline separation of isobaric species but also a 2-fold reduction 
of matrix suppression compared to a column with 2.5µm particles (data not shown).  
To achieve reproducible and accurate results, a set of 7 stable isotope labeled 
BAs were used as internal standards (Tab. 1). This way we could show an excellent 
accuracy and overall imprecision below 11% CV for all analyzed BAs (Suppl.-Tab. 
2.). Based on these data, we could conclude that the selected set of internal 
standards together with a matrix calibration were suitable to compensate matrix 
effects or other variations in analytical conditions. In contrast to most existing 
methods, this study shows a detailed validation according to FDA criteria including 
evaluation of matrix effects, extraction efficiencies and sample stability (20). 
Moreover, analysis of BAs in large clinical studies (>5000 samples) showed the 
robustness of our analytical set-up despite the use of crude samples.  
We determined bile acid concentrations in serum and EDTA-plasma samples 
from 29 (11 females, 18 males) healthy volunteers. The concentrations for individual 
bile acid species were in a similar range as those recently reported by Burkard et al. 
(8).  
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6.6 Conclusion 
 
In conclusion this study, presents a rapid LC-MS/MS method for the 
simultaneous determination of 18 bile acid species from serum (plasma). 
Improvements compared to previous LC-MS/MS methods were observed regarding 
run time and separation of isobaric BAs as a result of application of 1.8µm column 
particles and a mobile phase with basic pH. This novel LC-MS/MS method 
represents a valuable tool for screening bile acid profiles in routine diagnostics and 
clinical studies.  
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6.8 Data supplement 
 
Suppl.-Table 1. Values represent the percent recovery of standards spiked before and after 
extraction. 
Bile acid spiked concentration  
[µmol/L] 
recovery [%] found 
concentration 
[µmol/L] 
Accuracy  
[%] 
CA 0.22 
0.66 
1.33 
92±2 
86±4 
88±4 
0.24±0.014 
0.64±0.08 
1.29±0.11 
107±6 
96±12 
97±8 
CDCA 0.4 
1.2 
2.4 
96±8 
101±9 
99±5 
0.45±0.38 
1.27±0.1 
2.61±0.115 
113±9 
105±8 
109±6 
DCA 0.259 
0.776 
1.55 
93±7 
85±6 
87±7 
0.25±0.024 
0.75±0.046 
1.55±0.051 
97±9 
96±6 
100±3 
LCA 0.01 
0.03 
0.06 
86±6 
97±7 
92±5 
0.024±0.002 
0.065±0.005 
0.13±0.010 
111±9 
110±9 
104±9 
UDCA 0.24 
0.71 
1.41 
97±8 
98±6 
100±7 
0.23±0.018 
0.70±0.066 
1.41±0.076 
98±8 
98±9 
100±5 
HDCA 0.24 
0.71 
1.41 
88±7 
95±4 
98±10 
0.25±0.016 
0.72±0.060 
1.43±0.122 
106±7 
102±8 
101±8 
GCA 0.47 
1.41 
2.81 
98±11 
95±8 
99±9 
0.52±0.046 
1.47±0.098 
3.05±0.183 
111±8 
105±7 
108±7 
GCDCA 1.41 
4.23 
8.45 
99±12 
99±5 
103±5 
1.25±0.096 
4.53±0.41 
7.92±0.62 
89±7 
92±6 
94±7 
GDCA 0.166 
0.497 
0.994 
92±9 
87±9 
96±7 
0.17±0.015 
0.52±0.045 
1.06±0.052 
103±10 
104±9 
107±7 
GLCA 0.02 
0.06 
0.12 
84±3 
81±9 
90±6 
0.011±0.001 
0.028±0.002 
0.061±0.006 
108±10 
96±6 
102±10 
GUDCA 0.016 
0.048 
0.096 
93±6 
86±3 
88±8 
0.014±0.001 
0.045±0.004 
0.089±0.006 
92±9 
95±9 
111±8 
GHDCA 0.016 
0.048 
0.096 
88±6 
82±10 
90±6 
0.015±0.0007 
0.046±0.005 
0.089±0.007 
96±5 
96±11 
93±7 
TCA 0.14 
0.42 
0.84 
79±9 
84±4 
80±9 
0.14±0.01 
0.43±0.033 
0.88±0.051 
102±6 
104±8 
105±6 
TCDCA 0.46 
1.37 
2.75 
87±5 
93±8 
85±4 
0.45±0.04 
1.4±0.068 
2.84±0.14 
98±8 
102±5 
103±5 
TDCA 0.038 
0.115 
0.23 
80±4 
85±3 
92±9 
0.040±0.005 
0.115±0.004 
0.22±0.014 
105±13 
100±3 
95±6 
TLCA 0.01 
0.03 
0.06 
83±4 
84±10 
93±10 
0.008±0.0001 
0.027±0.003 
0.057±0.005 
95±3 
90±10 
95±8 
TUDCA 0.016 
0.048 
0.097 
86±4 
79±12 
88.2±6 
0.0017±0.0001 
0.044±0.004 
0.102±0.005 
104±7 
91±10 
106±6 
THDCA 0.016 
0.048 
0.096 
81±6 
86±5 
83±10 
0.014±0.001 
0.044±0.001 
0.087±0.006 
90±6 
91±4 
91±6 
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Accuracy is displayed as the mean of the assayed concentration (corrected by endogenous 
bile acid concentrations in human serum) in percent of the spiked concentration. Each value 
represents the average of three determinations ± standard deviation. 
 
Suppl.-Table 2. Precision of the BA species analysis.  
Bile 
acid 
Intraday- 
[µmol/L±S.D.] 
CV 
[%] 
Interday- 
[µmol/L±S.D.] 
CV[%] 
CA 0.065±0.004 
0.15±0.012 
0.348±0.025 
6 
8 
7.2 
0.077±0.006 
0.17±0.013 
0.33±0.032 
8.5 
7.4 
9.9 
CDCA 0.17±0.013 
0.18±0.014 
0.27±0.016 
7.6 
7.7 
5.8 
0.16±0.014 
0.20±0.018 
0.27±0.018 
8.6 
9 
6.6 
DCA 0.29±0.01 
0.20±0.017 
0.064±0.004 
3.9 
8.5 
6.3 
0.31±0.027 
0.25±0.01 
0.07±0.008 
8.6 
4.8 
11 
LCA 0.026±0.002 
0.025±0.002 
0.019±0.002 
6.2 
5.2 
8.1 
0.025±0.001 
0.025±0.002 
0.017±0.01 
5.6 
8.3 
6.4 
UDCA 0.068±0.002 
0.21±0.015 
0.567±0.032 
2.8 
7.1 
5.6 
0.06±0.004 
0.2±0.016 
0.055±0.06 
7.7 
8 
10.2 
HDCA 0.17±0.012 
0.1±0.005 
0.04±0.003 
7.1 
4.8 
7.5 
0.14±0.008 
0.11±0.009 
0.043±0.003 
5.7 
8.8 
8.2 
GCA 0.35±0.022 
5.62±0.7 
17±1.4 
6.4 
8.2 
8.7 
0.32±0.023 
6.0±041 
15.9±0.7 
7.2 
6.8 
4.7 
GCDCA 1.2±0.06 
4.82±0.38 
12.8±0.78 
4.9 
7.8 
6 
1.38±0.074 
5.06±0.49 
13.8±0.87 
5.4 
9.6 
6.3 
GDCA 0.36±0.025 
0.42±0.018 
0.62±0.045 
7 
1.9 
7.3 
0.42±0.038 
0.49±0.04 
0.58±0.039 
9 
8.7 
6.7 
GLCA 0.034±0.0018 
0.024±0.002 
0.62±0.0045 
5.2 
8.3 
7.3 
0.03±0.002 
0.028±0.0015 
0.07±0.0062 
6.6 
5.3 
8.6 
GUDCA 0.017±0.0009 
0.69±0.05 
2.3±0.18 
5.4 
7.2 
7.6 
0.21±0.01 
0.58±0.044 
2.51±0.04 
4.8 
7.5 
6 
GHDCA - - - - 
TCA 0.055±0.004 
2.71±0.18 
9.13±0.74 
7.2 
6.6 
8.1 
0.42±0.038 
3.02±0.27 
9.45±0.62 
9 
8.7 
6.6 
TCDCA 0.247±0.0016 
3.06±0.19 
9.24±0.74 
6.4 
6.2 
8.0 
0.26±0.024 
3.1±0.17 
10.3±1.1 
9.1 
5.4 
11.1 
TDCA 0.065±0.0004 
0.14±0.009 
0.3±0.024 
5.9 
6.4 
8.0 
0.063±0.0005 
0.14±0.009 
0.24±0.026 
9.1 
6.2 
7.7 
TLCA 0.017±0.001 
0.02±0.002 
0.031±0.002 
7.8 
10.4 
6.5 
0.021±0.0002 
0.025±0.001 
0.024±0.002 
10 
4 
9.2 
TUDCA - 
0.68±0.052 
2.67±0.083 
- 
7.6 
3.1 
- 
0.72±0.04 
2.3±0.15 
- 
5.5 
6.5 
THDCA - - - - 
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The displayed values are mean plasma concentrations in µmol/L and the coefficient of 
variation (CV) of 6 sample aliquots at 3 concentrations analyzed in series for intra-day and 
on 6 different days for inter-day precision. 
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Suppl.-Fig. 1. Calibration lines for CDCA, GCDCA and TCDCA.  
Calibration lines were established by standard addition of BAs to plasma before extraction, 
yielding BA concentrations in a range of 0 - 28.2µmol/L. The corresponding calibration line 
statistics are shown in Table 2. The data shown were calculated from 4 independent 
samples. CDCA, GCDCA and TCDCA are representative for unconjugated, glycine- and 
taurine-conjugated BA species. 
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7 Summary 
 
7.1 Summary in English 
 
The crucial role of lipids in cells, tissues and body fluids is demonstrated by a 
large number of studies and human diseases that involve the disruption of lipid 
metabolic enzymes and pathways. Examples for such diseases include cancer, type 
2 diabetes and atherosclerosis. Recent advances in research in the field of lipidomics 
has been driven by the development of new mass spectrometric (MS) tools and 
protocols for the identification and quantification of molecular lipid species in various 
biological matrices. However, the existing methods for minor sphingolipid (SL), 
glycerophospholipid (GP) and bile acid (BA) analysis show disadvantages like 
laborious sample preparation, time consuming LC-separation, high sample volumes 
or insufficient validation data, excluding these methods for high throughput analysis 
in huge clinical trials.  
The present work presents fast, specific, sensitive and robust LC-MS/MS 
methods for the analysis of SL, GL and BA species. Chromatographic-separation 
should provide co-elution of analytes and internal standards within each lipid class. 
The latter is of major importance to compensate for matrix effects and varying 
ionization efficiencies. Additionally, these methods should provide automated data 
analysis tools to allow high sample throughput, a prerequisite for lipid species 
quantification in huge clinical trials. Finally, these methods should be applied for lipid 
species analysis in various biological matrices, including plasma, cell homogenates 
and tissue samples. 
1. A method was developed for the simultaneous quantification of 
phosphatidic acid (PA), phosphatidylglycerol (PG), 
bis(monoacyl)glycerophosphate (BMP) and cardiolipin (CL) species using 
hydrophilic interaction chromatography (HILIC) coupled with ESI-MS/MS in 
positive ionization mode. GL extraction was performed in the presence of 
butanol. HILIC showed excellent peak shapes and the isobaric compounds 
PG and BMP were successfully baseline-separated. Furthermore, HILIC 
provides co-elution of lipid species and their internal standards. Since 
many lipid species differ only by their chain length and/or saturation 
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degree, co-elution may exhibit isotopic overlap which has to be corrected. 
Therefore, theoretically calculated isotope profiles were implemented into 
self programmed Excel Macros, which successfully corrected, for the first 
time, this complex isotopic overlap of an MS/MS experiment. 
2. As one major achievement of this thesis, LC-MS/MS methods for the 
analysis of various low abundant SLs were developed. Separation of 
distinct SL classes and co-elution of analytes and internal standards was 
achieved by HILIC. MS/MS-analysis was either conducted in negative 
ionization mode for S1P and LPA quantification, or in positive ionization 
mode for the quantification of SPH and metabolites as well as for HexCer 
and LacCer. Since these methods use the same butanolic extraction and 
LC components, it is possible to analyze both sets of analytes from one 
extract. Treatment of fibroblasts with myriocin, which inhibits the first step 
of SL biosynthesis, and sphingosine-kinase inhibitor, demonstrated the 
importance of methods covering multiple instead of single sphingolipid 
metabolites. Additionally, SLs were quantified in plasma and in lipoprotein 
fractions prepared by fast performance liquid chromatography (FPLC). SLs 
showed a specific distribution across lipoprotein classes and the SL 
species profiles in separated lipoproteins may help to address the origin of 
plasma SLs. 
3. BA species were quantified from human plasma/serum using ESI-MS/MS 
in negative ionization mode. LC-separation was performed with a reversed 
phase-C18 column and a gradient elution at basic pH was applied. 
Baseline-separation of eighteen BA species (free and conjugated) and a 
high sensitivity was achieved within 6.5 min runtime. The sample 
preparation procedure was based on protein precipitation with acetonitrile. 
Validation was performed according to FDA guidelines. This method 
provides a valuable tool for both, routine diagnostics and the evaluation of 
BAs as diagnostic biomarkers in large clinical studies. 
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7.2 Summary in German 
 
Die äußerst wichtige Rolle von Lipiden in verschiedenen Zellen, Geweben und 
Körperflüssigkeiten wurde durch eine Reihe von Studien gezeigt. Viele Krankheiten 
stehen in engem Zusammenhang mit Störungen im Lipid-Stoffwechsel. Beispiele für 
solche Krankheiten sind unter anderem Krebs, Typ 2 Diabetes und Arteriosklerose. 
Neueste Ergebnisse im Bereich der „Lipidomics“, wurde durch die Entwicklung 
neuartiger massenpektrometrischer Tools für die Identifizierung und Quantifizierung 
molekularere Lipid-Spezies in verschiedenen biologischen Materialien, 
vorangetrieben. Bereits existierende Methoden für die Analyse von gering 
konzentrierten Sphingolipiden (SL), Glycerophospholipide (GP) und Gallensäuren 
weisen deutliche Limitationen hinsichtlich aufwendiger Probenvorbereitungen, langen 
chromatographischen Trennungen, hohen Probenvolumina oder unzureichenden 
Validierungs-Daten auf. Aus diesem Grund sind diese Methoden nicht geeignet für 
Biomarker-Screening in großen klinischen Studien. 
Die vorliegende Arbeit beschreibt schnelle, sensitive und robuste analytische 
Methoden für die Quantifizierung von SL, GL und Gallensäuren mittels 
Flüssigchromatographie Tandem-Massenspektrometrie (LC-MS/MS). Die 
chromatographische Trennung sollte hinsichtlich der Co-Elution von Analyten und 
internen Standards optimiert werden. Diese ist Voraussetzung um potentielle Matrix-
Effekte und unterschiedliche Ionisationseffizienzen auszugleichen. Für den Einsatz in 
großen klinischen Studien, sollte die Datenauswertung automatisiert werden, um 
einen hohen Probendurchsatz zu gewährleisten. Neben Blutplasma sollten auch 
andere biologische Materialien, wie kultivierte Zellen und Gewebe eingesetzt werden. 
1. Zunächst wurde eine Methode für die simultane Analyse von 
Phosphatidsäure (PA), Phosphatidylglycerol (PG), 
Bis(monoacyl)glycerolphsophat (BMP) und Cardiolipin (CL) entwickelt. 
Quantifizierung dieser Lipide erfolgte durch hydrophile 
Interaktionschromatographie (HILIC) gekoppelt mit ESI-MS/MS im 
positiven Ionisations-Modus. HILIC zeichnete sich durch optimale Peak-
Qualitäten und Basislinien-Trennung der isobaren Komponenten PG und 
BMP aus. Zusätzlich wurde durch den Einsatz von HILIC eine Co-Elution 
der Lipid-Spezies und der zugehörigen internen Standards erreicht. Da 
sich viele Lipid-Spezies nur in ihrer Kettenlänge und/oder ihrem 
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Sättigungsgrad unterscheiden, führt Co-Elution zu einem Isotopen-
Überlapp der korrigiert werden muss. Aus diesem Grund wurden 
theoretisch berechnete Isotopen-Profile in selbst-programmierte Excel-
Makros implementiert. Der komplexe Isotopen-Überlapp wurde im 
Folgenden, zum ersten Mal, in einem MS/MS-Experiment erfolgreich 
korrigiert. 
2. Als weiterer Schwerpunkt dieser Doktorarbeit sollten neue analytische 
Methoden für den Nachweis und für die Quantifizierung von verschiedenen 
Sphingolipiden entwickelt werden. Durch die Anwendung von HILIC 
wurden die verschiedenen SL-Klassen errfogreich getrennt, und 
gleichzeitige Co-Elution von Analyten und Internen Standards konnte 
erreicht werden. Charakterisierung mittels MS wurde für S1P und LPA im 
negativen Ionisationsmodus, für SPH und Metabolite sowie für HexCer und 
LacCer, im positiven Ionisationsmodus durchgeführt. Da beide Methoden 
die identische butanolische Extraktion, und die gleichen 
chromatographischen Komponenten verwenden, konnte das komplette SL 
Profil aus demselben Extrakt bestimmt werden. Ein Inkubations-
Experiment von Fibroblasten mit Myriocin, einem Inhibitor des ersten 
Schrittes der SL-Biosynthese, und einem Sphingosinkinase-Inhibitor zeigte 
Veränderungen des SL Profils. Um weitere wichtige Erkenntnisse des SL-
Stoffwechsels in Zusammenhang mit verschiedenen Erkrankungen zu 
gewinnen ist es daher wichtig, kombinierte Methoden, die eine Vielzahl von 
Metaboliten erfassen, anzuwenden. In einem zusätzlichen Experiment 
wurden SL in Plasma und in FPLC-getrennten Lipoprotein-Fraktionen 
quantifiziert. SLs zeigten eine spezifische Verteilung über die 
verschiedenen Lipoprotein-Klassen. 
3. Gallensäuren wurden aus humanem Plasma/Serum mittels ESI-MS/MS in 
negativem Ionisations-Modus quantifiziert. Die chromatographische 
Trennung erfolgte mit einer Umkehrphase C18-Säule. Innerhalb von 6.5 
min wurden 18 verschieden Gallensäuren mittels Gradienten-Elution unter 
basischen Bedingungen getrennt. Als Probenvorbereitung wurde eine 
Proteinfällung mit Hilfe von Acetonitril angewendet. Da diese Methode im 
Rahmen der Routinediagnostik und in großen klinischen Studien 
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eingesetzt wird, wurde eine Validierung auf Grundlage der FDA-Richtlinien 
durchgeführt. 
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